Genetic events in colorectal tumorigenesis by Cripps, Kathryn Jane
GENETIC EVENTS IN 
COLORECTAL TUMORIGENESIS
Kathryn Jane Cripps









A B S T R A C T  3
C H A P T E R  1: I N T R O D U C T IO N
1.1 The Pathology o f  Colorectal Neoplasia 6
1.2 Colorectal Adenomas and Adenocarcinomas 7
1.3 Evidence for the Adenoma to Carcinoma Sequence 9
1.4 Environmental  and Dietary Factors Influencing Colorectal  Cancer  10
1.5 The Genetic Basis for Colorectal Cancer 12
1.51 Familial Polyposis Coli (FPC) 13
1.52 Gardner’s Syndrome 14
1.53 Heredi tary Non-Polyposis Colorectal Cancer (HN PC C )  15
1.54 T urco t ’s Syndrome 16
1.55 Heredi tary Flat Adenoma Syndrome 16
C H A P T E R  2: THE G E N E T IC  C H A N G E S  A S S O C I A T E D  W IT H  
C O L O R E C T A L  C A N C E R
2.1 The Short Arm o f  Chromosome 17 18
2 .11 T h e p53  gene 19
2.2 The Long Arm o f  Chromosome 18 26
2.3 The Long  Arm o f  Chromosome 5 28
2.31 The M CC  gene 28
2.32 The A PC  gene 30
2.4 Chromosome 12, the K-ras oncogene 38
2.5 Chromosome 8
2.51 The c-myc gene 39
2.52 8p 39
2.6 2 2 q, lp  and 14q 40
11
2.7 D N A  Repair Enzymes and Genome Instability 40
2.71 D N A  Polymerase ß 41
2.72 H N P C C  and Instability 41
2.721 2p 41
2.722 3p 43
2.8 D N A  Hypomethylat ion 44
2.9 The Clinical Relevance o f  Genetic Abnormalities Observed in
Colorectal Cancer 45
C H A P T E R  3: T H E  R E L A T I O N S H I P  B E T W E E N  P53 
M U T A T I O N S  A N D  PROTEIN  ST A B IL IS A T IO N  IN 
C O L O R E C T A L  C A R C I N O M A S
3.1 Introduct ion 54
3.2 Results 59
3.21 Mutation Analysis o f  PAb 1801 Positive Tumours  59
3.22 PC R-SSCP/MspI  Screening for Mutations in PAblSOl
Positive Tumours  60
3.23 Screening for Mutations in PA blSOl Negative Tumours  62
3.24 DO-7 and CM-1 Immunocytochemistry 62
3.3 Discussion 64
C H A P T E R  4: IS T H E  M CC  G E N E  I N V O L V E D  IN 
C O L O R E C T A L  C A R C IN O G E N E S IS ?
4.1 Int roduct ion 68
4.2 Results 70
4.21 PCR-SSC P o f  M CC  in Positive Controls 70
4.22 PCR-SSC P o f  M CC  in Five Young Patients 70
4.3 Discussion 73
I l l
C H A P T E R  5: T A R G E T I N G  O F  T H E  A P C  G E N E  IN A C O L O N  
C A R C I N O M A  C E L L  LINE
5.1 Introduct ion 76
5.11 The Role o f  APC in Normal and Neoplast ic Cells 76
5.12 Gene Target ing 77
5.13 The SW480 Cell Line 86
5.2 Experimental  Design 88
5.3 Results 90
5.31 Proper ties o f  the SW480  Cell Line 90
5.32 Construct ion o f  Targeting Vectors 91
5.33 G418 Resistant Clones and Analysis 92
5.4 Discussion 94
C H A P T E R  6: G E N E R A L  C O N C L U S I O N S  100
C H A P T E R  7: M A T E R I A L S  A N D  M E T H O D S
7.1 The Relationship Between p53  Mutat ion and Protein Stabilisation
in Colorectal Carcinomas 107
7.11 Immunocytochemistry 107
7.12 PCR-S SC P 108
7.13 Sequencing o f  Tum our DN A 111
7.2 Is the M CC  Gene Involved in Colorectal Carcinogenesis? 115
7.21 Clinical Material and D N A  preparat ion 115
7.22 PCR-SSC P o f  Exons 1-17 115
7.23 Sequencing o f  Polymorphic Exons 116
7.3 Target ing o f  the APC  Gene in a Colon Carcinoma Cell Line 117
7.31 Generat ion o f  a “Hit and Run” Target ing Vector  p P N T .A PC  117
7.32 Generat ion o f  the Targeting Vector  pPN T.A PCw t  123
7.33 Cell Culture and Analysis o f  SW480  Cells 123
7.331 APC  Analysis o f  SW480 Cells 123
7.332 Fluorescent In-Situ Hybridisation (FISH) Analysis o f
APC  in SW480  Cells 125
7.34 Transfection o f  Target ing Vector  pPNT.APC 127
Appendix and Suppliers 130
References 138
ACK NO W LEDGEM ENTS
This project was funded by the Cancer Research Campaign and I am grateful to them 
for their financial support.
My supervisors for this project were Professor  Andrew Wyllie and Dr Mart in Hooper ,  
and I would like to thank them both for their help, patience and enthusiasm.
I would also like to thank Professor Bird and all members  o f  the Pathology 
Department  who contributed to this thesis. In particular I would like to thank Susan 
White  and Derek Bishop for immunocytochemical  data, and Dr  Colin Purdie  and Dr 
Pauline Carder for additional p53 data. I am also grateful to Drs Jill Bubb and Sarah 
Gledhill for helpful discussion and Bob Morris for technical assistance.
FISH analysis o f  APC  was performed at the Western General Hospital M R C  Human 
Genet ics Unit under the supervision o f  Judy Fantes, Shelagh Boyle and Susan 
Farrington. The SW480 cell line was kindly provided by Dr Chris Marshall  ( ICRF).  I 
would also like to thank Dr Alan Clarke for helpful (!) comments  on the APC  
targeting study.
I am grateful to Lucy Curtis for the SSCP analysis o f  M CC  positive control  samples 
(kindly provided by Dr Ken Kinzler), and additional sequencing data, also for helpful 
discussion along the way.
I would also like to extend my grat itude to M r  Malcolm Dunlop for providing D N A  
samples for M C C  analysis.
Finally, on a more personal note, I would like to thank all who have helped to keep 
me the same calm, well balanced, sane and rational individual I was when I arrived in 
the Department ,  in no particular order, Ann, Lucy, Steve, Jude, Emma,  Dave,  Ian and 
last but not least Damian. 1 would also like to express my love and thanks to my 
family tor their continued support both emotional and financial over  the previous 
years, and I would also like to assure Dad that I am at last going to get  a "proper  job" 
and anyway his smile will make it all worthwhile!
THE G E N E  W IL L  OUT!
2
DECLARATION
The work  presented in this thesis has been carried out  by myself  except  where 
specifically indicated in the acknowledgements.
K.J.Cripps June 1995
ABSTRACT
M ore  is known about  the genes involved in colorectal tumorigenesis than for any 
other  human cancer. Mutat ions have been identified in many genes,  including K-ras, 
APC, MCC, DCC  and p53. However ,  whilst much is known  about these events, there 
are many questions that remain unanswered.  Three specific quest ions involving the 
p53, M C C  and APC  genes  were addressed in this thesis.
Firstly, the relationship between p53  mutat ion and stabilisation o f  p53 protein was 
assessed. It had been previously assumed that stabilised p53 protein product  was 
indicative o f  point mutation within the p53  gene. M ore  recently, however,  situations 
have been described in which this relationship is not absolute. Accordingly, the 
incidence o f  stabilised product detected by immunocytochemistry ( ICC) using p53 
specific antibodies, was compared in a series o f  47 colorectal carcinomas with that o f  
mutation, detected by single strand conformational polymorphism analysis (SSCP)  
and sequencing o f  p53 exons 5-8. The results suggest  a high correlation between the 
detection or absence o f  p53 protein stabilisation and the presence or absence o f  
mutat ions within the gene (35/47:74%).  However ,  specific incidences are highlighted 
in which concordance is not absolute. In particular, mutat ions in exon 6 o f p53  do not 
appear to result in stabilised protein and 2 tumours  with a high degree o f  staining 
contained no apparent  mutation within the entire coding region o f  the gene. Eight 
tumours  within the series with positive ICC staining have also been shown to have no 
mutat ions within exons 4-9, a region where the majority o f  mutations o f  p53  have 
previously been shown to occur. Possible explanations for the observed lack o f  an 
absolute concordance are discussed.
Secondly, mutat ions in M CC  were  studied in a subset o f  colorectal carcinomas. 
Although the M C C  gene, on chromosome 5q21, was identified prior to APC , and
found to be mutated in some colorectal cancers (hence Mutated  in Colorectal 
Cancer),  its role in colorectal carcinogenesis is still uncertain. Only five sporadic 
colorectal tumours  with M C C  mutat ions have been published and no germline 
mutat ions o f  the gene have been identified in Familial Polyposis Coli (FPC) patients. 
A previous study from the Edinburgh Cancer Research Campaign Group  had shown 
that whilst 5q21 allelic losses in a series o f  twenty colorectal carcinomas invariably 
involved M CC, no mutat ions o f  the remaining allele could be detected.  It remained 
possible however , that M C C  might be significant in other forms o f  colon cancer. 
Mutat ions were therefore sought  in the coding region o f  M C C  by SSCP in five 
colorectal tumours  from non-polyposis patients who had presented with colon cancer 
at a young age (less than 48 years). Tumours  had been maintained as xenograf ts in 
SCID mice and were therefore considered to be free from human contaminating 
(normal) stromal elements. No  mutat ions were found in any o f  the young cases, 
although all previously published tumours  with M CC  mutat ions were detectable by 
the same analysis. These results therefore add to the evidence that inactivation o f  
M C C  by mutation is not important in colorectal carcinogenesis at least at the level 
detectable by this study.
Finally, essential preliminary steps were taken in establishing an experimental system 
in which to study the role o f  APC  mutation in colorectal carcinogenesis.  APC, which 
is close to  M C C  on 5q21, is mutated in at least 60 % o f  sporadic colorectal tumours,  
and germline transmission o f  APC  mutat ions are responsible for FPC. Mutat ions  in 
APC. are believed to be an early event in colorectal tumour progression and are 
detectable at equal frequency in benign and malignant tumours.  It is o f  interest to 
establish whether  such 'early' events are still important in determining the phenotype 
o f  tumours  at later stages ot progression, as this would influence gene therapy 
strategies in colorectal cancer. Accordingly, gene targeting constructs  were designed
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to execute a "Hit and run" strategy that would convert a known t runcat ing mutation 
in the APC  gene in the colorectal cancer  cell line SW480 to wild type. The  SW480 
cell line was characterised by a variety o f  techniques and shown to contain three 
mutated copies o f  the APC  gene, no normal copies and to be tumorigenic in SCID 
mice. In addition to a putative correcting construct (which remains to be confirmed 
and tested), a similar construct  was made that would introduce a novel mutat ion 21 
codons from the corrected one. This latter construct  has provided a control  for the 




1.1 The Pathology of Colorectal Neoplasia
Neoplasms o f  the colon and rectum are very common.  Malignant tumours  o f  the large 
intestine are a frequent cause o f  human cancer  mortality in the Western world with 
approximately 19,000 deaths in the UK per annum from colorectal cancer. Benign 
neoplasms may occur with a frequency o f  one person in three in the general 
population over the age o f  sixty (Cancer  Research Campaign,  1993).
Cancer  o f  the colorectum becomes increasingly common in older generat ions and the 
risk o f  a malignancy developing increases with age (Kozuka et al., 1975; Konishi et 
al., 1982). The idea that cancer may be a multistep process was proposed as long ago 
as 1949 and colorectal cancer provides an excellent model o f  this multistep nature 
(Berenblum and Sluibik, 1949; Armatige and Doll, 1957; Foulds,  1958). Bo th  benign 
and malignant neoplasms are relatively easy to obtain from surgical resection and 
colonoscopic polypectomy specimens, al though often only after symptoms o f  
carcinoma have been identified. The study o f  both benign and malignant tumours  
combined with evidence that colorectal cancer  has both a genetic and environmental 
aspect can provide an analysis o f  both inherited and somatic gene changes and their 
relative roles in the multistep nature o f  colorectal cancer to be studied.
1.2 Colorectal Adenomas and Adenocarcinomas
Adenomas o f  the colorectum are benign tumours  derived from the epithelium o f  the 
large intestine and are found relatively frequently th roughout  the population. It is 
thought that defects in stem cells near the base o f  the intestinal crypts may lead to 
adenoma formation as stem cells already have many o f  the characteristics o f  neoplasia 
e.g. they are immortal and undifferentiated. Increases in the number  o f  stem cells 
wi thout  changes in the differentiation that occurs as cells migrate up the crypt may 
create the disturbance required for adenoma format ion (Pot ten et ah, 1984). 
Colorectal adenomas may be either polypoid or flat. Polypoid adenomas can be small 
or large, sessile or pedunculated. There  is a range o f  histological types associated with 
polypoid adenomas o f  the colorectum presenting as a spectrum from tubular through 
tubulovillous to villous. Tubular  forms are the most  common and villous adenomas 
the least often found but the latter have the highest malignant potential (Morson,  
1990; Clark et ah, 1985; Muto,  1975). The cytological organisat ion within both 
polypoid and flat adenomas shows a wide spectrum o f  localised dysplasia, merging at 
its most severe with the diagnosis o f  carcinoma in situ. Small adenomas usually 
exhibit mild dysplasia and are evenly distributed throughout  the colorectum, whilst 
larger adenomas have more severe dysplasia, a correspondingly higher malignant 
potential and tend to concentrate in the left colon and rectum, especially the sigmoid 
section. Flat adenomas are generally moderately dysplastic (Muto,  1975; Enterline et 
ah, 1962; Konishi et ah, 1982.). An increase in dysplasia has been linked with
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increasing age, number  and size o f  polyps, especially those with a villous type 
histology. Commonly,  severely dysplastic adenomas are associated with frank 
adenocarcinoma in the same region o f  the colon, leading to the suggest ion that 
dysplasia may be a useful marker  for increased colorectal cancer  risk (Kalus, 1972). 
The size and level o f  dysplasia as well as number  o f  adenomas correlates  with 
malignant potential (Muto  et al., 1975) It should be noted that dysplasia is important  
in other  clinical contexts in the colorectum such as ulcerative colitis, Crohn's disease 
(which has been shown to predispose to colorectal cancer at a younger  than average 
age) and schistosomiasis (Morson, 1990; Hamilton, 1985 Ming-Chai  et al., 1980;). 
There  is evidence for the generation o f  malignant tumours  from generalised dysplastic 
epithelium in patients with Ulcerative Colitis wi thout  an adenomatous stage 
suggesting de novo  carcinoma can also arise (Hamilton 1992). In general,  histology 
reveals a cont inuous spectrum o f  adenomas from small with mild dysplasia (most  o f  
which do not grow  and may even regress) to large, highly dysplastic polyps with 
villous architecture and an increased malignant potential.
Several physical factors affect both occurrence and distribution o f  colorectal 
adenomas.  Firstly, the distribution o f  adenomas appears to be age related. The left 
colon and rectum are the most common sites for adenomas in young patients, whilst 
the right colon is more common in older patients (Gerharz  et al., 1987). In all areas o f  
the colon, adenomas are more common in males, whilst at sites other  than the colon 
the cancer bias is slightly towards females. Other studies show that adenomas in the
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sigmoid colon and rectum are generally larger and more dysplastic in females (H of f  et 
al., 1985). Therefore age, sex and site are important variables in adenoma formation. 
Additionally, abnormal D N A  content  or aneuploidy is less common  in adenomas than 
carcinomas and increases with increasing dysplasia indicating a poorer  prognosis (Goh 
and Jass, 1986; Quirke et al., 1986; Enterline and Arvan, 1967; Armitage et al.,
1985). The majority o f  cancers o f  the colorectum are adenocarcinomas al though rarer 
types also exist (Jass and Morson,  1987; Morson,  1974). Multiple neoplasms both 
benign and malignant are common in the colon and rectum, and synchronous and 
metachronous carcinomas are more common in cases with synchronous adenoma.
The literature remains divided on the true origins o f  colorectal carcinomas and it has 
been proposed that carcinomas may arise both from within existing adenomas,  in what 
has been termed the adenoma to carcinoma sequence (M uto  et al., 1975), or via areas 
o f  generalised dysplasia (de novo) without  an adenomatous stage. Whilst it is probable 
that some colorectal cancers originate in adenomas,  the majority o f  adenomas do not 
appear to progress to carcinoma and indeed may even regress (Knoernschild,  1963).
1.3 Evidence for the Adenoma to Carcinoma sequence
Many pieces o f  evidence, both temporal and spatial, support  the adenoma to 
carcinoma sequence. Firstly, it has been suggested that carcinomas develop from 
within adenomatous tissue (Bussey and Morson,  1975; Eide, 1983) and that as the 
carcinoma expands it destroys the surrounding adenomatous tissue (Morson,  1974).
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Another  study has stated that some colorectal cancers have residual adenomatous  
tissue at their periphery (Muto et al., 1975). Secondly, adenomas arise at an earlier 
aee  than carcinomas and are more common in carcinoma associated than non-O
carcinoma associated bowel-t issue (Eide et al., 1986). Thirdly, removal  o f  adenomas 
decreases the incidence o f  associated carcinoma o f  the colon or rectum (Gilbertson 
and Nelms, 1978). Finally, carcinomas are clonal (Fearon et al., 1987), carrying the 
same genetic lesions (usually with additional lesions) as associated adenomas. This 
will be discussed in detail later. These data strongly suggest  that at least some 
carcinomas arise from within existing adenomas.
1.4 Environmental and Dietary Factors influencing Colorectal  
Cancer
Environmental  factors such as diet and geographical  location have been implicated in 
colorectal and other tumour development  (Doll and Peto,  1981; Bussey, 1990). 
Variation in the frequency o f  colorectal cancer has been noted over  geographical  
areas. For example, cancer o f  the colorectum is common in North America and 
Europe, rare in Asia and uncommon in Africa (Boyle et al., 1985). This has been 
linked to environmental factors rather than racial features. Migrant  studies on 
Japanese immigrants to the United States show that colorectal cancer,  until recently 
uncommon in Japan, becomes an increasing problem as lifestyles adapt to the  Western 
way o f  living (Haenszel and Kurihara, 1967). It has been suggested that animal fat in 
the diet may play a role in colorectal cancer  development  whilst cereal fibre intake,
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vitamins C, D and E and calcium may show a negative correlation with colorectal 
cancer  as well as cancer o f  the breast, prostate and ovary (Jain et ah, 1980; Rose et 
ah, 1986; Garland 1985; DeCosse et ah, 1989; N ew m ark  et ah, 1984). However ,  
studies on Maori  populations who eat a high fat diet but  have a low incidence o f  
colorectal cancer suggest other  factors are also involved (Smith et ah, 1985). The 
specific dietary factors involved have not as yet been identified (Bruce,  1987). 
However  a mutagenic lipid compound (faecapentaene) causes mutation,  including 
single strand breaks and sister chromatid exchanges, in human cell lines and has been 
isolated from the faeces o f  people in high risk areas for colorectal cancer (Plummer et 
ah, 1986). Faecapentaene is produced by the action o f  anaerobic bacteria and its 
synthesis is stimulated by an increase in concentrat ion o f  bile acids (G upta  et ah, 
1984). Animal fat in the diet may increase faecal pH thereby promoting the format ion 
o f  bile acids such as deoxycholic acid and lithocholic acid which may cause small 
adenomas to progress to larger adenomas (Hill, 1975; van der W e r f  et ah, 1983). 
Deoxychol ic and lithocholic acids are co-mutagens and increase the number  o f  
mutat ions in D N A  over the mutagen alone (Wilpart et ah, 1983). In animal models,  
bile salts and dietary fat also increase colonic ornithine decarboxylase activity which is 
involved in polyamine synthesis and is required for cell proliferation (Takano et ah, 
1984, Rozhin et ah, 1984). Inhibition o f  ornithine decarboxylase by 
difluoromethylornithine has been shown to prevent  chemically induced colonic 
tumours  developing in mice (Kingsnorth et ah, 1983). Adenomas and carcinomas have 
about 3 times the ornithine decarboxylase and 2 times the polyamine levels seen in
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normal colonic mucosa and ornithine decarboxylase activity is higher in the normal 
tissue from colorectal cancer  patients over non-affected individuals (LaMuragl ia  et ah,
1986). Additionally, bile salts may activate protein kinase C (PKC) which is a 
regulator o f  cellular differentiation and growth (Craven et ah, 1987). PKC activity is 
increased in colorectal cancers, compared to normal colon and also in patients with 
adenomas (McGarr ity and Peiffer, 1994). However ,  case control studies o f  matched 
cancer and normal patients often show no direct link with fat, bile acids etc. This, and 
the recognition o f  families in which colon cancer  is common (al though families may 
share common diets and environment),  suggest that genetic elements may be involved 
in colorectal cancer development.
1.5 The Genetic Basis for Colorectal Cancer
Whilst evidence on environment,  diet, age and sex suggest  that these are risk factors 
for colorectal cancer, the lack o f  confirmation o f  involvement o f  these factors in all 
cases may suggest an underlying genetic basis for cancer  formation. The  majority o f  
colorectal cancers are not associated with clear inherited syndromes al though 
hereditary forms do exist, including Familial Polyposis Coli (FPC),  Gardner 's 
Syndrome,  Hereditary non-Polyposis Colorectal Cancer  (H N P C C )  and Turcot ' s 
Syndrome. Other  gastrointestinal syndromes such as Peutz-Jeghers  disease and 
familial juvenile polyposis have only a slightly increased risk o f  colon carcinoma 
development  compared to the normal population and will not be discussed.
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The study o f  families suggested that colorectal cancer often occurs  in families without  
a clear form o f  inheritance. Close relatives o f  patients with cancer were shown to 
develop cancer themselves at a higher frequency than the general population (Lovett ,  
1976). More  recently a study has estimated that first degree relatives o f  colorectal 
cancer  patients have a 2-3 fold increase in risk o f  developing the disease themselves 
(Burt et ah, 1985). However ,  in this study, when cancer cases alone were considered, 
no clear Mendel ian inheritance pat tern existed. Family members,  however ,  had a 
greater  number o f  adenomas than control populat ions and when cancers and 
adenomas were analysed together  an autosomal  dominant inheritance o f  susceptibility 
to adenoma formation emerged. Large numbers o f  kindreds exist either with single 
adenomas or family clusters o f  colon cancer. This suggests that genetic factors may 
determine susceptibility to either cancer or adenoma formation, whilst additional 
genetic or environmental factors determine which susceptible individuals become 
affected (Cannon-Albright et ah, 1988). The epithelial cell proliferative compartment  
shows a shift towards the luminal surface o f  colonic crypts in subjects with a st rong 
family history and this abnormal proliferation is also seen in both FPC and H N P C C  
(Gerdes et ah, 1993). Abnormal proliferation may also be seen in surrounding normal 
colorectal mucosa preceding neoplastic changes (Risio et ah, 1991).
1.51 Familial Polyposis Coli (FPC).
FPC has several characteristic features, including the appearance at a young  age 
(usually in the late teens/twenties) o f  numerous (100's to 1000's) adenomatous  polyps
lining the colorectal epithelium, an increased incidence o f  associated carcinomas (also 
at a correspondingly early age), and a known genetic origin (Bussey, 1990). 
Adenomas are usually distributed evenly around the colorectum or tend to the  left 
(distal) side and most patients will develop randomly sited carcinomas if a colectomy 
(removal o f  the colon) is not performed (Lynch et ah, 1991). A genet ic element has 
been established by the study o f  many family histories, the first o f  which was reported 
in a brother and sister in 1882 (Cripps, 1882). FPC is inherited in an autosomal 
dominant fashion with a high penetrance and is a predisposition to adenoma formation 
not carcinoma pci' sc. There is much reported variability within families in terms o f  
age o f  onset, number  and size o f  polyps and severity o f  disease. Extracolonic 
manifestations are also associated with FPC including desmoid tumours ,  thyroid, 
periampullary or duodenal cancer  and hepatoblastoma (Jagelman, 1987; Iwama et ah, 
1993; Garber  et ah, 1988). Polyposis accounts for only a small percentage (typically 
<1%) annually o f  colorectal cancers, but it provides a good model in which to study 
the progression o f  tumours and provides a f ramework in which to  study the more 
common sporadic tumours.  FPC allows the study o f  small adenomas usually not 
detected in patients with sporadic tumours  until carcinoma symptoms are present.  A 
locus linked to FPC was mapped to chromosome 5q21 by the study o f  a patient with 
both polyposis and mental retardation (Bodmer  et ah, 1987; Leppert  et ah, 1987). The 
genetic elements o f  FPC will be discussed later.
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1.52 Gardner's Syndrome.
This syndrome applies to FPC families with additional extracolonic features such as 
multiple osteomas in all parts o f  the skeleton, multiple epidermoid cysts, f ibromas o f  
the skin, dental abnormalities and desmoid tumours  o f  the abdomen and abdominal 
wall (Gardner 1951; Gardner  and Richards, 1953). An additional feature is abnormal 
retinal pigmentation termed C H R P E  (congenital hypert rophy o f  the retinal pigment  
epithelium) (Blair and Trempe, 1980). These are ocular lesions varying in size, 
configuration and distribution (Traboulsi  et al., 1990). Osteomas are generally benign, 
and Gardner's Syndrome (GS) associated desmoid tumours  do not metastasise. 
However ,  complications from desmoid tumours  are the second most  com mon  cause 
o f  death behind metastasis o f  the primary tumour in FPC (Boland et al., 1989). 
Previous abdominal surgery seems to predispose to desmoid tumour  format ion 
(Gurbuz et al., 1994). Gardner's syndrome has been linked to chromosome 5q21, the 
same locus as FPC (Herrera  et al., 1986).
1.53 Hereditary Non-Polyposis Colorectal Cancer (HNPCC).
H N P C C  accounts for 4-13% o f  colorectal cancers in Industrial countries. Unlike both 
FPC and Gardner's Syndrome multiple adenomas do not cover  the entire colon, but 
small clusters or isolated adenomas and carcinomas occur,  particularly in the right 
(proximal) and t ransverse colon (Lynch et al., 1993a). H N P C C  is classified as follows: 
Families in which at least 3 relatives in 2 generations,  one o f  which must  be a first 
degree relative of the other 2, are affected, with at least one diagnosis o f  colorectal
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cancer made at less than 50 years (Vasen et al., 1991). Tum ours  at o ther sites are 
common in H N P C C  patients, including the endometrium,  stomach,  and biliopancreatic 
and urinary tracts (Mecklin and Jarvinen, 1991).
1.54 Turcots's Syndrome.
This disease involves multiple adenomas o f  the colon in combinat ion with 
neuroepithelial central nervous system tumours  (Turcot  et ah, 1959). The most  
common tumour is glioblastoma. It has been postulated that Turcot 's  Syndrome is a 
pleiotropic, incompletely penetrant allelic variant o f  FPC and Gardner's syndrome 
with linkage to the FPC locus (Lewis et ah, 1983; Lasser et ah, 1994).
1.55 Hereditary Flat Adenoma Syndrome.
This is an autosomal  dominantly inherited predisposition to multiple colonic 
adenomas,  al though usually less than 100 in number. Adenomas are generally located 
in the proximal colon and are flat not polypoid. There is a st rong association with 
cancer which tends to be mainly right sided and a median- to- la te  age o f  onset o f  
adenoma formation o f  about 55 years (Lynch et ah, 1991). This syndrome is also 
linked to the 5q21 FPC locus and presents similar upper  gastrointestinal tract 
abnormalities to FPC. For example, cancer o f  the small intestine and fundic gland 
polyps o f  the stomach are commonly associated with Flat Adenoma Syndrome (Lynch 
et ah, 1993b)
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In summary,  many studies o f  colorectal cancer have revealed multiple variables  
in cancer formation.  There is evidence for an adenoma to carcinoma sequence,  
although it is probable that most adenomas never progress to carcinoma.  There  
is also evidence for colorectal carcinoma deve lopment without  a clear  
adenomatous precursor lesion. Finally, much evidence exists to suggest  both an 
environmental and genetic aspect  to colorectal cancer and hereditary forms of  
colon cancer have been described.
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Chapter 2 
The Genetic Changes Associated with Colorectal Cancer.
A widely held belief is that neoplasia is a result o f  activation o f  oncogenes,  coupled 
with the inactivation o f  tumour suppressor  genes.
Mutat ions in oncogenes tend to generate  dominant  growth  promoting phenotypes.  In 
contrast tumour suppressor genes usually follow Knudson's tw o  hit model  for 
inactivation with concomitant loss o f  function in a recessive manner (Knudson, 1985). 
Studies o f  allelic deletions in tumours  have often suggested the location o f  putative 
tumour suppressor  genes. One such study applied restriction fragment length 
polymorphisms (RFLP) analysis to study allelic losses in a series o f  colorectal cancers 
in what  was termed an allelotype (Vogelstein et al., 1989). 75% o f  the tumours  
showed loss o f  17p and 18q. 25-50% showed losses in lq,  4p, 5q, 6p, 6q, 8p, 9q, 18p 
and 22q. In most deletions the loss occurred in only one o f  the 2 chromoso me arms 
and therefore did not represent loss o f  the whole  chromosome.  Tumours  with multiple 
deletions had a poorer  prognosis than those with few deletions. Other  studies showed 
loss o f  heterozygosi ty (LOH) by RFLP in both FPC and sporadic tumours  on 
chromosomes 5, 14, 17, 18 and 22 (Sasaki et al., 1989; Monpezat  et al., 1988). 
Several oncogenes and tumour suppressor  genes have been shown to play a definite
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role in colorectal tumorigenesis, whilst at other  loci a correlation between L O H  and 
colorectal cancer is less well defined.
2.1 The short arm of chromosome 17
Greater  than 75% o f  colorectal carcinomas, but few adenomas show losses o f  17p 
(Vogelstein et ah, 1988). Loss o f  17p is therefore generally considered to be an event 
occurring around the adenoma to carcinoma conversion (Nigro et al., 1989). 
Polymorphic 17p markers detected a common region o f  deletion in colorectal cancers 
localising to 17p 13 (Baker et ah, 1989), a region previously shown to contain t h e p53  
gene (van Tuinen et ah, 1987).
2.11 The p53  gene
p53 was initially discovered due to its interaction with the SV40 large T antigen in 
transformed cells and, because large T antigen was required to maintain the 
t ransformed state, p53 was termed a tumour antigen (Lane and Crawford,  1979). 
Subsequently p53 was found in tumour and transformed cell lines whilst genomic and 
cD NA clones o f p53  were  found to immortalise cells in culture and could co-operate  
with the ias  oncogene to transform primary rat embryo fibroblasts. p53  was therefore 
called an oncogene (Jenkins et ah, 1984; Eliyahu et ah, 1984; Parada et ah, 1984). It 
was later discovered, however,  that these t ransforming clones o f  p53  were mutant  
(Hinds et ah, 1989). However,  wild type p53  has been shown to suppress the 
t ransformat ion o f  cells by other oncogenes,  the growth o f  t ransformed cells in culture,
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and the tumorigenicity o f  cells in animals. Additionally, wild type p53  alleles are 
commonly lost or  mutated in human tumours  (Finlay et ah, 1989; Eliyahu et ah, 1989; 
Baker  et ah, 1990a; Chen et ah, 1990; Baker  et ah, 1989). These characteristics have 
led to the classification o f  p53  as a tumour  suppressor.  Moreover ,  gain-of-function 
mutants o f p53  exist which can stimulate cell division even when in the heterozygous 
state (Halevy et ah, 1990; Dit tmer et ah, 1993; W o l f  et ah, 1984; Chen et ah, 1990).
The p53  gene encodes a 393 amino acid nuclear phosphoprotein  and several 
functional domains o f  the protein have been elucidated (Figure 1). An acidic N- 
terminus o f  the protein has transcriptional transactivational activity (Raycrof t et ah, 
1990; Fields and Jang, 1990; Farmer  et ah, 1992), whilst a sequence specific D N A  
binding region located in the central core  region o f  the protein has important 
functional significance (Kern et ah, 1991; Bargonett i  et ah, 1993; Pavletich et ah,
1993). p53 binds to p53 response elements in the D N A  o f  target  genes, and with 
nearby promoter  sequences, stimulates expression o f  target  genes in a p53 dependent 
manner (Farmer  et ah, 1992). A consensus site for p53 binding to D N A  has been 
described (El-Diery et ah, 1992). p53 can also negatively regulate some genes that  do 
not contain p53 response elements including R B I, PCNA IL-6 and p53  i tself 
(Santhanam et ah, 1991; Shiio et ah, 1992). The N-terminal transcriptional activation 
domain o f  wild type, but not mutant p53 can also bind to the T A T A  binding protein 
(TBP) which may suggest that p53 functions by regulating genes  involved in 
transcription either by direct interference with TBP or by blocking another factor from 
binding to TBP (Seto et ah, 1992).
A non-sequence specific DNA binding region o f  p53 is contained in the basic C- 
terminus o f  the protein, the sequence o f  which is predicted to form helical structures.
The C-terminus also contains regions necessary for nuclear localisation signals, single 
strand reannealing and protein tetramerisation (Shaulsky et al., 1990; Wang  et al., 
1993; Pavletich et ah, 1993).
Oncoproteins o f  some t ransforming D N A  viruses can bind to and inactivate wild type 
p53 function. These include the previously ment ioned SV40 T antigen, the adenovirus 
E1B protein and the Papilloma virus type 16 and 18 E6 protein (Sa rnow et ah, 1982; 
Werness et ah, 1990; Bargonet ti  et ah, 1991; Mietz  et ah, 1992). Cellular 
oncoproteins can also bind to p53. These include the M D M 2,  TBP and RepA  proteins 
(Momand et ah, 1992; Olson et ah, 1993: Seto et ah, 1992; Dut ta  et ah, 1993). 
Recent  studies have also discovered two more cellular p53 binding proteins 53BP1 
and 2, both o f  which bind to the central region o f  the p53 protein, which is also where 
SV40 T binds (Figure 1) (Iwabuchi et ah, 1994). The half-life o f  mutant  p53 can be 
altered by binding o f  p53 to the heat shock protein hsp70 (Finlay et ah, 1988).
Wild type p53  is believed to be involved in monitoring D N A  damage at various cell 
cycle checkpoints in a role that has been termed the "guardian o f  the genome" (Lane,
1992). The p53-dependent  response to D N A  damage can involve induction o f  a G1 
arrest o f  the cell cycle possibly to allow D N A  repair (Kuerbi tz et ah, 1992; Kastan et 
ah, 1991). Primary murine fibroblasts that lack p53 are deficient in, or fail to activate 
a G1 checkpoint in response to ionising radiation (Kastan et ah, 1992). Wild type p53 
levels rise transiently in the skin after UV irradiation, possibly to allow the repair o f  
specific UV induced mutat ions such as pyrimidine dimers (Hall et ah, 1993).
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Figure 1. The structural domains of  the p53 protein
L ocution o f  the  m a jo rity  o f  p53 po in t m u ta tio n s
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Structural domains on human p53 (based on Prives & Manfredi,  1993). The  shaded 
boxes containing roman numerals represent the 5 conserved domains o f  p53. The 
three nuclear localisation signals (NLS) are also shown. The mutational hot spots are 
identified by amino acid number ( e.g. HS175).  TBP is the T A T A  box binding protein.
Defects in this response to UV or ionising radiation can be seen in the cells o f  patients 
with the chromosome instability disorders o f  Ataxia Telangiectasia and Bloom's 
Syndrome (Kastan et ah, 1992; Lu and Lane, 1993).
p53 can also induce apoptosis in some cells and this response may depend on the 
physiological state and type o f  the cell (Yonish-Rouach et ah, 1993; Shaw et ah, 
1992; Slichenmyer et ah, 1993), p53 has been shown to be essential for the apoptotic  
response to IR (ionising radiation) in murine thymocytes (Clarke et ah, 1993, Lowe et 
ah, 1993a.)
Mutat ions  o f p53  have been detected in many types o f  human cancers including, lung, 
breast, liver, bladder colon and ovary and in chronic myelogenous leukaemia cells in 
blast crisis, usually at an advanced stage o f  neoplastic development  (Nigro et al., 
1989; Hollstein et al., 1991). In contrast,  studies on some oesophageal  and brain 
tumours have indicated that mutat ion o f p53  occurs  earlier in tumour development  at 
a pre-malignant stage (Bennet t et al., 1991; Sidransky et al., 1992). The  majority o f  
mutations are point mutat ions and are generally nrissense mutations that p roduce  a 
protein with an altered conformation,  stability and biochemical propert ies such as loss 
o f  DNA binding activity and associated transcriptional activation (Gannon et al,
1990). Greater  than 90% o f  the point mutat ions seen in tumours  are clustered 
between amino acids 130-290 in the central core region o f  the protein and localised to 
one o f  four phylogenetically conserved regions between amino acids 117-142, 171- 
181, 234-258 and 270-286 (Figure 1) (Levine et al., 1991; Soussi et al., 1990). 
Moreover,  there are at least three hotspots for mutation, at codons 175, 248 and 273. 
The majority o f  point mutations occur  in the sequence specific D N A  binding region o f  
the gene suggesting that this region is fundamental to the growth  suppressive effects 
o f  p53. The mutations themselves have different biochemical and biological propert ies 
which may be relevant in prognosis o f  patients with tumours  (Raycroft  et al., 1990; 
Fields and Jang, 1990). The frequency and distribution o f  mutat ions varies between 
tumour types perhaps reflecting differing cellular environments and cell specific 
selection pressures. The majority o f  mutat ions in both colon and gastric tumours  are 
G-A transitions at CpG dinucleotides; in breast tumours  by contrast,  G-T
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transversions are more common and rarely occur  at CpG  sites (Hollstein et al., 1991; 
Uchino et al., 1993). The majority o f p53  mutation are seen in tumours  with a loss o f  
17p. Consequently,  it has been proposed that point mutat ion o f  the gene is a rate 
limiting step and 17pLOH occurs after mutation, usually at the transition from benign 
to malignant neoplasm (Kikuchi-Yanoshi ta et al., 1992; Baker  et al., 1990a; Shaw et 
al., 1991). Additionally, germline mutat ions o f  the p53  gene are found between 
codons 245 and 258 in patients with the rare autosomal dominant  Li-Fraumeni 
Syndrome in which affected individuals develop a spectrum o f  tumours  at an early age 
(Li et al., 1988; Malkin et al., 1990; Srivastava et al., 1990).
It is o f  interest that the M D M 2  oncogene is overexpressed in some sarcomas in which 
there is no p53  mutation, and cervical cancers with H PV  16 and 18 also appear  to 
contain no m uta tedp53  (Oliner et al., 1992; Scheffner et al., 1990). This suggests that 
binding o f  cellular or viral oncoproteins is sufficient to destroy or abrogate  wild type 
p53  function without mutation o f  the p53  gene itself. In the case o f  the H P V  16 and 
18 E6 protein, this is in the form o f  degradat ion o f  p53 protein by the ubiquitin 
protease pathway (Scheffner et al., 1990). Mutant  p53 protein complexes with the 
heat shock protein hsp70 in the cytoplasm (Stiirzbecher et al., 1987) and it has been 
proposed that mutant protein may also complex with wild type protein thereby 
preventing wild type p53 from reaching the nucleus with concomitant loss o f  function, 
therefore representing a dominant  loss o f  function mutation. Additional evidence for 
this includes the obseivat ion that a large amount  o f  mutant  protein is required to
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transform cells in culture and similarly, experiments with temperature  sensitive 
mutants o f  p53  have shown that wild type protein protects cells from ras induced 
t ransformation whereas p53 in the mutant  conformat ion co-operates  to t ransform cells 
(Hinds et al., 1989; Martinez et al., 1991). The relative amounts o f  wild type to 
mutant  protein may be critical. Overexpression o f  wild type protein in cells also 
expressing mutant  p53 suppresses cell growth,  t ransformat ion and tumorigenici ty o f  
the cells (Finlay et al., 1989; Baker  et al., 1990b, Mart inez et al., 1991). Additionally 
mutant  p53 has been shown to gain new functions in experiments where it was placed 
in cells with no endogenous wild type protein. This resulted in an increased ability o f  
the cells to form tumours  in animals (Wol f  et al., 1984).
Further  evidence for a critical role for p53 in tumorigenesis is provided by murine 
models, in which mice have been created with no p53  protein. These animals are 
developmentally normal but die o f  multiple tumours,  particularly lymphomas,  at an 
early age (Donehower et al., 1992). Heterozygous animals also develop tumours  but 
the onset o f  development  is delayed compared to the null animals (Harvey et al.,
1993).
In summary,  the p53  gene has been shown to have growth suppressive  
properties and its mutated forms are frequently oncogenic.  Wi ld-type p53 has  
transcriptional transactivation and repression activity,  can bind DNA either  
specifically or non-specifically,  forms tetramers with itself and probably
functions in the control of  DNA damage  repair ei ther by creating a G1 arrest or 
inducing apoptosis.  Mutations in p53, especially in the conserved regions  
containing the sequence specific DNA binding domain,  are com m on in many  
tumour types. These mutations are usually missense and abrogate sequence  
specific DNA binding and transcriptional  transact ivation of  the protein,  
occurring commonly at the adenoma to carcinoma transition.
2,2 The long arm of chromosome 18
Deletions within the long arm o f  chromosome 18 occur  in 75% o f  colorectal 
carcinomas, 47% o f  large adenomas and less than 10% o f  small adenomas in both 
sporadic and FPC patients (Cho and Vogelstein,  1992; Fearon and Vogelstein,  1990; 
Miyaki et al., 1990). Panels o f  polymorphic probes detected common regions o f  
deletion to 18 q 2 1.3 and a gene, DCC  (for deleted in colon cancer ), was identified 
(Fearon et ah, 1989). It was shown to encode a membrane bound protein, the 
extracytoplasmic portion o f  which shows significant sequence homology to neural cell 
adhesion molecules and other  related cell surface glycoproteins in the immunoglobul in 
superfamily. This is o f  interest as changes in cell surface interactions have been 
implicated in abnormal colonic differentiation (a characteristic o f  neoplasia).  
Additionally, tumour cells lose cell/cell and cell/basement membrane contacts  and 
form inappropriate contacts during metastasis (Pignatelli and Bodmer,  1988). 
NIH3T3 cells expressing DCC  can stimulate neurite ou tg rowth o f  rat PC 12 cells 
when in cell/cell contact,  thus replacing the endogenous neural cell adhesion
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molecules (Pierceal et al., 1994). Relatively few somatic mutat ions o f  DC C have been 
described either in primary tumours,  cell lines or xenografts,  but those that have 
include point mutations in both introns and exons, a homozygous  deletion o f  the 5' 
end o f  the gene and 10 cases o f  small insertions within an 170bp fragment 
immediately downstream o f  an exon (Fearon et al., 1990; Clio et al., 1994). DCC  is 
expressed in most normal tissues but expression is greatly reduced in colorectal 
tumours,  especially liver metastases,  and loss o f  18q correlates with a poorer  
prognosis (Itoh et al., 1993, Kikuchi-Yanoshi ta et al., 1992; Jen et al., 1994). A study 
o f  318 primary tumours  with no loss o f  18q, revealed no amplifiable DCC  mRNA, 
suggesting that epigenetic inactivation o f  the gene can occur  as well as genetic 
inactivation (lino et al., 1994). The addition o f  antisense DCC  D N A  has been 
reported to be tumorigenic in Rat-1 cells (Narayan et al., 1992). Additionally, 
microfusion o f  chromosome 18 to cancer cells decreases tumorigenici ty (Tanaka  et 
al., 1991; Goyet te et al., 1992).
In summary,  the status of  18q correlates with prognosis and LOH of  18q is very  
common,  occurring in about 75% of colorectal tumours,  usually after malignant  
conversion.  The gene D C C  has sequence homology to neural cell adhesion  
molecules and although point mutations of  the gene are relatively un com m on,  
decreased mRNA expression is commonly  seen in colon tumours.
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2.3 The long arm of chromosome 5
Losses o f  the long arm o f  chromosome 5 occur  in up to 60 % of sporadic adenomas 
and carcinomas (Vogelstein et al., 1988; Solomon et ah, 1987; Ashton-Rickar t et al.,
1989) and the gene for FPC has also been mapped to this region (Bodmer  et al., 1987; 
Leppert et al., 1987; Meera-Khan et al., 1988). T w o  genes within 5q21, M C C  and 
APC  have been identified (Kinzler et ah, 1991a; Joslyn et ah, 1991; Kinzler et ah, 
1991b; Nishisho et ah, 1991; Groden et ah, 1991). Additionally, the tumorigenici ty o f  
colon cancer cells has been shown to be suppressed by the introduction o f  a normal 
chromosome 5 (Tanaka et ah, 1991; Goyet te  et ah, 1992). This provides evidence for 
the location o f  a tumour suppressor gene (or genes) within 5q21 which may be 
important in colorectal cancer.
2.31 The MCC gene
M CC  was the first gene identified within the region o f  5q21 commonly deleted in 
colorectal cancer by the discovery o f  a somatically rearranged restriction fragment  in 
the D N A  from a colon tumour (Kinzler et ah, 1991a). The  gene encodes an 829 
amino acid protein which shows sequence similarity to the region o f  the m3 
muscarinic acetylcholine receptor which specifies which G protein is involved in the 
acetylcholine stimulation o f  phospholipase C. This suggests that a possible function 
for M CC  may be to bind and inhibit some G proteins thereby inhibiting signalling 
through the calcium dependent phosphoinositide pathway,  a pathway that is mitogenic 
for some cells (Bourne et ah, 1991a). Analysis o f  the M CC  gene s tructure suggests a
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discontinuous pattern o f  coiled coil domains separated by hinge regions like those 
seen in intermediate filaments, which may indicate homo- or  hetero-dimerisat ion 
potential. The presence and distribution o f  heptad repeats within the gene suggest  an 
ability to form a  helices perhaps in a kink-and-rod model  (Bourne et al., 1991b). The 
M CC  gene is expressed in both rodent  and human colonic mucosa and disrupt ions to 
the gene have been identified in some colorectal tumours.  Many studies have 
identified losses in 5q21 involving the region including and surrounding MCC. Allele 
losses o f  5q have been identified in a variety o f  tumour types such as colon, lung, 
oesophagus,  breast, kidney, liver and stomach (Miki et ah, 1991; Ashton-Rickardt  et 
ah, 1989; D'Amico et ah, 1992; Boynton et ah, 1992; Thom pson  et ah, 1993; Mori ta  
et ah, 1991a and 1991b; Fujimoro et ah, 1991; Sano et ah, 1991). Losses o f  this 
region are also associated with dysplastic and cancerous ulcerative colitis (Greenwald 
et ah, 1992).
A somatic rearrangement found within 5q21, disrupted the coding region o f  the gene 
and an additional six somatic mutations were identified in M CC  in sporadic colon 
tumours: lour amino acid substitutions and two splice site alterations (Nishisho et ah, 
1991; Kinzler et ah, 1991a). The link between G proteins and colon cancer is 
strengthened by studies o f  the anticancer drug sulindac. Sulindac is a cyclooxygenase 
inhibitor and has been shown to cause the regression o f  benign tumours  in patients 
with FPC and GS (Waddell et ah, 1989; Labayle et ah, 1991). G proteins have been 
shown to regulate phospholipase 2A activity in the generat ion o f  arachidonic acid
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from phospholipids, a process requiring cyclooxygenase (Jelsema and Axelrod,  1987; 
Kurachi et al., 1989). M CC  was therefore considered to be an important gene in 
colorectal tumorigenesis and a candidate for the gene responsible for FPC.
However,  no germline mutations o f  M CC  have been found in FPC patients. 
Furthermore,  the discovery o f  another  gene close to M CC  on 5q21 termed APC  (see 
below) which is mutated in the germline o f  FPC patients has meant  that M C C  is no 
longer considered a candidate for the FPC gene. In a recent study from our  ow n 
laboratories o f  non-selected sporadic colorectal tumours,  it was shown that allele 
losses on 5q21 invariably involved both M CC  and A PC, neither gene being lost 
individually (Curtis el al 1994). In addition, in those cases which demonstrated L O H  
in M CC , no mutations o f  the remaining M CC  allele were found al though these would 
have been expected if M CC  were  a conventional oncosuppressor  gene disabled in 
both alleles in these tumours (Knudson 1985). Also, few mutations o f  M C C  in 
sporadic colorectal cancers have been identified, whereas  mutat ions o f  the APC  gene 
are common in both FPC and sporadic colorectal tumours.  The role o f  M C C  in 
colorectal cancer, therefore, remains uncertain.
2,32 TheAlPC gene
The second gene to be identified on 5q21 was found by studying the region o f  5q21 
linked to FPC. Linkage analysis had shown that 5q21 markers were tightly linked to 
the development o f  adenomas in many FPC kindreds (Bodmer  et al., 1987; Leppert et
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al., 1987; Dunlop et al., 1990; Meera-Khan et al., 1989). T w o  approaches were used 
to identify genes in this region o f  5 q 2 1. The first involved the use ot cosnud markers 
to the region to screen YAC libraries. Mapping experiments showed that the coding 
region o f  M CC  was outwith the region o f  deletion seen in a FPC kindred, suggest ing 
that another gene was responsible for the disease. The M C C  gene was then used to 
generate YAC clones to identify genes near M CC  that were involved in the deletion. 
Cross hybridisation studies followed by cD N A  walking identified a nucleot ide 
transcript and the gene was called APC  (for adenomatous polyposis coli) (Kinzler et 
a!., 1991b). The second approach involved the characterisation o f  nested deletions in 
FPC patients. This study yielded three genes in the deleted region. M CC  was again 
shown to be outside the region o f  deletion. One o f  the genes  termed DP2.5 was 
shown to be the same as APC  (Joslyn et al., 1991).
The gene was shown to encode a large 2843 amino acid protein with coiled coil 
regions in the N terminus and one other coiled coil region in the central portion. The 
presence o f  these heptad repeats like those observed in M CC  suggested the format ion 
of a  helices and the first 55 amino acids o f  APC have been shown to be sufficient to 
form stable parallel dimers suggesting that APC may form dimers with itself (Joslyn et 
al., 1993). Local similarities to myosins, intermediate filament proteins such as desmin 
and vimentin were found. Database searches also identified homology to the ral2 yeast 
protein implicated in regulation of ras and, like MCC, the m3 muscarinic acetylcholine 
receptor. The genomic structure o f  APC  was identified and shown to have an
unusually large fifteenth exon. (Kinzler et al., 1991b; Groden et al., 1991). Reverse  
t ranscription PCR (RT-PCR) showed that APC  was expressed in normal colonic 
mucosa, a variety o f  other human tissues, both foetal and adult, and also in cell lines 
from both sporadic and FPC tumours  (Kinzler et al., 1991b). Wild type APC  has been 
localised by antibody staining throughout  the cytoplasm and colocalised with 
microtubules. Staining is more intense in the basolateral margins o f  epithelial cells and 
increases in the upper  portions o f  the crypt, suggest ing an increase in expression o f  
APC  with maturation o f  the cell By contrast mutant  APC  presents as a diffuse 
cytoplasmic stain (Smith et al., 1993; Smith et ah, 1994). Immunoprécipi tat ion 
experiments revealed that APC  associates with P-catenin (Rubinfeld et ah, 1993; Su et 
ah, 1993a). P-catenin is involved in adherens junct ions which mediate cell adhesion 
and may be responsible for the contact inhibition signal. P-catenin also shows 
homology to plakoglobin and the Drosophila armadillo protein which is thought  to. 
be part o f  the signalling pathway for the cell/cell signalling protein Wingless (McCrea  
et ah, 1991). The binding o f  APC  to catenins may regulate transmission o f  the contact  
inhibition signal. Loss of contact inhibition and the forming o f  inappropriate cell/cell 
adhesions are characteristics o f  neoplastic cells.
Once the gene had been found, its involvement in FPC was established by the 
identification o f  mutations in the germline o f  FPC patients (Nishisho et ah, 1991; 
Groden et ah, 1991). Both RNase protect ion assays and SSCP (single strand 
conformational polymorphism) analysis identified mutat ions in the germline o f  both
FPC and Gardner's Syndrome patients. The APC  gene was therefore considered to be 
the gene responsible for FPC. The majority of mutations produced t runcating stop 
codons. Additionally several somatic t runcating mutat ions were identified in sporadic 
tumours some o f  which had no loss o f  5q21 (Nishisho et al., 1991; Groden et al.,
1991). Many studies have since identified APC  mutat ions in adenomas and carcinomas 
o f  both FPC and sporadic colorectal tumours.  One study showed 67 % o f  FPC 
patients had germline mutations in APC  with 68% o f  these clustered in the 5' half o f  
exon 15 (Miyoshi et al., 1992a). The remaining 23% cases without  apparent  APC  
mutation were provisionally explained as due to lack o f  sensitivity in detect ion and 
mutations occurring in regions o f  the gene not studied. The majority o f  mutat ions 
discovered in APC  result in a predicted truncated protein product either by nucleotide 
substitutions creating stop codons, or small deletions leading to frameshifts. Most  
mutations occur at CpG  or CpA dinucleotides in both germline and somatic 
mutations. The frequency o f  point mutations and frameshifts is similar for both 
germline and somatic mutations. Greater  than 60% o f  somatic mutat ions o f  APC  are 
clustered in a region of exon 15 (codons 1286-1513) that accounts for less than 10% 
o f  the coding region and which has been termed the M C R  (for mutation cluster 
region) (Miyoshi et al., 1992b). Two small deletions account for 15-20% o f  
mutations seen in APC  in FPC and sporadic tumours  (Groden et al., 1993). One o f  
these mutations is in a tandem repeat A A A A G  which creates a frameshift and 
subsequent truncation. The repeat may be a target for deletion by polymerase slippage 
during replication or unequal sister chromatid exchange (Miyoshi et al., 1992a;
Varesco et al., 1993; Ichii et al 1993). Variations were found in adenoma density, 
size, distribution, age o f  onset and extracolonic manifestations in patients with this 
same A PC  mutation. Additionally carcinomas were shown to occur  in the proximal 
colon as well as the more usual rectosigmoid colon. Therefore  this mutation at codon 
1309 accounts for intra- and interfamilial phenotypic variation. Additionally identical 
mutations were observed with variable phenotype in FPC patients (Paul et al., 1993), 
This suggests the involvement o f  other factors either genetic or  epigenetic that 
influence the disease phenotype. Interestingly, an identical mutat ion o f  a C-T at codon 
302 caused Gardner's Syndrome in one patient but no evidence o f  extracolonic 
abnormalities was seen in another patient (Paul et al., 1993), Somatic mutat ions in 
adenomas from FPC patients were shown to cluster in small regions o f  within 15bp o f  
codon 1490 and within 24 bp o f  codon 1429. This clustering may represent  regions o f  
differing carcinogen sensitivity within the colon and evidence for this is provided by 
the study o f  APC  mutations in gastric cancers which show a different spectrum and 
distribution ol mutat ions compared to colon tumours.  Alternatively the germline 
mutation may affect the normal copy o f  the gene by 'directing' the second hit, or the 
nuclear location o f  the APC  gene may be fixed, thereby 'fixing' the regions exposed to 
carcinogen (Nakatsura  et al., 1992; Ichii et al., 1993).
An attenuated form ol FPC termed AAPC (for at tenuated adenomatous polyposis 
coli) is characterised by fewer adenomas than FPC but with a high rate o f  relatively 
eaily caicinoma formation. The AAPC locus has also been mapped to the FPC locus
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(Spirio et al., 1993). The APC  mutat ions identified were truncat ions like FPC but 
were close together  and more 5' than those seen in FPC but separated from the most 
5' FPC mutations by only lObp. This may represent a functional boundary between 
FPC and AAPC.
This less severe phenotype may be explained if mutant  APC  protein complexes with 
wild type in a dominant negative fashion. In this case the mutat ions in A A PC  may 
produce a protein incapable o f  binding to, or inactivating, the wild type copy o f  the 
protein. Evidence for this is provided by the finding that t runcated APC  associates 
with wild type APC in vivo (Su et al., 1993b), APC products  o f  less than 80kd are not 
seen (Smith et al., 1993) and that the first 55 amino acids are sufficient for homodimer 
formation (Joslyn et al., 1993). But this theory does not explain the large deletions o f  
APC  seen in FPC. Phenotypic variation due to the location o f  an APC  mutation is 
evident in FPC patients where mutations after exon 9 are often associated with 
CFLRPE (Olschwang et al., 1993).
The number  o f  polyps has also been linked to the location o f  germline mutat ions with 
profuse adenomas common in tumours with mutat ions within codons 1250-1464 
(Nagase et al., 1992). A recent study showed APC  mutat ion in 60 % o f  sporadic 
carcinomas and 63% o f  adenomas including very small polyps (5mm) therefore 
suggesting that APC  mutation is an early event in colorectal tumorigenesis.  Some 
studies suggest that the loss ol both copies ol the gene is necessary for adenoma
formation (Ichii et al., 1993). Other studies, however,  suggest  that adenomas may 
form even if a normal copy o f  APC  remains (Miyoshi et al., 1992b; de Benedet ti  et ah, 
1994; Miyaki et ah, 1990). This apparent  conflict remains unsolved.
Germline mutat ions o f  the APC  gene have been found in three cases o f  Turcot 's  
Syndrome (Mori et ah, 1994). Somatic mutat ions were also seen in the adenomas o f  
these patients but not in the CNS tumours  {APC  mutat ions have not been detected in 
sporadic CNS tumours).  This suggests that APC  is important in colorectal tumours  
but not the associated CNS tumours  which may suggest that Turcot 's  Syndrome is a 
random association between A PC  mutat ion and CNS tumours  and not an incompletely 
penetrant variation o f  FPC as previously reported.
Losses o f  APC  are not seen in adenomas from FPC patients but losses arise in the 
carcinomas o f  these patients with the same frequency as that seen in sporadic tumours 
(Vogelstein et ah, 1988; Sasaki et ah, 1989). The inherited mutation in the adenomas 
o f  FPC patients has led to 2 theories concerning the fact that mutat ion o f  one copy o f  
the gene is sufficient to allow adenoma formation. The first involves a threshold effect 
in which the wild type copy o f  APC  in adenomas produces  enough protein to maintain 
a non malignant phenotype (Bodmer et ah, 1987). The second theory is that the 
microenvironment  o f  the adenoma in the colonic crypts is important.  All cells in FPC 
patients will contain the mutation, therefore perhaps presenting less o f  an inhibitory 
effect on the adenoma development  than normal cells in the colon o f  an individual
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with a sporadic adenoma (Paraskeva and Williams 1990). Additionally, A PC  
mutations have also been seen in gastric cancers, especially well differentiated 
adenocarcinomas,  and early gastric adenomas (Nakatsura  et ah, 1992; Tamura  et ah,
1994).
A murine model  o f  FPC exists in the form o f  the min  (for multiple intestinal neoplasia) 
mouse (Moser  et ah, 1990). These mice have a nonsense mutation in the murine APC  
gene induced by the chemical carcinogen ENU (ethyl ni trosourea) which cosegregates 
with the disease phenotype (Su et ah, 1992). Heterozygous mice die at around day 
120 (dependent  on the genetic background)  from widespread anaemia, perhaps caused 
by the presence o f  multiple adenomas within the intestine. Homozygous min  mice die 
in iilero. There  is also evidence for an APC  modifier locus resulting in a decrease in 
the number  o f  adenomas and an increased lifespan in the mice (Moser  et ah, 1992).
In summary,  a region o f  chromosome 5 has been shown to be com mon ly  deleted  
in many  colorectal tumours of  both sporadic and inherited origin. Tw o  genes  
have been identified within the region of  loss. One, A P C  has been shown to be 
the gene for FPC and is also commonly mutated in sporadic  tumours as an early 
event.  A P C  has been shown to bind to proteins involved in cell/cell and  
cel l/basement membran e  adhesion and signalling. The  other gene, M C C  has 
been shown to be mutated in only a small num ber  of  sporadic  tumours and its 
role in colorectal tumorigensis is unclear.
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2.4 Chromosome 12, the K-Rcis oncogene
The ras genes comprise a large gene superfamily including H-ras , K-rcis and N-ras, 
encoding cytoplasmic membrane bound signal transduct ion proteins with GTPase 
activity. Single base pair mutat ions in either codon 12, 13 or 61 activate the gene and 
when mutated,  ras can t ransform immortal cells in culture and also co-opera te  with 
other genes to t ransform diploid primary cultured fibroblasts (reviewed in Bos 1989). 
Somatic mutat ions in codon 12 o f  K-ras occur  in 9% o f  sporadic adenomas greater  
than l c m  in diameter, 22% o f  adenomas l -2cm in diameter,  60 -75% o f  adenomas 
greater than 2cm and 50-65% o f  carcinomas but in only 7% o f  all FPC adenomas 
(Bos et al., 1987; Forrester  et ah, 1987; Farr et ah, 1988; Vogelstein et ah, 1988). In 
tumours  that contain both adenomatous tissue and cont iguous carcinoma,  the same 
mutat ion is present in carcinomatous tissue as in the adenoma,  therefore,  suggesting 
that ras gene mutat ions precede malignancy. This is analogous to the mutat ions 
observed in the H-ra.v gene in skin papillomas and malignant carcinomas chemically 
induced by dimethylbenzanthracene and tumour promoters  (Quintanilla et ah, 1986).
In summary,  the K-ras gene is commonly mutated as an early event  in colorectal  
tumorigenesis in one of  three codons 12, 13 or 61. Different mutations within  
these codons may relate to prognosis and survival.
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2.5 Chromosome 8
2.51 The c-myc gene
C-myc is the proto-oncogene  analogue o f  the avian retrovirus M C 2 9  v-myc gene. 
Elevated levels o f  the c-myc transcripts are seen in colorectal tumours  especially left 
sided cancers e.g. FPC and some sporadic tumours  (Rothberg et al., 1987, Sikora et 
al., 1987). However ,  the increase in c-myc has been associated with the increase in 
ornithine decarboxylase observed in colorectal tumours  and may therefore represent 
an increase in the number  o f  cycling cells rather than over-expression o f  c-myc itself 
(Calabretta et al., 1985).
2.52 8p
The short arm o f  chromosome 8 shows losses o f  2 regions, 8p23.2-22 and 8 p 2 1.3-
11.22 in 42%  o f  colorectal cancers and associated with clinicopathological stage 
(Fujiwara et al., 1993). This may indicate the presence o f  2 tumour suppressor  genes 
in this region. However  other studies indicate a similar region o f  loss but with no 
associated relationship to site or stage (Cunningham et al., 1993; Yaremko et al.,
1994). Losses o f  8p have also been identified in liver and lung tumours  (Emi et al.,
1992).
39
2.6 22q, lp , and 14q
Loss o f  the long arm o f  chromosome 22 is recorded in 20 -50%  o f  sporadic colorectal 
tumours  (Vogelstein et ah, 1989) and have been associated with lymph node 
metastases in sporadic tumours  (lino et ah, 1994).
42%  o f  sporadic colorectal carcinomas show a loss o f  lp  usually involving the region 
1 p35 and this frequency o f  loss is higher in metastases  (Leister et ah, 1990). 
Additionally, a series o f  cell lines derived from an adenoma removed from a FPC 
patient has genetic changes within this region (Williams et ah, 1993). This is intriguing 
as this region possibly corresponds to the region in the murine genome that contains a 
modifier o f  the murine APC  gene, Mom-1 for modifier o f  M in  (Dietrich et ah, 1993). 
53% o f  colorectal tumours have losses in 14q but no losses have been observed in 
adenomas. There  is a significant correlation between 14q loss and site, with tumours  
o f  the distal colorectum associated with M q L O H  (Y oung et ah, 1993).
In summary,  loci other than 17p, 18q and 5q are also sites for losses in colorectal  
cancers.  The role of  these other loci and genes within them is less well  
characterised than the previously described genes.
2.7 DNA Repair Enzymes and Genome Instability
Mutat ions  o f  genes involved in the replication and repair o f  D N A  damage have been 
suggested to be critical in tumorigenicity (Loeb et ah, 1974). Genet ic instability has 
been shown to predispose to cancer in diseases such as ataxia telangiectasia,
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xeroderma pigmentosum and Bloom's syndrome. This has lead to suggest ions that 
genes involved in DNA repair and replication may be targets for mutat ion themselves.
2.71 DNA polymerase P
Mutations in the catalytic domain o f  the D N A  repair gene D N A  po lymerase P have 
been identified in a small group o f  colorectal tumours  when compared  to normal 
tissue, placental tissue and blood controls (Wang et ah, 1992). This gene is involved 
in repair o f  chemically damaged DNA (Wang et ah, 1991).
HNPCC and instability
Recently, D N A  repair genes have been associated with H N P C C  as well as some 
cancers previously considered to be without an inherited predisposition.
2.72 2p
N o  linkage has been found between H N P C C  and any tumour suppressor  genes 
previously implicated in colorectal cancer. Linkage was shown however  to a 
microsatellite marker on chromosome 2 (Aal tonen et ah, 1993; Pel tomaki  et ah, 
1993a). Microsatellites are short repeated sequences scat tered throughout  the 
genome.  They are highly polymorphic between individuals and are therefore highly 
informative as markers for linkage studies. However ,  unlike loci containing 
established suppressor  genes such as APC, no losses o f  chromosome 2 were observed 
in either familial or sporadic tumours.  However ,  microsatellite D N A  at the
41
chromosome 2 marker  varied in length from tumour  to tumour,  often at [CA]n or 
[CAG]n sites and this variation was apparent  at o ther  sites studied. Another  group 
also reported microsatellite instability in colorectal tumours  (Thibodeau et ah, 1993). 
The fact that so many changes had been reported at many different sites made it highly 
unlikely that they had arisen independently and suggested a widespread infidelity in 
D N A  replication at microsatellite sites. This phenotype was termed R ER + (for 
replication error). 13% o f  sporadic tumours  were RER+,  and these tumours  had 
similar biological properties to familial RER+ cancers. They tended to be right-sided 
tumours and were all either diploid or near diploid (Aal tonen et ah, 1993). [CA]n 
shifts were studied on chromosomes 5q, 15q, 17p and 18q and all showed variation in 
length in 28% o f  tumours (Thibodeau et ah, 1993). These shifts also showed 
correlation with tumours  o f  the right side o f  the colon, were associated with an 
increased survival rate and inversely correlated with LO H  on 5q, 17p and 18q. The 
mutat ion rate o f  CA shifts was shown to be 100 times higher in a small number  o f  
R ER + tumour cell lines when compared to RER- cells consistent with the association 
o f  a defect in strand specific mismatch repair (Parsons et ah, 1993). The latter mutator  
phenotype has been postulated to be recessive and to represent loss o f  function o f  a 
protein involved in recognising or repairing simple repeat mismatches in D N A  
(Thibodeau et ah, 1993). Traditional cloning methods using polymorphic markers to 
2 p l 6  identified a region containing the H N P C C  locus (Fishel et ah, 1993). Another  
approach was also used to link mismatch repair and HNPCC.  The same region was 
cloned by virtue o f  its sequence homology to bacterial and yeast mismatch repair
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genes, the E.coli m ulS  and the S.cerevisicte M SH2  genes respectively (Leach et al.,
1993). M utS  has been shown to encode a protein that recognises mismatches and it 
has been proposed that replicative D N A  polymerases have a high slippage rate on 
simple repeat sequences, which are repaired by the mismatch repair machinery 
(Modrich et al., 1991; Kunkel 1993). Defects in this machinery could therefore be 
responsible for some o f  the high levels o f  instability seen in neoplasia. Germline 
mutat ions o f  the gene termed hMSH2 were  detected in H N P C C  kindreds and somatic 
mutat ions were also found in RER+ tumour  cells (Fishel et al., 1993). Additionally, 
microsatellite instability has been shown in sporadic gastric and endometrial  cancers 
which are characteristics o f  the H N PCC syndrome, but not lung, breast or testicular 
tumours  which have no association with H N P C C  (Peltomaki et al., 1993b).
2.73 3p
Recently a second gene involved in mismatch repair has been identified and shown to 
be located on the short arm o f  chromosome 3 (Papadopoulos  et al., 1994; Lindblom 
et al., 1993). This gene has shown homology to another mismatch repair protein, the 
homologue o f  the E.coli M ull, gene termed hM LH l. M ull, is thought to encode a 
protein that stabilises the MutS  protein and an endonuclease (the M utH  protein 
product).  Both studies identified mutations o f  hM LH l in H N P C C  patients. The 
replacement o f  chromosome 3 into colon cell lines with homozygous mutat ions in 
hM LH l  reduced mismatch repair and microsatellite instability (Koi et al., 1994).
T w o additional homologues o f  MutL  have since been identified, hPM Sl  and 2, 
located on chromosomes 2 and 7 respectively (Nicolaides et al., 1994). Inactivation o f  
any o f  the three MutL-related genes can result in HNPCC.  Microsatelli te instability 
has also been observed in other tumour  types such as oesophagus and chronic 
myelogenous leukaemia (Meltzer et ah, 1994; Wada  et ah, 1994; Horii et ah, 1994). )
In summary,  it has been suggested that mutations in several o f  the genes  
involved in DNA mismatch repair and replication may cause the genomic  
instability and high mutation rate observed in H N P C C  and some sporadic  
colorectal tumours,
2.8 DNA Hypomethylation
D N A  methylation is a covalent modification o f  the mammalian genome that occurs 
almost exclusively at CpG  dinucleotides and approximately 70% o f  cytosine bases are 
methylated in normal differentiating cells (Doerfler et ah, 1983). Changes in 
methylation occur  during normal differentiation and in primary tumours  (Feinberg et 
ah, 1988). Hypomethylat ion may predispose genes to expression and may inhibit 
chromosome condensat ion leading to mispairing and non-disjunction (Groudine et ah, 
1981; Harrison et ah, 1983). Hypomethylat ion is a characteristic o f  human colonic 
tumours  and often precedes malignancy. D N A  from colorectal adenomas and 
carcinomas is selectively hypomethylated to a similar degree when compared to 
normal tissue (Goelz et ah, 1985; Feinberg et ah, 1988).
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In summary,  there are a num ber  of  recognised com m on genetic  events  
implicated in the genesis o f  colorectal tumours involving both oncogenes  and  
tumour  suppressor genes. Some of  these such as mutation o f  the A P C  gene and  
ras oncogene are generally considered early events involved in adenoma  
formation and progression. Others,  including mutation and deletion o f  the p53  
and D CC  genes are more closely associated with adenom a to carcinoma  
transition and carcinoma progression. Recent  identification o f  errors in the  
genes control ling mismatch repair pathways has suggested a novel  mechanism  
for some colorectal tumour  development.  Whilst  many of  the genes involved in 
colorectal carcinogenesis are common to both sporadic  and inherited forms of  
the disease the way  the various gene products interact and function in disease  
progression is still unclear.
2.9 The Clinical Relevance of Genetic Abnormalities observed in 
Colorectal Cancer.
Many studies have attempted to relate specific genetic abnormalities to 
clinicopathological grade o f  tumour. This has lead to a certain level o f  confusion with 
some studies apparently contradicting others. However ,  there are general comparisons 
to be made between genetic lesions and tumour pathology al though the meaning o f  
these correlations is not always clear.
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Specific lesions have been related to specific situations. For example, losses o f  17p 
have been correlated with vascular invasion in one study (lino et al., 1994). This 
finding seems at odds with the previously reported role o f  p53  in the transition from 
adenoma to carcinoma (Nigro et ah, 1989). p53  mutat ions have also been shown to 
occur  in a small subset o f  adenomas regardless o f  size and whether  from sporadic or 
familial patients (Baker et ah, 1990b). Additionally, studies o f  p53 mutation in both 
the oesophagus and brain indicate that this is an "early" event in these tum our types 
(Bennett  et ah, 1991; Sidransky et ah, 1992). This suggests that whilst in the majority 
o f  colon tumours  loss o f  p53 function by mutat ion and LOH occurs during or  around 
the conversion to malignancy, in other  tumour  types and in a subset o f  colon tumours  
p53  mutation may occur  either prior to or post-malignant conversion. This may reflect 
different pathways in neoplastic progression and suggests that loss o f  p53 is a 
preferred "early" event in colorectal tumorigenesis,  but is not essential for malignant 
conversion. Mutations o f  p53  are often observed in the context  o f  a destabilised 
genome,  with D N A  amplifications and aneuploidy common (Yin et ah, 1992; 
Livingstone et ah, 1992). It is unclear, however,  whether it is the p53  mutat ion itself 
that causes the instability or whether the mutation allows the survival o f  cells with 
gross chromosomal changes that would normally be eliminated by p53-mediated 
control and which become progressively more unstable. An early loss o f  p53 function 
could render an adenoma genetically unstable and by removing a p53-induced block 
to malignant progression allow the accumulat ion o f  other  critical genet ic lesions 
involved in tumour progression. A study o f  colon cancer metastases showed that the
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presence o f  a mutant  p53 protein, regardless o f  whether a wild type protein was also 
present, correlated with lymphatic spread, whereas loss o f  the wild type allele (LOH)  
correlated to haematological spread and distant metastases (Goh et al., 1994). 
However ,  this does not prove that the p53 loss with or without concomitant  retention 
o f  the wild type allele, was causative o f  the metastatic behaviour  o f  the tumour.  In 
general it has been noticed that colorectal tumours  with p53  mutat ion are usually 
more aggressive and relate to a shorter survival (Yamaguchi et ah, 1992). This is, 
perhaps, consistent with the idea o f  widespread genomic instability, a l though not all 
studies agree with this idea. (Starzynska et ah, 1992; Hamelin et ah, 1994). Additional 
evidence for the increased instability potentially afforded by p53 mutat ion can be seen 
from studies that show p53  mutation more commonly in tumours  with 17p LOH. 
Further evidence comes from studies o f  familial breast cancer  (FBC). FBC has a 
higher association with p53  mutation than sporadic breast tumours.  FBC tumours  also 
show changes in number  o f  dinucleotide repeats on chromosome 17 suggest ing that 
D N A  replication and repair defects induced by p53  mutation may create instability at 
least in this tumour type (Glebov et ah, 1994).
The spectrum o f p53  mutat ions seen in different tumour types may reflect the differing 
cellular environments and responses to carcinogens. Thus the timing o f p53  mutat ion 
may simply be a reflection o f  the genetic background o f  the cell with respect to 
carcinogen sensitivity.
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A recent study suggests that tumours  with losses o f  18q may be associated with a 
poorer  survival rate than those with no 18q loss (Jen et al., 1994). The losses that 
generally occur  late in tumour  development  i.e. during malignant progression,  such as 
18q LO H  linked to liver metastases and 22q to lymph node metastases may reflect the 
ability o f  invading metastatic cells to implant at different sites (Itoh et ah, 1993; lino 
et ah, 1994). Another study suggests that changes in D CC  are related to  the degree o f  
lymph node metastasis and degree o f  differentiation in oesophageal squamous cell 
carcinoma (Miyake et ah, 1994). However ,  this could simply represent  t issue specific 
differences.
There  is also evidence for inactivation o f  A PC  leading to the accumulat ion o f  
mutat ions or abnormalities in other  genes and at other sites such as ras, p53  and 8p. 
In one study, the frequency o f  A PC  mutation observed in adenomas from FPC 
patients was the same regardless o f  size or histopathology but the frequency o f  K-ras 
mutation increased in adenomas with increasing dysplasia and size. Additionally, 17p 
and 8p losses are generally rare events in adenomas but common  in carcinomas (Ichii 
et ah, 1993). In contrast,  another study suggested that the frequency o f  APC  
mutat ions was higher in tubulovillous and villous adenomas than tubular adenomas,  
indicating a link with histological type (de Benedetti  et ah, 1994). A tendency was 
observed for the frequency o f  APC  mutations observed in colon tumours  to increase 
with increasing loss o f  differentiation. However,  in gastric tumours  APC  mutation 
occurs in well differentiated cancers (Nakasuru et ah, 1992; Miyaki et ah, 1990). This
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suggests that APC  abnormalities may occur  later in tumour progression in some 
sporadic colorectal cancers.
The question o f  APC involvement in all cases o f  colorectal tumours  is unclear. For 
example the literature is divided on whether both alleles o f  APC  need to be inactivated 
in the formation o f  adenomas or whether  disruption o f  one allele is sufficient. Some 
studies show some adenomas with one allele o f  APC  inactivated and other adenomas 
with both alleles disrupted (de Benedetti  et al., 1994). The quest ion also remains as to 
whether  mutat ions o f  APC  function as dominant negative mutat ions or  whether 
mutat ions result in reduced amounts o f  APC  protein perhaps below a threshold level 
required for normal function. I f  mutat ions in APC  function in a dominant negative 
manner,  adenomas with a mutation in only one allele may nonetheless have no or 
reduced APC function. Additional loci are very probably involved in the modification 
o f  APC in most  colorectal tumours.  This is evident in cases o f  FPC in which identical 
APC mutat ions result in differing phenotypes in different individuals.
The relevance o f  specific K-ras mutat ions is also unclear. A study by Shibata 
suggested that certain ras mutat ions present in adenomas may be more likely to cause 
progression to a carcinoma (Shibata et al., 1993). Other studies which have looked at 
the relevance o f  ras gene mutat ions have shown a high association between codon 12 
mutations and colorectal cancer and suggested that codon 12-val and codon 13-asp 
mutat ions are found in tumours  limited to the bowel  wall, whereas  other mutations,
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particularly codon 12-asp may be associated with metastasis (Finkelstein et al., 1993). 
In contrast,  in another  study, G-T and G-C transversions e.g. 12-ala and 12-val have 
been associated with Dukes C colorectal tumours  with metastases (Moerkerk  et ah,
1994). This recent study also identified multiple point mutat ions in codon  12 in some 
tumours  associated with increasing stage o f  the tumour.  Another  study however  has 
found no correlation between ras mutation and metastasis (Roehl itz et ah, 1993). 
Additionally it has been reported that codon 12 and 13 mutat ions except  12-asp are 
more common in patients with recurrent disease (Benhatter  et ah, 1993) and may be 
directly involved in tumour progression in a dominant  manner (Forrester  et ah, 1987). 
Ras mutat ions are less common in flat adenomas (typically only 16%) and no 
significant difference in mutation spectrum was seen between flat or  polypoid 
adenomas and carcinomas (Minamoto et ah, 1994). However ,  the correlation between 
ras mutat ions and clinicopathologica! variables remains unclear.
In general, sporadic tumours and those associated with FPC tend to be located in the 
distal and sigmoid colon and rectum (left sided), whereas tumours  associated with 
H N P C C  and flat adenoma syndrome tend to be located in the caecum and ascending 
colon (right sided). The basis o f  this site bias is unknown but may be related to 
differing concentrations o f  faeces and carcinogens as well as responses to gut 
carcinogens at different sites along the colon. Left and right sided cancers may have 
important clinical distinctions as they can differ in both mucus composi t ion and 
associated blood group antigens (Yonezawa et ah, 1982; Denk et ah, 1974). Losses o f
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5q 14q and 18q are more common in left sided tumours  (lino et al., 1994; Young  et 
al., 1993).
I f  it is accepted that a number  o f  carcinomas arise from pre-existing adenomas then a 
general model  for tumour progression may be proposed.
1. APC  mutat ion results in a.) the format ion o f  mutant /wild type heterodimers
and b.) Probable adenoma formation.
2. LO H  \n\APC  and K-ras mutation result in the progression to a moderately 
or severely dysplastic adenoma.
3. LO H  17p leads to the format ion o f  intramucosal carcinomas.
4. LO H  18/22q results in invasive carcinomas
This model suggests that LO H  increases with increasing dysplasia (Miyaki et al.,
1990) and is consistent with the model proposed by Fearon and Vogelstein (Fearon 
and Vogelstein,  1990). How eve r  whilst this model may account  for perhaps the 
majority o f  colorectal cancers, evidence presented earlier shows that situations arise in 
which this model is not applicable.
A novel mechanism for colorectal tumorigenesis is evident in colorectal cancers from 
H N P C C  families, in which a relatively normal karyotype o f  diploid or near-diploid is 
commonly observed (Kouri et al., 1990). Sporadic R ER + tumours  have less 
chromosome losses and p53  mutation than sporadic RER- tumours,  in contrast  to the 
familial breast tumour data presented earlier (Thibodeau et al., 1993; Aal tonen et al.,
1993: Glebov et al., 1994). Cells in adenomas are usually diploid or  near-diploid
whereas those o f  most  colorectal carcinomas contain aneuploid subclones.
Aneuploidy increases with size and histopathological type o f  adenoma but  not 
dysplasia (Quirke et al., 1987; Hiddemann et al., 1986; Jarvis et al., 1987). A 
decreased incidence o f  aneuploidy is observed in cases o f  adenocarcinoma in 
association with adenoma compared with colorectal cancer  in general.  p53  mutat ion 
has been shown to precede and possibly initiate the divergence o f  aneuploid subclones 
in colorectal tumours  (Carder et al., 1993; Carder  et al., 1994). Cells with abnormal  
p53  are at a higher risk o f  replication o f  the entire genome prior to complet ion o f  cell 
division, leading to tetraploidy via endoredupl icat ion (Carder et al., 1993). This
suggests at least 2 ways to generate  the genetic heterogenei ty that is observed in
colorectal neoplasia. The first involving gross chromosomal changes and losses 
leading to a highly aneuploid phenotype,  involves p53 in the generation and 
maintenance o f  the instability. This suggests that only cells that have lost p53 remain 
viable due to the otherwise catastrophic effects o f  such widespread genet ic damage. 
This model is possibly that seen in FPC and some sporadic tumours.  The second 
pathway involves small multiple changes throughout the genome created by errors in 
mismatch repair, whilst retaining a diploid or near diploid karyotype-l ike tumour 
observed in H N P C C  families and some sporadic cases.
In summary,  many of  the genetic abnormalities  associated with colorectal  
tumorigenesis have been correlated with clinicopathological  variables.  There is
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still however much confusion in the l iterature regarding the role some of  these  
lesions play in carcinogenesis.  Some of  the questions raised above  will be 
addressed in the fol lowing chapters,  including the role o f  M C C  in colorectal  
neoplasia,  and the effect A P C  mutation as an early event  plays in colorectal  
cancer progression.  Addit ional ly ,  the relationship between mutation o f  the p53  
gene and stabilisation o f  the protein will be studied.
Chanter 3
The relationship between p53  mutation and protein 
stabilisation in colorectal carcinomas.
3.1 Introduction
In normal cells, p53 protein is expressed at a low level and has a short half-life (6 
minutes in the spleen, Rogel et al. 1985). A change in molecular configuration may 
lead to stabilisation o f  the protein so that its half life is greatly extended, thereby 
allowing detection by immunocytochemistry (ICC). A number o f  human and murine 
antibodies to p53 exist, some o f  which identify both wild type and mutant 
configurations, whilst at least one antibody is specific for the mutant conformation 
alone. (Jenkins et al. 1985; Gannon et al., 1990). These antibodies have been applied 
to both W estern analysis and Immunoprécipitation studies o f  p53. Their use in 
distinguishing between mutant and wild type protein on denatured, fixed sections in 
ICC is, however, not so certain. Many studies have shown the presence o f  stabilised 
mutant p53 protein in different tum our types by immunocytochemistry (Cattoretti et 
al., 1988; Bârtek et al., 1990; Iggo et al., 1990; Van den Berg et al., 1989; Rodrigues 
et al., 1990; M arks et al., 1991; Gusterson et al., 1991; Purdie et al., 1991). M any o f  
the tumour-associated missense mutations in p53  occur in cases with stabilised protein 
and it has often been assumed that stabilised p53 visualised by ICC is equivalent to 
mutated p53. Recently however, it has become clear that the association between
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stabilisation o f  the protein and mutation o f  the gene is far from absolute (W ynford-
Thomas, 1992). Both false negatives and positives have been reported Gross
deletions or nonsense mutations may alter translation o f  the protein, although
truncating mutations are rare except in some sarcomas. Alternatively point mutations 
may fail to  stabilise the protein to a level detectable by ICC and may or may not still 
retain some normal function, both o f  which result in a false negative (Borresen et al., 
1991; Rodrigues et al., 1990). False positives have been identified in clonal cell lines 
on which the argument that insensitivity o f  the mutation detection technique fails to 
locate a mutation are inappropriate (Rodrigues et al., 1990; Lehman et al., 1991). The 
relationship between mutation and stabilisation may reflect both the type o f  mutation 
and the nature o f  the cell in which it occurred. A study o f  p53  in 33 lung cancer cell 
lines with no normal p53  revealed a correlation between missense mutations in exons 
5-8 o f  the gene and strong overexpression o f  the protein, whilst a low expression o f  
protein correlated with deletion, splicing or nonsense mutations as well as missense 
mutations outside exons 5-8 (Bodner et al., 1992). Conversely, not all p53  mutations 
result in a stabilised protein product. For example, Li-Fraumeni patients carry
germline p53  mutations yet mutant protein is detectable in only a proportion  o f  cases 
(Frebourg et al., 1992). Not all stabilised protein is mutated. Wild type p53  protein 
levels rise after D NA  damage as the natural response to agents such as UV irradiation 
and the protein assumes a stable configuration detectable by ICC (Hall et al., 1993). 
Some cancer family patients express stabilised wild type p53  protein in a substantial 
proportion o f  their cells (Barnes et al., 1992). An enzyme-linked immunoassay has
recently shown that p53  stabilisation occurs in some colorectal adenom as in the 
absence o f  mutation but not in surrounding normal mucosa (Tom inaga et al , 1993). 
This p53  protein is not in the mutant conformation and may be located within the 
cytoplasm. This may suggest the presence o f  a subset o f  colorectal tum ours in which 
loss o f p53  function, perhaps due to retention within the cytoplasm, occurs as an early 
event. A study o f  p53  staining in breast cancers revealed cytoplasmic staining o f  wild- 
type p53  protein in 37%  o f  cases, suggesting that nuclear exclusion may be a further 
mechanism in the inactivation o f  p53  tum our suppressor activity in some tum ours 
(Moll et ah, 1992). Finally there is evidence to suggest that wild type p53  protein can 
be stabilised through the activation o f  other genes already implicated in cancer, such 
as c-myc and ras. Under these circumstances, wild type p53 function may be 
abrogated without mutation o f  the gene (Lu et ah, 1992). Recently it has been 
suggested that the tum our cell environment may impose a stable configuration on wild 
type protein, perhaps causing the loss o f  its normal grow th  regulatory responses 
(Vojtesek and Lane, 1993).
This study has attempted to determine the frequency with which m utation and 
stabilisation occur in colorectal tumours. There are particular reasons for s tudy ingp53  
in colorectal cancer in this way.
Firstly it has been shown that the presence o f  stabilised p53  correlates with a 
particular class o f  cancers in which there are multiple divergent, near-tetraploid
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tum our cell clones and the suggestion has been made that such abnormal p53  may 
facilitate endoreduplicative events leading to aneuploidy (C arder et ah, 1993). 
Secondly, there are interesting comparisons to be made between primary cancers o f  
the colorectum and at other sites. Existing evidence suggests that p53  can be involved 
in carcinogenesis in different ways. Thus, both colorectal and breast cancer show 
frequent stabilisation, but point mutation frequency in breast cancer is relatively low, 
commonly 20-38%  (Bartek et ah, 1991; Dunn et ah, 1993; Jacquem ier et ah, 1994) 
whilst in existing series o f  colorectal cases, the incidence o f  p53  point m utations is 
greater than 50% (Rodrigues et ah, 1990; Nigro et ah, 1989). Overexpression o f  p53 
protein without mutation in high grade non-Hodgkin 's lymphomas has also been 
demonstrated (Villuendas et ah, 1993).
Thirdly, p53 ICC in colorectal tumours, as in other cancers, shows a variety o f  
staining patterns. In some, staining is intense and affects the majority o f  nuclei (often 
associated with mutation) (Rodrigues et ah, 1990; Baas et ah, 1994), in o thers it is 
widespread but involves fewer nuclei (Lu et ah, 1992), and in some there is only focal 
staining that may affect a very low proportion o f  nuclei (often not associated with 
mutation and may represent a focal response to local DNA damage) (Vojtesek et ah, 
1993; Baas et ah, 1994; Fritsche et ah, 1993). Alternatively, the presence o f  sporadic 
staining nuclei may represent the emergence o f  new clones within the tum our and this 
has been seen within adenomas (Kikuchi-Yanoshita et ah, 1992). W idespread staining 
involving few nuclei is also seen with wild type p53  (Bartek et ah, 1990; Midgley et 
ah, 1992; Casey et ah, 1991; Gannon et ah, 1990). High p53 expression also
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correlates with cells showing abnormal cell cycle control and mitotic failure, 
suggesting that carcinoma cells may well have high levels o f  genom e instability (Lu et 
al., 1992; Kastan et ah, 1991). Different patterns o f  staining probably represent a 
different biological basis for the expression o f p53  protein.
In an attem pt to resolve some o f  these questions, 47 colorectal carcinomas, originally 
classified as positive or negative dependent on staining with the p53 monoclonal 
antibody PA blSO l (Purdie et ah, 1991; Carder et ah, 1993), were examined. 
M utations w ere defined in ICC positive cases by sequencing through exons 5-8, the 
region in which over 90%  o f  all p53  mutations have been shown to occur in previous 
studies (Levine et ah, 1991). A method for screening for mutations using PC R -SSC P 
and an M spI restriction enzyme digest was than validated with ICC positive cases and 
applied to ICC negative cases. Finally, the 47 cases were re-examined with a second 
antibody, D 0 7 ,  under conditions which were more sensitive in detecting stabilised 
p53. M utations outside exons 5-8 were sought. In the few cases with consistent, 
strongly positive nuclear staining with both antibodies but no evidence o f  mutation 
within exons 5-8, sequence data were determined for the remainder o f  the gene The 
combined data support a strong relationship between stability and mutation, but 
highlight specific situations where stability and mutation are not concordant.
Figure 2. PAbl801/im m unoperoxidase detection of p53 in colorectal 
carcinoma specimens.
a.) Immunocytochemically negative colorectal carcinoma.
b.) Immunocytochemically positive colorectal carcinoma. Nuclear staining o f  p53 
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Figure 3. Sequence analysis of exon 7 of the p53 tumour suppressor  
gene in colorectal tumours.
a.) Sequence analysis o f  exon 7 o f  p53 in tum our T14 showing a C G G -T G G  
(Arginine to  Tryptophan) mutation at codon 248.
b.) Sequence analysis o f  exon 7 o f  p53 in tum our T15 showing a C G G -T G G  
(Arginine to Tryptophan) mutation at codon 248.
c.) Sequence analysis o f  exon 7 o f  p53 in tum our T16 showing a C G G -T G G  
(Arginine to Tryptophan) mutation at codon 248.
d.) Sequence analysis o f  exon 7 o f  p53 in tum our T4 showing a C G G -C A G  
(Arginine to Glutamine) mutation at codon 248.
The presence o f  bands indicating the wildtype sequence reflects contaminating stromal 




Figure 4. Sequence analysis of exon 5 of the p53 tumour suppressor  
gene in colorectal tumours.
a.) Sequence analysis o f  exon o f  p53 in tum our T2 showing a C G C -C A C  
(Arginine to Histidine) mutation at codon 175.
b.) Sequence analysis o f  exon o f  p53 in tum our T6 showing a C A T -T A T  
















3.21 Mutation analysis of PAbl801 positive tumours
Paraffin sections o f  47 colorectal carcinomas fixed in PLPD  and previously identified 
as either im munocytochemistry positive or negative (ICC+ or ICC-), were restained 
with the antibody PA blSO l as previously described (Purdie et ah, 1991)(Figure 2). In 
this analysis a tum our w as classified as ICC positive if any  nuclear staining was 
observed within the section and so included all 3 staining patterns previously 
described. Positive staining was observed in 27 o f  the tumours. Sequencing o f  exons 
5-8 o f  the p53  gene in these cases revealed 19 mutations in 18 (67%) o f  the tum ours 
(Table 1 and Figures 3 and 4). Interestingly, one case, (T4), contained 2 different 
mutations, C G C —>CAC in codon 175 and C G G —̂ CAG in codon 248. T4 had no 17p 
allele loss detectable using a number o f  polymorphic markers (data not shown) and 
therefore the tw o mutations were presumed to be in different alleles. T w o mutations 
in the same gene are rare but have been previously reported in the literature. The 
majority o f  mutations (12/19) clustered within 2 recognised hotspots at codons 175 
and 248 (Hollstein et ah, 1991).
In one case, (T8), a mutation was found at an exon/intron boundary (G —>A o f  the first 
base o f  intron 5), whilst in another, (T12), a conservative base change at codon 227 
was detected. O f  19 mutations, 17 were either C —>T or G —»A transitions, 13 
occurring at C pG  dinucleotides. The remaining 2 cases were a G —>T and a T —>G
transversion. The nature o f  these mutations is therefore in agreement with the 
published literature in which the majority o f  p53  mutations in colorectal cancer are 
base pair transitions occurring at CpG dinucleotides within recognised hotspots 
(Hollstein et al., 1991). O f  the 27 tumours with stabilised p53, 9 (33% ) did not 
contain a m utation within exons 5-8. In order to determine whether this was due to 
the presence o f  mutations outwith exons 5-8, the entire coding region was sequenced 
in the 3 tum ours showing the strongest staining o f  the majority o f  nuclei with 
P A b l8 0 1 .  These w ere considered to be the most likely to contain mutation o f  the 
gene. A mutation in exon 4 was detected in one o f  the tum ours resulting in a 
phenylalanine to serine amino acid change at codon 113 (data not shown). M utations 
in exon 4 and 9 o f  the p53  gene have previously been reported in the literature and 
therefore exons 4 and 9 were sequenced in the remaining 6 ICC+ cases but no further 
mutations were found. Therefore 8/27 (30%) cases with positive PA bl801  
immunocytochemistry appear to have no mutation at least within the regions studied 
which comprise the most commonly mutated regions.
3.22 PCR-SSCP/M spI screening for mutations in PAM 801 positive 
tumours
R ather than search for mutations in all the PAblSOl negative cases by sequencing, a 
more rapid but accurate screening method based upon SSCP of exons 5-8 was 
developed. This method derived from that o f  Orita et al., 1988 but did not use 
radioactive isotope. The basis o f  SSCP analysis is that, upon electrophoresis o f  single
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stranded D N A  through a non-denaturing gel, the D NA  will adopt a secondary 
conformation dependent upon its base sequence. M utation o f  even a single base can 
alter the secondary structure and in a proportion o f  cases allow their detection by 
comparison o f  abnormally migrating D N A  bands and corresponding 'normal' samples. 
In this experiment PC R  products were not radiolabelled and the D N A was visualised 
in the gel by a silver staining technique. To validate the method it was first applied to 
the PA bl801  positive tum ours where the sequence within exons 5-8 was known. 
13/19 (68% ) o f  the sequence-detected mutations revealed an abnormal band migration 
pattern under standard SSCP condition, whilst 6 mutations were not detectable by this 
method (Figure 5). One o f  these was the exon/intron boundary mutation in tum our 
T8, which would have been masked by the PCR primers used to amplify exon 5 for 
SSCP analysis. The conservative base change at codon 227 was also undetectable as 
an SSCP. The remaining 4 cases were all codon 248 C G G —>CAG mutations. SSCP 
analysis w as repeated under different conditions o f  4 °C  in the absence o f  glycerol, but 
no further mutations were detected. In order to extend this screening method to 
include reliable detection o f  the common codon 248 mutations, a PC R  fragment 
containing exons 7-9 w as digested with the restriction enzyme Mspl. Disruption o f  
the C C G G  M spl recognition site at codon 248 by mutation resulted in the loss o f  
135bp and 168bp bands and addition o f  a 303bp band (Figure 6). The combination o f  
SSCP and M spl digestion detected 89% o f  mutations known to exist in exons 5-8 on 
the basis o f  sequencing. Moreover, all SSCP abnormalities were confirmed as 
mutations; that is, there were no false positives.
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Figure 5. Single Strand Conformational Polymorphism analysis of  
exons 5, 7 and 8 o f  the p53 gene amplified by the 
polymerase chain reaction in immunocytochemically  
positive colorectal tumours.
In each pair o f  lanes, normal D N A  (on left) is compared with tum our D N A  from the 
same patient (on right). M utations detectable as bands o f  altered mobilities are
marked by arrows.
Lanes 1 and 2 T um our T22: Exon 8
Lanes 3 and 4 T um our T19: Exon 7
Lanes 5 and 6 T um our T 17: Exon 7
Lanes 7 and 8 T um our T4: Exon 7.
Lanes 9 and 10 T um our T4: Exon 5.
Lanes 11 and 12 T um our T3: Exon 5.
Lane 13 D N A  marker V (Boehringer Mannheim)
! 2 3 4 5 6 7 8 9 10 11 12 13
’4 -= =  h-
Figure 6. Agarose gel o f MspI digested exons 7-9 PCR amplified  
DNA identifying exon 7 codon 248 mutations of p53.
0.8%  agarose gel stained with ethidium bromide
Lanes 1 and 2 Normal D N A  sample and corresponding tum our T4
Lanes 3 and 4 Normal D N A  sample and corresponding tum our T19.
Lanes 5 and 6 Norm al D N A  sample and corresponding tum our T15.
Lane 7 and 8 Normal D N A  sample and corresponding tum our T 13.
Lane 9 D N A  M arker VI (Boehringer Mannheim)
Tum ours T4 and T19 contained G-A mutations at codon 248 which w ere 
undetectable as bands o f  altered mobility on SSCP analysis. In contrast tum our T15 
contained a C-T mutation at codon 248 that was detectable by SSCP analysis. 
M utation at codon 248 disrupts a M spI restriction digest site observed as an extra 
band o f  303 base pairs on digestion o f  a PC R  fragment containing exons 7-9 o f  the 
p53 gene with MspI. Contaminating normal D N A  in tum our sample T4 is identified 
by the retention o f  135 and 168 base pair bands which are identifiable in all the normal 
D N A  samples presented. T um our T13 contained a mutation at codon 245 and hence 
did not reveal the loss o f  an MspI site at codon 248. The constant bands at 
approximately 280 and 290bp are due to the presence o f  two internal M spI restriction 
enzyme sites unaffected by the presence or absense o f  a mutation at codon 248.
N-normal D N A  sample. 
T -tum our D N A  sample.

3.23 Screening for mutations in PAbl801 negative tumours
O f  the 47 tum ours studied, 20 were classified as ICC negative. In these, no PA bl801  
staining w as seen within the section (Figure 2). Nonetheless, when these tum ours 
w ere  studied by the SSCP/M spI screening method, 4 tum ours (20% ) showed an 
abnormal SSCP band pattern when compared to the corresponding normal sample 
(Figure 7). These abnormalities w ere confirmed by sequencing. One o f  the mutations 
w as at codon 175 within exon 5, whilst the remaining 3 were all in exon 6 at codons 
202, 203 and 213. In contrast, no exon 6 mutations were found amongst the P A bl801  
positive cases (Table 1).
3.24 DO-7 and CM-1 Immunocytochemistry
It w as possible that failure to identify stabilised product in the presence o f  mutated 
p53  merely reflected the sensitivity o f  the method o f  staining. To address this, the 
sections w ere  restained under optimised conditions o f  microwave pre-treatment with 
the human p53  specific murine monoclonal antibody DO-7 (Cattoretti et al., 1993). 
Both  PA blSO l and D O -7 showed similar patterns o f  staining with the 3 classes o f  
staining pattern discussed above being readily discernible (data not shown). Although 
microwave pre-treatm ent and DO-7 staining produced fewer negative cases than 
PA blSO l (9 versus 20), the 4 PAblSOl negative cases with mutation w ere also all 
clearly negative with DO-7. The epitopes recognised by PAblSOl and DO-7 are both 
within the N-terminal domain o f p53  (Banks et ah, 1986; Vojtesek et ah, 1992) and it
62
Figure 7. Single Strand Conformational Polymorphism analysis of  
exons 5, 6, 7 and 8 of the p53 gene amplified by the 
polymerase chain reaction in immunocytochemically  
negative colorectal tumours.
M utations detectable as bands o f  altered mobilities are marked by arrows.
Lanes 1 and 2 Exon 5
Lanes 3 and 4 Exon 5
Lanes 5 and 6 E xon 8
Lanes 7 and 8 E xon 7
Lanes 9 and 10 T um our T9: Exon 6
Lanes 11 and 12 Exon 8
Lanes 13 and 14 T um our T5: Exon 5
Lanes 15 and 16 T um our T10: Exon 6
Lanes 17 and 18 Exon 7
Lane 19 D N A  marker VI (Boehringer Mannheim)
Lanes 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 17 and 18. Normal (N) and tum our (T) D N A  from 
immunocytochemically negative tum ours with no p53 mutation detectable.
1 2 3 4 5 6 7 8 9 10 1112 13 14 15 16 17 18 19
was therefore possible that both antibodies might have failed to detect a genuinely 
stabilised protein through some epitope masking phenomenon. To exclude this, the 3 
cases with exon 6 mutations that were negative with both antibodies w ere stained 
with the polyclonal antibody CM-1. N o  positive staining was seen, although CM-1 
convincingly detected stabilised protein in 3 further know n D O -7 positive cases 
included in the same run (data not shown). Finally, no cases with single scattered 
positively staining nuclei with either PA blSOl or D O -7 contained mutations, but 
m utations w ere found in 2 cases with only 30-50%  moderately strongly positive nuclei 
on staining with DO-7. As mentioned earlier, 2 tum ours in which the majority o f  
nuclei stained strongly with both PA bl801  and D O-7 failed to reveal mutations in the 
entire coding region o f  the gene.
3.3 Discussion
The data clearly show that positive ICC staining with either D O-7 or P A bl801  does 
not correlate exactly with p53  mutation. It is difficult to give absolute figures for this 
disparity as the proportion  o f  cells staining differs with the method and antibody used 
and the percentage o f  positive cases is also dependent upon the extent to which 
tum ours  with sparsely or focally distributed positive nuclei are included. Variations 
are evident in several studies o f  both cervical and colorectal cancers in which m ethod 
o f  fixation, type o f  antibody and section pretreatment affected the staining patterns 
observed (Lambkin et al., 1994; Baas et al., 1994). The methods used for ICC will 
affect the threshold o f  detection and it has been suggested that the number o f  cells 
staining is probably m ore important than the intensity o f  stain (Hall and Lane, 1994). 
This study shows, however, that mutations can be found in approximately 20%  o f  
colorectal carcinomas that are ICC negative, and that mutation in exons 5-8 cannot be 
found in as many as 33%  o f  ICC positive colorectal cancers. The conservative base 
change in T12 is unlikely to be responsible for the stabilisation o f  the protein, which 
must therefore be attributable either to a second mutational event outside the region 
studied or to a non-mutational mechanism. The group o f  ICC positive cancers without 
apparent p53  mutation in exons 5-8 contain all the cases in which stabilised p53  
protein w as evident only in rare widely-dispersed nuclei. H ow ever there w ere also 3 
cases that showed the m ore familiar staining pattern, with the majority o f  nuclei 
strongly positive. One o f  these was shown to contain an exon 4 mutation at codon 
113. Occasional mutations in both exons 4 and 9 have been reported in the literature
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and although this w as the only mutation recorded outwith exons 5-8 in this study, 
these observations suggest that previous studies restricted to exons 5-8 may have 
slightly under-represented the true incidence o f  p53  mutations in colorectal tumours. 
Am ongst the mutated cases that were ICC negative, w e noted a predominance o f  
mutations in exon 6. It is probable that these tum ours contained only mutant protein 
as data derived by colleagues showed that 2 o f  the 3 tum ours had lost alleles within 
p53  whilst the remaining case was non-informative with a variety o f  polymorphic 
probes. Previous studies o f  ICC and mutation in colorectal and ovarian cancers also 
suggested that exon 6 mutations often failed to  result in a stabilised protein (greater 
than 64%  o f  total cases studies) (Kikuchi-Yanoshita et al., 1992; Cunningham et ah, 
1992; Teneriello et ah, 1993). Taken together these results suggest that exon 6 
includes a region o f  the gene in which mutations frequently fail stabilise p53, whilst 
still conferring a selective grow th advantage.
The presence o f  mutations in occasional ICC negative tum ours and the absence o f  
m utations in some strongly ICC positive tum ours suggests that alternative 
mechanisms o f  p53  abnormality (stabilisation, mutation or both) occur relatively 
frequently in colorectal cancers, a tum our type in which identity between stabilisation 
and m utation has often been assumed. An absence o f  direct correlation between 
stabilisation and mutation has been reported in other tum our types including breast 
carcinoma and non-Hodgkin 's lymphoma (Dunn et ah, 1993; Villuendas et ah, 1993) 
and high levels o f  p53  protein have been associated with poor prognosis in breast
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cancer (T hor et al., 1992). Studies on tw o breast cancer cell lines transfected with a 
murine mutant p53  suggested that the mutant murine protein was only stable in a 
cellular environment where the endogenous gene was stable suggesting that the 
cellular environment creates the stability and not the mutation p er se (Vojtesek and 
Lane, 1993). It has been shown that p53  protein accumulates in cells with D N A  
dam age (possibly including mutation o f  p53  itself), levels o f  the protein transiently 
rise, then fall again possibly after repair o f  the D N A  damage. Regulation o f  mutant 
p53  is how ever altered and so levels o f  protein may remain high and are therefore 
'permanently' detectable by ICC. In this case the cellular environment o f  the cell (i.e. 
the D N A  damage) stimulates p53  overexpression and mutation o f  p53  itself may 
render the protein incapable o f  accurately responding to D N A  damage. I f  this is the 
case, the p53  overexpression seen in tum ours may represent a response to the 
increasing num ber o f  genetic errors seen in the increasingly unstable D N A  and not to 
the mutation o f  the gene itself. Alternatively binding to cellular oncoproteins like 
M D M -2  may stabilise p53 protein without mutation o f  the gene, or as in the case o f  
cervical tum ours  with H PV  16 or 18 infection, p53 may be degraded by the action o f  
the E6 protein.
As larger case numbers accrue in which the distinction is made between mutational 
and non-mutational mechanisms o f  stabilisation including the role o f  cellular 
oncoproteins, it should be possible to determine whether this distinction is 
accompanied by differences in tum our behaviour.
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In summary,  a high correlation between stabilisation of  p53 protein and 
mutation o f  the gene has been established in colorectal tumours but specific  
cases exist in which  this concordance is not absolute. These include both cases of  
ICC- tumours with mutations predominately in exon 6 and IC C+ tumours in 
which the stabilised product  did not seem to be associated with a point  mutation  
of  the gene. Positive ICC may therefore generally be accepted as indicative of  
point mutation within the gene although the lack of  complete  concordance  
should be noted.
Chapter 4
Is the M C C  gene involved in Colorectal Carcinogenesis?
4.1 Introduction
As discussed earlier (Chapter 2), several tum our suppressor genes have been 
implicated in colorectal cancer. A region on chrom osom e 5q21 is commonly deleted 
in sporadic colorectal carcinomas and several genes have been mapped to this region 
including both A PC  and MCC. In contrast to AFC, no mutations o f MCC  have been 
found in the germline o f  patients with FPC nor have they been reported in any other 
inherited colorectal cancer syndrome. Even in apparently large series o f  sporadic 
carcinomas, the incidence o f  somatic mutations o f  MCC  is small (Kinzler et al., 
1991b; Nishisho et al., 1991). Although the data cast doubt over the general 
significance o f  MCC  mutations in colorectal cancer it remains possible that MCC  
m utations may be important in special groups o f  colorectal tumours. O f  particular 
interest are cancers that arise in younger patients and those that cluster in family 
groups. Therefore, the entire coding region o f  the MCC  gene was screened for 
m utations in a small subset o f  clinically important colorectal tum ours from non­
polyposis patients who presented with the disease at a young age (under 48 years). 
By contrast, FPC patients usually present with colon tum ours in the second or third 
decades o f  life whilst sporadic tum ours usually occur in patients over 60 years. Three 
o f  the selected patients had a family history o f  colorectal disease, with one conforming
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to the criteria for hereditary non-polyposis colorectal cancer (H N PC C ) (Table 2). 
T um ours  had been grow n for at least 4 passages as subcutaneous xenografts in SCID 
mice. This provided a renewable source o f  tissue, which w as free from human stromal 
elements that could have 'masked' any mutations that may have been present. 
M utational analysis was performed by screening for single strand conformational 
polymorphisms within individual exons (PC R -SSC P) on matching blood and 
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4.21 PCR-SSCP of M CC  in positive controls
The P C R -S S C P  technique used here had previously been employed to screen for 
mutations o f  the p53  gene in a large series o f  colorectal cancers and detected about 
85%  o f  mutations shown to be present by sequence analysis (Cripps et al., 1994a and 
Chapter 3).
In order to  assess the sensitivity o f  this technique in identifying point mutations in the 
M C C  gene, however, D N A  from all five o f  the sporadic colorectal cancers previously 
reported to have M C C  point mutations (Nishisho et ah, 1991) were screened by PCR- 
SSCP in the relevant exon. In every case, mutated DNA was detectable through the 
presence o f  bands o f  altered mobility when compared to relevant normal samples. 
However, in one tumour, two mutations occurred in the same exon and PC R  
fragment, thus rendering it impossible to determine whether one or both mutations 
w ere detectable (Figure 8 and Table 3).
4.22 PC R-SSCP of M CC  in five young patients
All 17 exons o f  M C C  in matching tum our (after maintenance as xenografts in SCID 
mice) and blood D N A  samples were analysed by PC R -SSC P from the five selected 
young, non-polyposis patients. No mutations were detected in any o f  the exons in any 
o f  the five cases.
Figure 8. Single Strand Conformational Polymorphism analysis of
M C C  positive control samples.
M C C  m utations (Nishisho et al., 1991) detectable as bands o f  altered mobilities 
com pared to  appropriate  normal samples.
Lane 1 D N A  M arker VI
Lanes 2 and 3 T35 and N35: Exon 12
Lanes 4 and 5 T91 and N 9 1 : Exon 17
Lanes 6 and 7 T91 and N 9 1: Exon 15
Lanes 8 and 9 T(Sp)83 and N91: Exon 12 (No normal material for T9Sp)83
available).
Lanes 10 and 11 T35 and N35: Exon 12
The apparent band differences between samples T35 and N35 in the 2 gels (lanes 2/3 
and 10/11) is believed to be due to variations in running conditions betw een gels. 
Differences in band patterns between gels has previously been noticed, however, in 
both gels the difference assumed to be due to a point mutation between the normal 
N35 and tum our T35 sample is clear. Reproducibility o f  SSCP band patterns appears 
to depend on the gel running conditions (temperature, glycerol, polyacrylamide and 
T B E  concentrations etc.) as well as the PC R  fragment studied and may be 
problematic if  the routine detection o f  specific mutations is required. How ever, in this 
study the SSCP technique was used to search for differences between normal and 
tum our samples (therefore indicating a mutation) and such differences w ere  readily 
detectable on all gels studied.
I 2 3 4 5 6 7
8 9 IO II
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Table 3. P O SIT IV E  C O N T R O L  M U T A T I O N S  I D E N T IF IA B L E  A S SSCP
A B N O R M A L I T I E S
M U T A T I O N T U M O U R SSC P A B N O R M A L I T Y
Exon 12 G -A  1517 Arg-Gln T35 +
Exon 12 G-C 1793 Gly-Arg Sp83 +
Exon 13 C-T  1677 Pro-Leu F8, F17 +
Exon 13 C-T 1753 silent N35, T35, Sp83 +
Exon 15 C-T 2093 Ala-Val 
T-C 2124 silent
T91 +
How ever, three polymorphisms in the PCR fragments containing exons 10, 14 and 15 
w ere found (Figures 9, 10 and 1 1). The exon 10 fragment polymorphism has been 
observed by others and contains a 14bp deletion within intron 9 (K. Kinzler, pers. 
comm.) This polymorphism reportedly present in up to  50% o f  alleles is evident in 
tw o  o f  the five cases, one heterozygous for the polymorphism (termed A1/A2) and 
the o ther hom ozygous (A2/A2). Sequencing o f  the exon 15 polymorphism confirmed 
a G C C -G C T  silent mutation at codon 708 as previously described (D'Amico et ah, 
1992)(Figure 12). One patient was hom ozygous (C2/C2) for this polymorphism 
(Table 2). The exon 14 P C R  fragment polymorphism was found to be a tw o  base pair 
change within intron 13, immediately prior to exon 14 (Figure 13) and the patient with 
the hom ozygous polymorphism in exon 15 was also hom ozygous (B2/B2) for the 
intron 13 polymorphism (Table 2). The exon 15 and intron 13 polymorphisms in the 
five cases, therefore, appeared to show linkage. In order to study this suggested 
linkage further, SSCP o f  the PC R  fragments containing exons 14 and 15 was carried 
out on an additional 19 constitutional D N A  samples from young, non-polyposis, 
colorectal cancer patients and 18 normal control D N A  samples.
The linkage suggested by the five original cases was confirmed in this larger sample 
(data not shown). Samples exhibiting heterozygosity or homozygosity for the 
polymorphism in exon 15 exhibited similar allele status in intron 13. The frequency o f
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Figure 9. Single Strand Conformational Polymorphism analysis of
exon 10 o f  MCC.




X enograft (X) D N A  sample
Lane 3 Normal (N) D N A  sample
Lane 4 X enograft (X) D N A  sample
Lane 5 Norm al (N) D N A  sample
Lane 6 X enograft (X) D N A  sample
Lane 7 Norm al (N) D N A  sample
Lane 8 Xenograft (X) D N A  sample









Normal and xenograft samples from patients 2 and 3 contain an exon 10 deletion 
polymorphism identified as bands o f  altered mobility compared to patients 1, 4 and 5. 
Patient 2 is hom ozygous and patient 3 is heterozygous for the polymorphism.
1 2 3 4 5 6 7 8 9  10
Figure 10. Single Strand Conformational Polymorphism analysis of
exon 14 of M CC.
Lane 1 Norm al (N) D N A  sample
}from patient 1
Lane 2 X enograft (X) D N A  sample 
Lane 3 Norm al (N) D N A  sample
}from patient 2
Lane 4 X enograft (X) D N A  sample 
Lane 5 Norm al (N) D N A  sample
}from patient 3
Lane 6 X enograft (X) D N A  sample 
Lane 7 Norm al (N) D N A  sample
}from patient 4
Lane 8 X enograft (X) D N A  sample 
Lane 9 Normal (N) D N A  sample
}from patient 5
Lane 10 Xenograft (X) D N A  sample
Patient 2 contains a hom ozygous polymorphism in exon 14 o f  MCC.
1 2 3 4 5 6 7 8 9  10
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Figure 11. Single Strand Conformational Polymorphism analysis of
exon 15 of M CC.
Lane 1 Xenograft (X) D N A  sample
}from patient 5
Lane 2 Normal (N) D N A  sample
Lane 3 X enograft (X) D N A  sample
}from patient 4
Lane 4 Normal (N) D N A  sample
Lane 5 X enograft (X) D N A  sample
}from patient 3
Lane 6 N orm al (N) D N A  sample
Lane 7 X enograft (X) D N A  sample
}from patient 2
Lane 8 Norm al (N) D N A  sample
Lane 9 X enograft (X) D N A  sample
}from patient 1
Lane 10 Normal (N) D N A  sample
Lane 11 D N A  M arker V (Boehringer Mannheim)
Patient 1 contains a heterozygous and patient 2 contains a hom ozygous polymorphism 
in exon 15 o f  M CC.
4
Figure 12. Sequence analysis of exon 15 of the M CC tumour  
suppressor gene
Sequence analysis o f  exon 15 o f  M C C  in the xenograft tum our sample from patient 2 
showing a G C T -G C C  silent polymorphism at codon 729.
For unknow n reasons but assumed to be due in some way to secondary structure, 
bands in tw o lanes per position w ere seen throughout the gel. The darker band has 
been assumed to be the correct sequence for this tum our and corresponded to the 
published sequence o f  the gene except at the position indicated above
C T A G
G
C
T - C <r.;
•O -  1
• * r t k i T f S * v >
•*’ • V
•täte-;«
Figure 13. Sequence analysis of intron 13 of the M CC tumour 
suppressor gene
Sequence analysis o f  intron 13 o f  M C C  in the xenograft sample from patient 2 
showing a 2 base pair substitution G C -T G  at the 10th and 11th bases before the 
start o f  exon 14

polymorphisms within the young cancer patient series showed no significant difference 
to the normal population.
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4.3 Discussion
The lack o f  mutation in the M CC  gene in this study may be explained in several ways.
A  first, trivial, explanation could be that the technique may not have been sensitive 
enough to  detect subtle point mutations within the gene. Although SSCP does not 
have a 100% detection rate, this explanation is unlikely for several reasons. All the 
samples with known point mutations were detectable as bands o f  altered mobilities on 
SSCP analysis under standard conditions. A previous study o f p53  mutations by the 
m ethod o f  PC R -SS C P  detected the majority o f  mutations in p53  in a large series o f  
colorectal tum ours (Cripps et al 1994a and Chapter 3). Additionally, SSCP analysis 
did detect polymorphisms, including both single and double base pair changes, one o f  
which in intron 13 was previously unreported. This suggests that the technique was 
sensitive enough to have detected any mutation o f  M C C  that might have been present 
in our series (including splice acceptor/donor alterations).
A second reason for failure to detect mutations in tum our samples may be due to the 
masking effect o f  contaminating normal tissue. The use o f  xenograft material in this 
study however, eliminated contaminating human stromal elements. The risk o f  cross 
contamination with murine stromal tissue was considered negligible due to the use o f  
intron based P C R  primers.
Finally, the small sample size may not have been representative o f  the MCC  gene in 
this subset o f  colon cancers from young patients. This criticism is difficult to dismiss 
completely, but the following argument is proposed. All o ther established genetic 
lesions in colorectal cancer occur with a frequency o f  around 50%  or greater within 
the appropriate  populations e.g. abnormalities o f  APC, p53, and K-ras in sporadic 
cancers, and m ore recently the R E R  phenotype in H N PC C  (Powell et al., 1992; Baker 
et ah, 1989; 1990, Bos et ah, 1987; Aaltonen et ah, 1993). W ere the true incidence o f  
M C C  m utations similar (i.e. 50%), the chance that 5 independent cases without MCC  
mutation would be drawn at random from such a population would be (0.5)5 or 0.03, 
substantially less than the 0.05 level normally accepted as a limit o f  statistical 
significance. The data from this small but comprehensively studied series o f  colorectal 
carcinoma patients, therefore, do not suggest a major role for MCC  mutation in 
colorectal carcinogenesis (Cripps et ah, 1994b).
An earlier study which addressed sporadic colorectal cancer in the older age groups 
also showed that the residual copy o f  MCC  was not mutated in a series o f  21 cases 
selected on the basis o f  allele loss in MCC and analysed for mutations by the same 
P C R -S SC P  technique (Curtis et ah, 1994). Additionally, evidence against a role for 
M C C  in colorectal carcinogenesis comes from studies o f  patients with FPC in which 
no mutations o f  the MCC  gene have been detected in patients with FPC. No linkage 
between MCC  and disease was found in another hereditary form o f  colorectal cancer, 
hereditary non-polyposis colorectal cancers (Groden et ah, 1991; Joslyn et ah, 1991;
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Kinzler et al., 1991b; Nishisho et al., 1991; Peltomaki et al., 1992). M ore recently, the 
genes responsible for H N PC C  have been shown to be involved in mismatch repair and 
create microsatellite instability (Aaltonen et al., 1993; Fishel et al., 1993; Leach et al., 
1993; B ronner et al., 1994; Papadopoulos et al., 1994).
The above findings, taken together with this study o f  a small but nevertheless 
im portant clinical group o f  colorectal tum ours strongly suggest that M C C  is not an 
independently functioning tum our suppressor gene mutated in colorectal cancers at 
least at the level studied. H ow ever its possible role as a modifier gene in this, as well 
as in o ther  tum our types remains to be established.
In summary,  the results from this and other studies from the laboratory indicate  
that the M C C  gene is unlikely to play an important  role in colorectal cancer  




Targeting of  the A P C  gene in a colon carcinoma cell line 
5.1 Introduction
5.11 The role of APC in normal and neoplastic cells
There is much evidence to suggest that APC function is essential for normal grow th 
and development. Firstly, genetic analysis o f  human colonic adenom as and carcinomas 
from patients either with sporadic colorectal cancer or FPC commonly reveal 
m utations o f  the A P C  gene. Secondly, the recent finding that APC binds to (3-catenin 
in cell adhesion complexes is interesting when characteristics o f  both normal and 
neoplastic cells are considered. Cell adhesion and cellular contacts are vital 
com ponents  o f  normal cell grow th and signalling and are frequently disrupted in 
neoplasia. Finally, studies from the mill mice show that mice with hom ozygous 
m utation o f  the murine APC  gene are not viable and die in ulero. These observations 
suggest an important role for APC in normal cell function, yet little is know n o f  the 
cell biology o f  the APC protein especially in neoplastic cells. One way to address the 
question o f  the role o f  APC in neoplasia would be to introduce wild type protein into 
neoplastic cells. Previous experiments with this aim, transfected a whole chrom osom e 
5 into colon cancer cells by microcell transfer. These microcell hybrid studies on two 
colon cell lines, SW 480 and COKFu showed that introduction o f  chrom osom e 5 
reduced tumorigenicity as assessed by subcutaneous injection o f  5 x l0 6-107 cells into
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athymic nude mice and also affected cellular m orphology (Tanaka et al., 1991; 
G oyette  et ah, 1992). The addition o f  chrom osom e 5 to both colon cancer cell lines 
also resulted in an increase in cell doubling time and a decrease in grow th in soft agar, 
both  com m on markers o f  tum our cell aggressiveness in vitro. These chrom osom e 
transfer experiments however only suggest the presence o f  a suppressor gene on 
chrom osom e 5. In order to  address whether the suppressor activity comes from the 
APC  gene located on 5q21, a more precise method o f  analysis is required.
5.12 Gene Targeting
One way in which to determine whether APC mediates this response would be to 
in troduce a normal copy o f  the gene into cancer cells. This could be achieved by the 
use o f  an APC  transgene where the gene would be placed under the control o f  an 
exogenous prom oter  and transfected into cells. In view o f  its large size, however, 
A PC is likely to transfer into target cells with a low efficiency. M oreover, transgenic 
strategies have the generic disadvantage o f  lack o f  control o f  expression o f  the gene 
once stably transfected. In general, transfection o f  genes under exogenous prom oters 
leads to  overexpression o f  the gene product which in the case o f  a suppressor protein 
may be sufficient to kill the cell. A better method for expressing potentially 
physiological levels o f  protein within a cell is gene targeting by hom ologous 
recombination.
H om ologous  recombination allows the exchange o f  genetic material between 
sequences o f  D N A  that show sequence homology and was first exploited
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experimentally in mammalian cells between tw o exogenous plasmid sequences in 
murine fibroblasts and rat cells (Folger et al., 1982). The exact mechanism o f
78
hom ologous recombination is still uncertain, but tw o  major theories exist (Taken from
Figure 14. M eselson-Radding theory o f  hom ologous recombination.
In the first theory, a single strand break initiates recombination (Figure 14). The 3' end 
o f  the nick (3' D N A  ends marked with a half arrow) acts as a primer for D N A  repair 
synthesis displacing a single strand that invades the other hom ologue displacing a D-
loop (1). The D-!oop is degraded and, by a combination o f  D NA  synthesis on the 
donor and degradation on the recipient chromatid, an asymmetric heteroduplex is 
p roduced (2). Ligation (3), produces a Holliday junction which can diffuse along the 
molecules by a zipper-like branch migration mechanism. The Holliday junction may 
resolve by cutting the crossed strands (4) to give tw o  double helical molecules each 
consisting o f  one parental strand and one strand that has undergone gene conversion 
w ithout crossover. The newly synthesised D N A  (dotted) has been copied from the 
donor homologue. Alternatively, the Holliday junction may undergo a process termed 
isomerisation in which the originally crossed strands becom e uncrossed and vice versa 
(5). This can then resolve by cutting the crossed strands (6) to produce crossover 
products  also with a segment that has undergone gene conversion.
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Figure 15 . Double  strand break-repair model o f  recombination.
In the second model, recombination is initiated by a double strand cut in one duplex, 
followed by exonuclease attack to give a gap flanked by 3' single-stranded ends 
(Figure 15). One 3' invades the other duplex (1), displacing a D -loop enlarged by 
repair synthesis until the other 3' end can anneal to complementary single-stranded 
D N A  (2). Repair synthesis from the second 3' end completes the gap repair, and 
ligation produces tw o  Holliday junctions both o f  which can diffuse by branch 
migration (3). There are than four possibilities for resolution, depending upon whether 
isomérisation occurs at neither junction (4), the left junction only (5), the right
junction  only (6), or both junctions (7). Resolutions (5) and (6) lead to crossover, 
whilst (4) and (7) do not.
In both  models, the recombination machinery o f  the cell can mediate either 
conservative or non-conservative recombination which results in either the retention 
or loss o f  exogenous D N A  respectively (Lin et al., 1984; Chakrabarti and Seidman 
1986). Additionally, reciprocal or non-reciprocal recombination can occur with non­
reciprocal hom ologous recombination being m ore com m on (Folger et al., 1985; 
Thom as et al., 1986). The frequency o f  recombination is dependent in an exponential 
manner on the length o f  homology that the tw o D N A  sequences share and targeting 
using isogenic D N A  has also been shown to increase the efficiency o f  hom ologous 
recombination over nonisogenic sequences (Hasty et al., 1991a; D eng and Capecchi, 
1992). As well as hom ologous recombination, the D N A  sequence can be incorporated 
into the endogenous D N A in a random fashion and mammalian cells preferentially 
mediate this non-hom ologous recombination or random integration (Figure 16)(Roth 
et al., 1985; Roth  and Wilson, 1985). Random  integration is not dependent on the 
stage o f  the cell cycle whereas hom ologous recombination occurs preferentially during 
the S-phase o f  the cell cycle (W ong and Capecchi, 1985; W ong and Capecchi, 1987). 
The com m on occurrence o f  random integration made essential the development o f  
m arkers to  select for correct hom ologous recombination events. This has previously 
been achieved either, by the incorporation o f  hprt (hypoxanthine phosphoribosyl 
transferase) minigenes into the targeting construct in such a way that when inactivated
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Figure 16. Positive-Negative Selection of Targeting events.
(Based on Capecchi 1989). Positive-Negative selection enriches for correctly targeted 
events. The neoT gene is inserted into the region o f  hom ology in such a way as to 
disrupt the gene sequence. The H S W-lk gene is linked to but outwith the region o f  
homology.
H om ologous  recombination between the exogenous vector sequences and the 
endogenous gene will result in the disruption o f  the endogenous gene. Cells 
containing this event will be G418 resistant due to the presence o f  the m o x gene 
and ganciclovir resistant due to the lack o f  the HS W-lk gene.
N on-hom ologous recombination or random integration occurring via the 
exogenous D N A  ends results in the retention o f  the HSV-/& gene linked to  the 
neoT gene. Such cells would be G418 resistant but ganciclovir sensitive.
Selectable marker genes are shown in blue. Regions o f  homology are shown in red for 
the exogenous vector sequences and pink for the endogenous gene respectively. 
Additional plasmid sequences are shown in brown and additional endogenous 
sequences are grey.

cells will g ro w  in the base analogue 6 thioguanine which kills cells with an active hprt 
gene. Or, by the functional replacement o f  an hprt gene by hom ologous recombination 
allowing selection in H A T  (hypoxanthine, aminopterrin, thymidine) medium (reviewed 
in Capecchi 1989). Another com m on method for selection o f  correctly targeted events 
is the introduction o f  drug resistance markers with the hom ologous D N A  (Folger et 
al., 1984; Smithies et al., 1984). Examples o f  this are the bacterial neomycin 
resistance gene (neo ) which in mammalian cells confers resistance to the drug G418, 
and the H erpes Simplex Virus thymidine kinase gene (H SV-tk) which confers 
susceptibility to the nucleoside analogue ganciclovir. The introduction o f  the neo  gene 
into the region o f  homology o f  the exogenous D N A  will allow the selection o f  
hom ologous recombination events and will disrupt the target gene thereby creating a 
null allele. Positive/negative selection (PNS) allows enrichment for hom ologous 
recombination events. This is achieved by the incorporation o f  the neo  resistance gene 
into the region o f  homology and the HSV-tk gene outside this region within a plasmid 
vector. D uring hom ologous recombination, the neo gene will be transferred with the 
region o f  homology, whereas the H SV-tk gene will not be transferred resulting in a 
selection for correct events in both G418 and ganciclovir. N on-hom ologous 
recombination and random insertions occur via the D N A  ends and normally involve 
the introduction o f  the entire sequence, resulting in the incorporation o f  the HSV-tk 
gene and subsequent sensitivity to ganciclovir (Thom as et al., 1986; M ansour et al.,
T here are tw o  com m on types o f  targeting vector, replacement and insertion vectors 
(Figure 17). As suggested by the name, replacement vectors replace the endogenous 
D N A  with the exogenous sequence. In contrast, insertion vectors insert the entire 
vecto r  sequence into the hom ologous locus. Some studies have suggested that 
insertion vectors  are m ore efficient than replacement vectors at mediating 
hom ologous recombination (Hasty et al., 1991b), whereas others have detected no 
difference in the targeting efficiency between the tw o types o f  vector (Thom as and 
Capecchi, 1987).
The majority o f  gene targeting to date has involved targeting into murine embryonic 
stem (ES) cells. M urine ES cells were first isolated by Evans and Kaufman, and 
M artin  in 1981. These cells are pluripotent and capable o f  contributing to the germline 
o f  animals created by the introduction o f  ES cells into host blastocysts. This has 
allowed the targeting o f  ES cells by transfection o f  modified DN A  sequences in vitro 
by standard molecular techniques. The ES cells are then selected for hom ologous 
recombination events as described above. Cells with a correct hom ologous 
recombination event are then reintroduced into a cultured host blastocyst by 
microinjection and the blastocyst is then replaced in a pseudo-pregnant female mouse 
which may or may not generate germline chimeras. Coat colour markers o f  host and 
recipient strains allow the distinction o f  the chimeras in which the ES cells have 
contributed and mating o f  the offspring o f  germline chimeras and wild type crosses
Figure 17. Gene disruption by replacement and insertion targeting  
vectors.
(Based on Capecchi 1989)
A sequence replacement vector contains the m o x gene within the gene to be 
targeted. H om ologous recombination between the regions o f  hom ology replaces 
the genomic sequence with the vector sequence containing the tieoT gene and 
therefore rendering the cells resistant to G418 whilst disrupting the gene o f  
interest.
Sequence insertion vectors are designed such that linearisation within the region o f  
hom ology places vector ends adjacent to each other. The pairing o f  these ends 
with the endogenous sequences and subsequent recombination results in the 
com plete insertion o f  the vector producing a duplication o f  the region o f  
homology. The presence o f  the m o x gene in the vector again confers resistance to 
G418.
Selectable m arker genes are shown in blue. Regions o f  hom ology are shown in red for 
the exogenous vector sequences and pink for the endogenous gene respectively. 
Additional plasmid sequences are shown in brow n and additional endogenous 
sequences are grey.

allows for the identification o f  homozygous animals (Bradley et al., 1984, reviewed in 
Capecchi 1989).
This approach has been particularly effective in the study o f  genes commonly involved 
in human disease such as the cystic fibrosis (CF), retinoblastoma (R b-J ) and p53  
genes (Dorin et al., 1992; Lee et al., 1992; Jacks et al., 1992; Clarke et al., 1992; 
D onehow er et al., 1992). The production o f  null alleles provides valuable data on 
gene function. H owever, a large number o f  genes are modified physiologically by 
m ore subtle alterations to their sequence such as base pair changes, for example 
activation o f  the K-ras oncogene and inactivation (or gain o f  function) o f  tum our 
suppressor genes such as APC  and p53. O ther targeting strategies have therefore been 
devised to allow more subtle modifications o f  the genom e to occur. The "hit and run" 
(alternatively called "in-out") strategy generates such cells without the permanent 
incorporation o f  selectable markers (Valancius and Smithies 1991; Hasty et al., 
1991c). Hit and run targeting vectors contain a region o f  homology, and selectable 
m arkers such as neo  and HSV-tk  within the plasmid backbone (Figure 18). The vector 
is linearised within the region o f  homology and in a single reciprocal recombination 
event the entire vector inserts into the locus generating a linear duplication o f  the 
hom ologous regions separated by selectable marker sequences. Selection in G418 will 
identify cells that have incorporated the vector containing the neo  resistance gene. 
Identification o f  correct homologous recombination events is then achieved by 
isolation o f  D N A  from these cells and a variety o f  screening methods commonly based
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Figure 18. Hit and Run Gene Targeting.
(Based on Hasty et al., 1991c).
Hit and run targeting allows a small mutation to be introduced into a nonselectable 
gene in a tw o  step recombination procedure.
The first step involves a single recombination event between the target gene and 
the linearised insertion vector. The vector contains the small required alteration 
within the target gene (*) as well as both the neoT and H SV -/£  genes. The entire 
vector inserts into the target locus creating a linear duplication o f  the genomic 
sequences. The cells can be selected in G418. G 418r clones o f  cells are screened to 
detect those  in which a correct recombination event has occurred.
The second step involves an intrachromosomal recombination event within the 
duplication. The plasmid, neoT, HSV-/& and the duplication from either vector or 
genomic origin are lost depending on the site o f  the recombination event. Cells can 
then be selected in ganciclovir due to the loss o f  the H SV -/£  gene. Ganciclovir 
resistant clones can then be screened for the presence o f  the mutation.
Selectable marker genes are shown in blue. Regions o f  homology are shown in red for 
the exogenous vector sequences and pink for the endogenous gene respectively. 

























on the generation o f  characteristic PCR fragments, or the use o f  radiolabelled D N A  
probes after Southern analysis to identify fragments unique to the correct event. Cells 
containing an hom ologous recombination event are then g row n in the presence o f  
ganciclovir which selects for a second reciprocal in trachromosomal recombination 
event and the loss o f  the tk gene, which depending on the exact site o f  the crossover 
rem oves the neo  and Ik sequences and one copy o f  the hom ologous region. I f  the 
cross over occurs before the sequence change, then the introduced change will be 
retained and the endogenous sequence lost.
The fact that most targeting has been done in ES cells means that little is known about 
the targeting frequency in non-ES cells such as cancer cells. One study o f  gene 
targeting in somatic cells disrupted an activated K-ras gene in tw o colon carcinoma 
cell lines. Morphological and biological changes such as a decrease in cell g row th both 
in vitro and in vivo were noted in targeted cells (Shirasawa et al., 1993). A significant 
problem with corrective targeting o f  a suppressor such as A PC  in cancer cells may be 
that production  o f  wild type protein may be sufficient to kill the cell. The chrom osom e 
transfer experiments described earlier, however, suggest that the presence o f  wild type 
A PC protein is compatible with cell grow th in vitro at least in the tw o  colon cancer 
cell lines studied. Targeting o f  the APC  gene will address the question o f  whether 
correction o f  an "early" event in tumorigenesis will have any effect on cell lines which 
have already accumulated additional genetic lesions normally associated with the later 
stages o f  tum our progression
M any colon carcinoma cell lines exist, and their study has provided valuable 
information on the progression o f  colorectal disease (Paraskeva et ah, 1984; M cBain 
et ah, 1984). One o f  the best characterised colon cell lines is SW480.
5.13 The SW 480 cell line
SW 480 was established from a D ukes B stage adenocarcinom a removed from a 50 
year old Caucasian male (Leibovitz et ah, 1976). Published karyotypes o f  SW 480 vary 
between studies. One such karyotype suggests that SW 480 has lost a copy o f  each o f  
chrom osom es 5 and 18 and also has a derived chrom osom e consisting o f  a reciprocal 
translocation between (5;20)(q 15;p 11) (Yaseen et ah, 1990). Another study suggests 
that there  is also an additional chrom osom e 17 and 2-4 copies o f  the derived 5;20 
translocation (Tom ita et ah, 1992). Studies on particular genes have shown an 
activating point mutation o f  K-ras in codon 12 (Gly-Val) (Capon et ah, 1983), 
amplification o f  c-myc (Suarez et ah, 1987), point mutations o f  p53  in codons 273 
(Arg-His) and 309 (Pro-Ser) (Nigro et ah, 1989), deletion and low expression o f  
D CC  (Yaseen et ah, 1990; Goyette  et ah, 1992), and finally loss o f  the normal allele 
o f  A PC  with a point mutation at codon 1338 (Gln-stop) in the remaining allele 
(Nishisho et ah, 1991).Tumorigenicity was originally assessed by injection o f  106 cells 
into athymic nude mice either into the footpad or subcutaneously (Trainer et ah, 
1988). Only the cells introduced into the footpad produced tumours, appearing 
approximately 21 days after injection, whilst a more recent study in which 107 cells
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injected subcutaneously produced tumours within 7 days (G oyette  et al., 1992). 
U nder optimal grow th conditions in vitro the cell line has a doubling time o f  around 
22 hours. The cells weakly express keratin and have microvilli, tight and adherens 
junctions and desm osom es (Trainer et ah, 1988).
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5.2 Experimental Design
T he basic strategy proposed involves the generation o f 'h i t  and run' insertion targeting 
vectors  incorporating approximately 3Kb o f  exon 15 o f  the AFC  gene, hom ologous to 
the region spanning the truncating mutation at codon 1338 found in SW 480 cells. 
C orrection o f  the point mutation should restore a PstI restriction enzyme site in the 
cells which would be identifiable by either Southern analysis or PCR-based 
technologies involving PstI restriction digestion. An exonic region o f  hom ology is 
generated  by P C R  amplification o f  "normal" genomic D N A  and therefore expected to 
behave m ore like isogenic than non-isogenic DN A  which has been shown to have a 
lower absolute targeting frequency. The vector also contains suitable selectable 
markers. The use o f  the neo resistance gene allows selection o f  a first recombination 
event with the resulting insertion o f  the entire vector sequence. Analysis o f  the G418 
resistant clones is by Southern blotting after i.)PstI and ii.)StuI restriction enzyme 
digestion and subsequent radiolabelled probing with a probe that spans the insertion 
point o f  the vector into the endogenous D NA  to identify a correct insertion event 
(Figure 19). The restoration o f  a PstI restriction site allows identification o f  both the 
endogenous mutant and exogenous wild type fragments created by the linear 
duplication o f  the hom ologous sequences thereby eliminating clones that have 
undergone branch migration events leading to duplication o f  either endogenous or 
exogenous sequences. Incorporation o f  the HSV-tk  gene into the vector allows 
selection for a second intrachromosomal recombination event. Correct clones are 
grow n and selected in ganciclovir to select for a recombination event in which the
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Linearised pPN T .A PC  or pPN T .A PC w t inserts into the exon 15 APC locus as 
previously described (Figure 16). (pPN T.A PC  and pPN T .A P C w t are assumed to 
be identical except for the presence o f  a truncating mutation (M) at codon 1359 in 
pPNT.APC).
The resulting linear duplication o f  the loci and subsequent resistance to G418 
allows screening for a correct insertion event by Southern analysis after a StuI 
restriction enzyme digest using the 2kb APC probe pAPC.KC. Correct insertion 
should reveal a unique 5.3kb band.
N-Nsil restriction enzyme site.
P-PstI restriction enzyme site.
P * -P stl  site mutated in the SW 480 cell line at codon 1338 replaced in targeting 
vectors  pPN T .A PC  and pPNT.APCwt.
E -E coR I restriction enzyme site.
B -B am H I restriction enzyme site.
S- StuI restriction enzyme site.
M -novel truncating mutation at codon 1359 in vector pPN T.A PC
Selectable marker genes are shown in blue. Regions o f  homology are shown in red for 
the exogenous vector sequences and pink for the endogenous gene respectively. 
Additional plasmid sequences are shown in brown and additional endogenous 
sequences are grey.
Figure 19. The Hit and Run protocol for corrective targeting of the
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sequence is resolved with the loss o f  the HSV-lk  gene and subsequent resistance to the 
toxic effects o f  ganciclovir (Figure 20). Ganciclovir resistant clones are analysed to 
establish w hether the resulting endogenous sequence has resolved back to the original 
mutation at codon 1338 or whether correction o f  the m utation has occurred. This 
depends upon the location o f  the second cross-over event. I f  this event is on the same 
side o f  the mutation to the first crossover (not necessarily where the vector linearises 
due to  branch migration) the resulting sequence will contain the original mutation. If  
how ever the cross-over occurs after codon 1338 then the mutation will be corrected. 
This is detectable by Southern digest after PstI digest and probing with a suitable APC  
probe. Correction o f  the codon 1338 mutation will restore a PstI site with 
characteristic band fragment size. This analysis should also reveal the codon 1338 
m utant fragment bands due to the tw o other copies o f  APC  present. As the results o f  
a correct targeting event o f  APC  in SW 480 cells w ere unknown, it was necessary to 
control the entire experiment by replacing the mutation in SW 480 with another 
m utation elsewhere in the APC  sequence. This would provide a control for the 
targeting itself without the risk o f  introducing suppressor protein which may for 
reasons previously discussed result in the production o f  no viable clones. In the course 
o f  making the correcting targeting vector a suitable mutated vector was derived.
The second intrachromosomal recombination event results in either a reversion to 
the original mutated sequence in SW 480 or the correction o f  the mutation as 
previously described (Figure 16).
Screening o f  ganciclovir resistant colonies by Southern analysis o f  PstI restriction 
digested DNA, probed with the 2kb APC probe pAPC.K C should reveal bands 
o f  1.4kb and 0.4 kb in corrected clones. The 1.8kb band previously seen (Figure 
19) will be evident in uncorrected SW 480 clones.
Figure 20. The Hit and Run protocol for corrective targeting of the
SW 480 cell line (2).
P-PstI  restriction enzyme site.
P * -P stl  site mutated in the SW 480 cell line at codon 1338 replaced in targeting vector 
pPN T .A PC  and corrected SW 480 clones.
M -novel truncating mutation at codon 1359
Selectable marker genes are shown in blue. Regions o f  hom ology are shown in red for 
the exogenous vecto r  sequences and pink for the endogenous gene respectively. 
Additional plasmid sequences are shown in brow n and additional endogenous 
sequences are grey.
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5.31 Properties of the SW 480 cell line
SW 480 D N A  w as digested with the restriction enzyme PstI and after Southern 
transfer and probed with a radiolabelled genomic P C R  product o f  2Kb to a region o f  
exon 15 o f  APC (nucleotides 2480-4498) spanning the codon 1338 mutation site. The 
size o f  the fragments observed indicated that these cells do not possess a wild type 
A P C  gene, only APC  D N A  with the codon 1338 mutation and hence without a PstI 
site at codon 1338 was present in the cell line (Figure 21).
M etaphase  chrom osom e spreads were prepared for fluorescent in-situ hybridisation 
(FISH ) studies. A small number o f  metaphase spreads were counted for chrom osom e 
number; the number o f  chrom osom es observed (50-60) was within the range reported 
in o ther studies (Yaseen et al., 1990; Tomita et ah, 1992). Fluorescent in-situ 
hybridisation (FISH) using probes to the 5q21 region and to the APC  gene revealed 3 
copies o f  5q21. Chromosomal locations o f  the three copies o f  the gene were identified 
by chrom osom e paints. One was shown to be a single copy o f  chrom osom e 5, whilst 
the other tw o  gene copies appeared to reside on derived chrom osom es t(5;20)(Figure 
22). This translocation is probably the t(5;20)(q 15;p 11) already reported (Yaseen et 
ah, 1990). It is not known whether the derived/translocated chrom osom e copies o f  
APC  are expressed.
5.3 Results
Figure 21. Southern Analysis of exon 15 of the ÆPC tumour 
suppressor gene in SW 480 and tumour genomic DNA  
samples.
Lane 1 SW 480 genomic D N A  digested with the restriction enzyme PstI and probed 
with the 2kb APC  probe pAPC.KC.
Lane 2 T um our sample X genomic D N A  digested with the restriction enzyme PstI 
and probed with the 2kb APC  probe pAPC.KC.
Lane 3 T um our sample Y genomic D NA  digested with the restriction enzyme PstI 
and probed with the 2kb APC  probe pAPC.KC.
Lane 4 T um our sample Z genomic D N A  digested with the restriction enzyme PstI 
and probed with the 2kb APC  probe pAPC.KC.
T um ours  X ,Y  and Z w ere randomly selected from the sporadic colorectal tum our 
bank (Dept. Pathology, Edinburgh).
The SW 480 digest in lane 1 shows a band o f  approximately 1.8kb com pared to  the 
three tum our samples in lanes 2, 3 and 4 which reveal bands o f  1.4kb. This indicates 
the loss o f  a PstI restriction enzyme site at codon 1338.
1.8kb
1.4kb
Figure 22. Fluorescent in situ  Hybridisation (FISH) on the SW 480  
cell line.
a.) C hrom osom e painting o f  SW 480 m etaphase spreads. C hrom osom e 5 sequences in 
red are detected by a Texas Red labelled chrom osom e paint, and chrom osom e 20 
sequences by a fluoroscene isothiocyanate (FITC) labelled chrom osom e 20 paint 
in green. This shows 1 copy o f  chrom osom e 5, 2 copies o f  chrom osom e 20, 2 
derived chrom osom e 5(5;20)(q 15;p 11) and 2 derived chrom osom e 
20(5;20)(q 15;p 11) reciprocal translocations.
b.) F IS H  analysis o f  m etaphase spread o f  SW 480 cells using an APC  YAC probe 
labelled with FITC  (green). Chrom osom es are counterstained with propidium 
iodide (PI)(red). The YAC binds to the centromeres o f  chrom osom es 1 and 16 by 
unknow n sequences. The APC  gene sequences are identifiable on the remaining 
copy o f  chrom osom e 5 and also on the 2 derived chrom osom e 20 translocated 
chromosomes. (Indicated by arrows).
c.) F ISH  analysis o f  m etaphase spread o f  SW 480 cells using an APC  cosmid probe 
labelled with Texas Red (red). C hrom osom e 20 sequences are labelled green with 
FITC  and chrom osom es are counterstained blue with DAPI. This confirms the 






Tum origenicity was assessed by subcutaneous injection o f  107 SW 480 cells into SCID 
mice maintained in incubators. Tum ours were visible in all animals three weeks post­
injection. Histological examination o f  these tum ours revealed characteristic poorly 
differentiated anaplastic carcinoma (Figure 23).
5.32 Construction of Targeting Vectors
A  "hit and run" targeting vector pPNT.APC, was constructed by the cloning o f  a 
2 .8Kb P C R  fragment o f  the A PC  gene exon 15 (nucleotides 3232-6017) into the 
plasmid pPNT. The source D N A  was morphologically normal mucosa from a patient 
with a sporadic colorectal carcinoma. PCR primers were designed to incorporate 
different restriction enzyme sites (BamHl and EcoRI) into the ends o f  the PC R  
product. Digestion o f  the pPN T parental vector with the same restriction enzymes 
allowed directional cloning o f  the product into pPN T  to generate the vector 
pPN T.A PC . Restriction mapping o f  the generated plasmid using a variety o f  
restriction endonucleases confirmed that pPN T.A PC  was as shown (Figure 19). In 
order to  confirm the suitability o f  this vector for corrective targeting, it was essential 
to  confirm that the entire 2.8Kb A PC  fragment was o f  the wild type sequence. In 
order to  sequence this relatively large fragment o f  D N A  it was excised from the pPN T 
vecto r  using Bam HI and EcoRI restriction digests and cloned into the pG EM 7Zf+  
plasmid as described previously. This vector is designed to allow the generation o f  
nested deletions o f  the fragment to be sequenced in the Erase-a-Base system.
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Figure 23. Haematoxylin and Eosin stained xenograft tumour
Highly anaplastic carcinoma removed from a SCID m ouse tw o  w eeks post 
subcutaneous injection o f  107 SW 480 cells and stained with haematoxylin 
and eosin, showing invasion o f  the fat layer (I) and characteristic apoptotic  
bodies (A).
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Unexpectedly, sequence analysis o f  the entire 2.8Kb APC fragment in pPN T.A PC  
revealed the existence o f  a truncating mutation in codon 1359 (A A A -TA A ) (Figure 
24). R easons for this will be discussed later.
In order to  generate a targeting vector with a wild type APC  sequence another vector 
pP N T .A P C w t (Figure 19), was established by the same method except, PC R  
amplification o f  the 2.8Kb fragment was from the genomic D N A  o f  an individual free 
from colorectal cancer. pPN T .A PC w t remains to be sequenced.
5.33 G418 resistant clones and analysis
The effect o f  introduction o f  a wild type APC gene into SW 480 is uncertain. It is 
possible that clones containing wild type APC protein may be either not viable or at a 
g row th  disadvantage compared with non-corrected clones. In order to assess the 
efficiency o f  targeting into SW 480 cells without producing a corrected APC protein, 
cells w ere  transfected with pPNT.APC, the vector containing the novel mutation. 
E lectroporation  conditions were optimised and 60p g  o f  linearised pPN T .A PC  was 
electroporated  into 108 SW 480 cells. The concentration o f  G418 for selection was 
established by analysing 104 SW 480 cells in varying concentrations o f  G418 sulphate. 
Cells g row n in 0, 200 or 400 pg/ml G418 were viable and confluent after 5 days. In 
contrast, cells grow n in 600, 800, or lOOOpg/ml were all dead by 5 days. 600pg/m l 
G418 was therefore chosen for selection. These results also suggested that the chance 
o f  a cell surviving selection without a transfected neo resistance gene is less than 1 in
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Figure 24. Sequence analysis of the pPNT.APC targeting vector
revealing a truncating mutation in codon 1359, exon 15 of  
the A P C  tumour suppressor gene.
Sequence analysis o f  the 2.8kb APC  exon 15 fragment in pPNT.APC. A truncating 
mutation A A A -T A A  (Lysine to Stop) was identified at codon 1359.
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104. After cell plating at densities o f  107 and 5 x l0 6 and subsequent selection in G418, 
approximately 300 G418 resistant clones were picked and plated into 24 well plates. 
211/300 clones grew  to  confluence and w ere harvested. Analysis o f  these G418 
resistant clones remains to be done.
5.4 Discussion
There is much evidence to support the idea that a gene important in the maintenance 
o f  a tum origenic phenotype in some colon cancer cell lines resides on chrom osom e 
5q21. Studies in which the entire chrom osom e 5 was replaced into the colon cancer 
cell lines SW 480 and CO KFu by microcell transfer revealed a substantial reduction in 
the tumorigenicity in the two lines (Goyette et ah, 1992; Tanaka et ah, 1991). In order 
to  establish w hether this response is mediated by the APC  gene this study attempted 
to  correct specifically the truncating mutation present at codon 1338 in the APC  gene 
in the SW 480 cell line. Characterisation o f  the SW 480 cell line by FISH revealed a 
potential three copies o f  the APC  gene, whilst restriction digestion with the 
restriction endonuclease PstI detected only APC  sequence with the codon 1338 
mutation.
SW 480 was considered a suitable cell line for theses experiments for a number o f  
reasons. The first o f  these is that it is relatively well characterised with regard to 
genetic abnormalities associated with colorectal cancer. However, there is confusion 
in the literature as to the number o f  copies o f  APC  contained in the SW 480 cell line. 
F rom  the FISH  studies presented here it appears that there are three copies o f  the 
gene. This is in contrast to the microcell transfer experiments on SW 480 which stated 
that only one copy o f  the A PC  gene was present (Goyette  et al., 1992). The reasons 
for the discrepancies are unknown however and may be due to variability between 
SW 480 subclones. However, three copies o f  A PC  have been confirmed in additional
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SW 480 subclones from other laboratories and it is possible that the SW 480 subclone 
used in the microcell transfer experiments may contain up to five copies o f  the mutant 
A P C  gene (J. G roden and A. Farmer Pers. Comm.) It is important to know  the 
num ber o f  potential targets for incorporation o f  the vector in this cell line so that 
potential gene dosage and dominant/negative effects can be assessed. As previously 
mentioned, it is possible that the potential reduction in tumorigenic properties may 
place corrected cells at a grow th disadvantage compared to cells containing only 
mutant APC  and therefore corrected cells may not be identifiable. This outcom e 
w ould  be indistinguishable from one in which hom ologous recombination had not 
occurred. In order to  assess the frequency with which hom ologous recombination 
occurs at this locus with the virtually identical targeting vectors, transfection with the 
pP N T .A P C  vector should allow correction o f  the codon 1338 mutation and 
introduction o f  a novel truncating mutation downstream at codon 1359. This will 
allow the targeting frequency to be assessed whilst still retaining mutant APC  which 
should retain the tumorigenic phenotype o f  the parental SW 480 cells. A further 
im portant monitor o f  the success o f  corrective targeting would be W estern analysis 
using N-terminal antibodies to the APC protein. Antibodies to the APC protein are 
currently being made in this laboratory.
I f  correction o f  the APC  gene by pPN T.A PC w t occurs and wild type protein is 
translated and results in viable cells, then by extrapolation from the microcell transfer 
experiments, a reduction in tumorigenicity might be expected. This could be assessed
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by com m on biological assays such as doubling times, g row th in soft agar and 
tumorigenicity in SC1D mice compared to the parental SW 480 cell line.
SW 480 is also a desirable cell line in which to correct one genetic lesion involved in 
colorectal tum our progression because this can be taken in the context o f  the other 
know n genetic abnormalities within the cell line. APC  mutation is generally considered 
to  be an early genetic event in colorectal tumorigenesis and it is o f  interest to consider 
the effect correction o f  an early event in an already highly malignant cell line may 
have. It should be noted that other colorectal cell lines may involve other pathways to 
progression. For example, the VACO 235 and its derived clone 411 colon cancer cell 
lines contain mutant ras protein, mutant APC protein, express no DCC transcripts and 
have only wild type p53 protein, in contrast to the SW 480 cell line which contains 
tw o  mutations o f  the p53  gene (M arkowitz et al., 1994; Goyette  et al., 1992). V ACO 
235 is non-tumorigenic despite the genetic lesions affected, whilst the grand daughter 
cell line V A C O  411 is tumorigenic in nude mice without acquiring any additional 
lesions in commonly affected genes including p53. This suggests that mutant p53 is 
not necessarily required for a tumorigenic phenotype, and that abnormalities in APC, 
ras and DCC  are not necessarily sufficient for a tumorigenic phenotype.
Targeting o f  the k-ras gene in the colon cancer cell lines DLD-1 and H C T116 
(Shirasawa et al., 1993) suggests that in cells prior to correction o f  the ras mutation, 
the genetic background on which the mutation exists was important. Correction o f  
either the p53  or DCC  gene abnormality in these lines may also have resulted in a
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reduced tumorigenic phenotype. As both APC  and rcis gene alterations are considered 
early events in colorectal tumorigenesis, they may represent 'gateway' options which 
allow disregulation o f  the other genes commonly associated with colon cancer. It is 
also probable that different cell lines have different requirements for malignant 
progression, o r  additionally it is possible that genes other than A PC  on chrom osom e 5 
mediate the tumorigenic response o f  cell lines such as SW 480 and COKFu. The 
experiments outlined above may help explain some o f  the questions raised above.
An important point to consider is why the apparently normal D N A  from an individual 
with a sporadic colon tum our yielded a mutant APC fragment. This may be explained 
by technical error either due to a mix up in D N A sample within our tum our bank, or 
an artefact o f  the PC R  and cloning methods. However, multiple PC R  reactions were 
pooled prior to cloning o f  the fragment into the pPN T vector and at least two 
separate clones have been analysed for the mutation which was identified in both 
(additionally, recent SSCP analysis has indicated different mutations in normal and 
tum our  tissue from this patient-data not shown). This suggests that the mutation 
exists in the normal cells o f  the individual and for this reason the patient was studied 
further. Mutational analysis o f  the tum our from this patient detected a C A G -T A G  
G ln-Stop mutation at codon 1338, but not the truncating mutation at codon 1359 
detected in the normal sample. However, recently this patient has been diagnosed as 
having a family history o f  colorectal cancer, mandibular osteom as and congenital 
hypertrophy o f  the retinal pigment epithelium (C H R PE) consistent with extracolonic
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manifestations seen in Gardner's Syndrome although with no associated polyposis. 
Such patients have been found to be carriers o f  defective D N A repair genes more 
frequently than the normal population, and are at risk o f  being mosaics. This patient 
could therefore potentially be an APC  mutant mosaic with tissues o f  different lineages 
containing different APC  mutations, a situation previously described anecdotally 
although the frequency o f  tissue mosaicism is unknown (Mandl et al., 1994).
Although incomplete, the experiments described in this section emphasise the 
following points:
1.) The value o f  a targeting approach in the analysis o f  APC  in colorectal neoplasia, as
well as the potential difficulties o f  selecting cells with correctively targeted 
suppressor loci.
2.) The need for the generation o f  vectors to control for this by the replacement o f
one APC  mutation with another within the same region o f  the gene.
3.) The necessity for confirmed wild type sequence correcting vectors.
4.) The unexpected possibility o f  the discovery o f  a patient exhibiting APC  mosaicism.
5.) A ccurate  characterisation o f  a commonly used colorectal cancer cell line with
respect to its APC  status.
In summary,  the generation of  two hit and run gene target ing vectors will allow 
functional  analysis o f  the role of  both mutant and wild type A P C  protein in a 
colon carcinoma cell line. Questions may then be asked regarding the role of






This thesis contains separate studies on three tum our suppressor genes previously 
implicated in colorectal tumorigenesis.
Firstly, the relationship between mutation o f  the p53  gene and stabilisation o f  p53 
protein w as addressed in a series o f  colorectal carcinomas. The general assumption 
that a stabilised p53 product was always equivalent to a mutated gene was shown to 
be false. Although there is a high correlation between mutation o f  the gene and 
stabilisation o f  p53 in colorectal tumours, mutation and stabilisation occur 
independently in a minority o f  cases. Specific circumstances exist in which mutated 
p53 protein is not stabilised, notably with exon 6 mutations. Similar previous studies 
on colorectal and ovarian neoplasms also commonly revealed mutations o f  p53  in 
exon 6 with no stabilisation o f  the protein detectable (Kikuchi-Yanoshita et al., 1992; 
Cunningham et al., 1992; Teneriello et al., 1993). This suggests a region o f  the p53  
gene not essential for the maintenance o f  a stabilised conformation o f  the protein. 
E xon 6 is not located in one o f  the five conserved regions o f  the gene, perhaps 
suggesting a less functionally important region o f  the gene compared to exons 5, 7 
and 8 (Soussi et al., 1990). This could be reflected in the protein structure and 
conformation. The recent publication o f  the 3-dimensional structure o f  the p53 protein
lends support to this idea and the mutations detected in exon 6 in this study would be 
located in regions not directly involved in D N A  binding (Cho et ah, 1994). 
Conversely, tum ours w ere shown to exist with stabilised protein product but with no 
apparent mutation. It is possible that mutations existed outwith the region o f  the gene 
studied. F o r  example, 5' and 3' untranslated regions, and the coding regions outwith 
exons 4-9 not examined in all cases. This criticism cannot be resolved by this study. It 
is possible, however, that non-mutational methods o f  stabilisation occur. This has 
been dem onstrated by the binding o f  both viral and cellular oncoproteins such as the 
SV40 T  antigen and the M D M -2 oncogene product (Sarnow  et ah, 1982; M om and et 
ah, 1992). It is probable that additional cellular oncoproteins that bind p53 exist. 
Alternatively, errors in protein degradation could result in an accumulation o f  non­
m utated  p53 protein.
Recently the effect o f  the cellular environment on stabilisation o f  the p53 protein has 
been considered. It has been proposed that it is not mutation o f  the gene that creates a 
stabilised product but the environment o f  the cell. The mutation itself results in an 
inability to  correctly respond to the stabilisation stimulus (Vojtesek and Lane, 1993). 
It may be extrapolated that the inability o f  the cell to respond to the stabilising 
stimulus due to a lack o f  functional p53 may itself create a permanent stimulus to the 
cell to  upregulate and hence stabilise p53 protein.
The effect o f  stabilised p53 protein, either wild type or mutant, should therefore be 
considered in the context o f  the cell in which it occurs. p53 is stabilised 
physiologically in a number o f  circumstances (for example, in skin keratinocytes after 
U V  irradiation), but the stabilisation is transient and levels return to normal after 360 
hours (Hall et ah, 1993). In contrast, the majority o f  colorectal cancer cells have 
permanently stabilised p53 protein. Additionally, many tum our cells exhibit genomic 
instability in the form o f  aneuploidy and gene amplifications, and p53 has often been 
p roposed  to  be involved in maintaining genome integrity (C arder et ah, 1994; 
Livingstone et ah, 1992). However, it is unclear whether loss o f  p53 function creates 
genom e instability, or whether the loss o f  p53 is a requirement for the viability o f  
unstable cells that would, under normal circumstances die. These represent subtly 
different roles for the protein. The first suggests p53 defects are a causative agent o f  
genom e instability (perhaps through permitting imprecise repair or inappropriate 
recombination events), whilst the second proposes a role for p53 as a monitor o f  
genom e integrity coupled to the activation o f  apoptosis. Experimentally they are 
difficult to  distinguish. W hether cause or effect, stabilisation o f  p53 protein is a 
physiological response to a stimulus that probably involves D NA  damage, and 
therefore studies on stabilisation o f  p53 protein should be interpreted after 
consideration o f  the cellular environment as well as the mutational status o f  the p53
Secondly, the role o f  M C C  was studied in a small subset o f  colorectal tum ours from 
non-polyposis patients who presented with colorectal cancer at a young age (<48 
years). Only one o f  these patients fulfilled all the Amsterdam  criteria for H N PC C  
(Vasen et ah, 1991) although one other patient had an affected first degree relative. 
N o  mutations o f  the gene were found in the entire coding region, although a novel 
polymorphism in intron 13 was identified. The method o f  analysis used in this study 
has previously identified greater than 70%  o f  point mutations present in the p53 gene 
in a series o f  colorectal cancers. Therefore, if M CC  was inactivated by mutation in a 
significant percentage o f  cases then this technique o f  PC R -SSC P would have been 
expected to detect the abnormality. Previous studies from other groups have failed to 
identity mutations o f  the gene in any FPC patients and the number o f  somatic 
m utations o f  M CC  identified in sporadic colorectal tum ours is low. A previous study 
from this laboratory showed that losses o f  5q21 invariably involved both the M CC  and 
A PC  genes (Curtis et ah, 1994). It remains possible that M CC plays a role in a 
minority o f  colorectal tum ours because firstly, deletions o f  5q21 often involve both 
APC  and M C C  and secondly, mutations o f  the gene have been shown in a small 
num ber o f  carcinomas (Kinzler et ah, 1991b). LOH studies, although often 
informative for the potential location o f  tum our suppressor genes may also reflect 
regions o f  the genom e more susceptible to breakage than other areas and this could 
explain the com m on finding o f  LOH at 5q21 which includes the M CC  gene. The small 
numbers o f M C C  mutations discovered to date may also be explained in light o f  the 
recent discovery that as many as 20%  o f  sporadic colorectal tum ours may be caused
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by errors in mismatch repair genes (Lothe et al., 1993) and the tum ours reported with 
MC,C mutations may simply represent a more widespread instability generated by 
errors in mismatch repair or processes. The results from both this and previous studies 
suggest that M C C  is not an important tum our suppressor gene in colorectal tumours.
Finally, experiments were designed to address the question o f  a possible role for APC  
mutation in a colon carcinoma cell line. Two targeting vectors have been created 
which may be transfected into the SW480 cell line in a 'hit and run' hom ologous 
recombination experiment to assess the role o f  APC in colorectal neoplasia in vitro. 
The first vec to r  was designed to correct a known truncating mutation within exon 15 
o f  the APC  gene at codon 1338 and was inadvertently found to contain a novel 
truncating mutation, 21 codons downstream o f  this site at codon 1359.
This, however, provided a useful control as it is more difficult to design experiments 
that aim to  correct genes with suppressor activity than it is to destroy their function. 
This is especially true when the suppressor gene is associated with a decrease in cell 
proliferation o r  an increase in apoptosis, both o f  which characteristics would render 
the cell disadvantaged in vitro when compared to cells retaining a mutant protein. The 
generation o f  a targeting vector that could assess the efficiency with which 
hom ologous recombination occurs without placing the cell at a potential growth 
disadvantage provides a good control for the experiment. This vector could also be 
used to generate APC  mutations in otherwise 'normal' diploid cell lines to mimic the 
early stages o f  colorectal tum our development seen in both FPC and sporadic 
tum ours. The mutation in APC  in pPN T.A PC  occurs in the M C R  region o f  the gene, 
a region in which greater then 60% o f  somatic APC mutations have been shown to 
occur in sporadic colorectal cancer (Miyoshi et ah, 1992b). These cells would
therefore represent an event frequently seen early in sporadic colorectal cancer 
development, and could provide valuable information on the early progression o f  
colorectal cancer with the subsequent accumulation o f  additional genetic events. A 
potential source o f  such cells may be from the "Immortomouse". This m ouse has a 
SV40 T antigen transgene incorporated under the M H C  prom oter  which is 
tem pera ture  and interferon y sensitive (Jat et al., 1991). Fibroblast lines from the 
m ouse  could be maintained in vitro by culture at the permissive tem perature  and in 
the presence o f  interferon y. Transfection o f  pPN T.A PC  and subsequent down- 
regulation o f  the SV40 T antigen would allow the effects o f  a mutant APC  gene to be 
considered. Additionally, cells containing both wild type and mutant APC protein will 
provide data on the possibility o f  dominant negative mutation o f  APC. Removal o f  the 
second copy o f  APC  by for example a deletion vector may mimic the situation seen in 
adenom as that have lost both copies o f  the APC  gene. This will provide in vitro 
information on the question o f  whether inactivation o f  both copies o f  the APC  gene is 
necessary for adenoma formation. Transfection with similar vectors disrupting other 
genes commonly mutated in colorectal cancer such as rcis and p53  would provide 
additional information on the progression o f  colorectal tumours. Alternatively, 
transfection o f  the mutant APC  vector on to other genetic backgrounds such as 
fibroblasts from Li-Fraumeni patients or ras transfected cells may provide data on the 
way these genetic lesions functionally interact. This could then be compared to the 
theory that it is the total number o f  genetic lesions acquired in colorectal 
tumorigenesis rather than their order which is important (Vogelstein et al., 1988). If  
this theory is correct, one question that may be asked is why there is a preferred order 
o f  genetic lesions in colorectal cancer development rather than a random 
accumulation and it is possible that the order o f  accumulation o f  genetic events 
produces characteristic phenotypes
A  second targeting vector containing putative wild type APC  sequence has been 
generated and will be used to correct the APC  gene in SW 480 colorectal tum our 
cells. This will also provide evidence for the progression o f  colorectal cancer. 
Correction o f  a genetic lesion frequently associated with the early stages o f  colorectal 
tumorigenesis, in a cell line with multiple genetic abnormalities should provide data 
on the functional interaction o f  the associated gene products in neoplasia. The 
question then to  be asked is whether mutation or loss o f  A PC  creates a 'gateway' 
th rough which subsequent genetic lesions like mutation o f  K-ras or loss/mutation o f  
p53  can arise. The fact that mutation o f  APC  is so commonly the first genetic 
abnormality associated with colorectal neoplasia in both sporadic or hereditary forms 
suggests a critical role for the protein in tum our progression The generation o f  the 




7.1 The relationship between p53  mutation and protein 
stabilisation in colorectal carcinomas.
7.11 Immunocytochemistry
Im m unocytochem istry had previously been performed on periodate lysine 
paraform aldehyde dichromate (PLPD) fixed, paraffin embedded tum our sections with 
the monoclonal antibody PAb 1801 (Oncogene Science) as previously described 
(Purdie et al., 1991; Carder et ah, 1993). Briefly, PAblSOl was applied to the tissue 
sections and a biotinylated rabbit antimouse secondary antibody linked to avidin was 
applied, conjugated with horse radish peroxidase and visualised by diaminobenzidine. 
ICC with the antibodies DO-7 (DAKO) and CM-1 (D. Lane) was performed on 
formalin fixed tissue in the same way except DO -7 sections were pre-treated with 
microwaves. Sections were incubated in a standard citrate buffer (Appendix) and 
exposed to microwaves in 3X5 minute treatments in a 650W  m icrowave on high 
pow er as described (Shi et ah, 1991; Cattoretti et ah, 1994)
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Table 4. Ant ibody epitopes and details:
A N T I B O D Y EP IT OPE  
(amino acids)
DE TAIL S R E F E R E N C E
PAbl801 32-79
Murine human specific 
monoclonal antibody that 
recognises both mutant and 
wild type protein.
Banks et ah, 1986
DO-7 1-45, probably 37- 
45
M urine human specific 
monoclonal antibody that 
recognises both mutant and 
wild type protein.
Vojtesek et ah, 1992
CM-1 pan specific
Rabbit human specific 
polyclonal antibody that 
recognises both mutant and 
wild type protein
Midgley et ah, 1992
7.12 PC R-SSCP
Genom ic D N A  was extracted using a proteinase K digestion method. Briefly, normal 
mucosal or tum our tissue was digested overnight at 55°C in lysis buffer (Appendix) 
containing 200pg/m l proteinase K. After 16 hours an equal volume o f  phenol was 
added, mixed and centrifuged at 13k rpm for 5 minutes. The upper phase was 
rem oved and an equal volume o f  phenokchloroform (1:1) added mixed and 
centrifuged as above. The upper phase was again removed and an equal volume o f  
chloroforrmisoamylalcohol (24:1) added and treated as above. An equal volume o f  
isopropanol was added to the upper phase and mixed until a white precipitate formed. 
The sample was centrifuged as above and the supernatent removed. The pellet was
washed in 70%  and then 100% ethanol and allowed to dry. The D NA  pellet was 
resuspended in TE buffer (Appendix).
The polymerase chain reaction was performed on 0.1-1 pig paired normal and tum our 
genom ic D N A  samples in an lOOpl reaction containing 20nmoles o f  each 
deoxynucleotide (Pharmacia), 50pmoles o f  each primer (Oswel D N A services), and 2 
units o f  a thermostable Taq polymerase in the relevant buffer (Life Technologies). The 
samples w ere overlaid with paraffin oil to eliminate sample evaporation. P C R  was 
perform ed in a D N A  thermocycler (Hybaid) with the following tem perature  profile: 1 
cycle o f  9 4 °C  for 5 minutes, 30 cycles o f  94°C  for 1 minute, 58 °C  for 1 minute, 
72 °C  for 1 minute and 1 cycle o f  72°C  for 10 minutes. The primers were as follows 
( 5 ' to  3'):
exon 5up T T C C T C T T C C T A C A G T A G T C  
exon 5reverse C G A T G G T G A G C A G C T G G G  
exon 6up C C T C A C T G A T T G C T C T T A G G  
exon óreverse C T G A G G T C T G G T T T G C A A C T  
exon 7up T G T G T T A T C T C C T A G G T T G G  
exon 7reverse G T C A G G A G C C A C T T G C C A  
exon 8up T C C T A T C C T G A G T A G T G G T  
exon Sreverse C G A G G T A A G C A A G C A G G A .
The samples w ere extracted once with 24:1 chloroform/isoamylalcohol to remove 
mineral oil. 5pl-10pl were then denatured in 80pM  NaOH, lOpM ED TA  at 4 8 °C  for 
5 minutes. 2pl sequencing stop solution (Appendix) was added, and the whole sample
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loaded onto  a 5% glycerol, lxT B E  (NBL), 0.5X M D E  Hydrolink gel (Hoefer). The 
gel w as run in lx T B E  on the SE600 PAGE apparatus (Hoefer) at 25°C , 20W  for 2-3 
hours, (additionally, alternative conditions o f  4 °C  in the absence o f  glycerol were 
used in some cases). Bands were visualised by a silver stain (BioRad) as per 
manufacturers instructions. Briefly, the gel was fixed in a 40%  methanol solution on 
an orbital shaker for at least 1 hour or overnight, followed by tw o  subsequent fixes in 
a 10% ethanol solution for 30 minutes. The gel was then oxidised in a solution 
containing potassium dichromate and nitric acid for 10 minutes. 12-15 tw o minute 
w ashes o f  deionised w ater were then applied to the gel until all the yellow colour was 
removed. A silver nitrate solution was then applied for 30 minutes and rem oved by a 2 
minute deionised w ater wash. Developing solution containing sodium carbonate and 
paraformaldehyde was added in 2 batches and left until the brown D N A bands were 
visible but before a high level o f  background was observed. The reaction was stopped 
using a 5% acetic acid solution for 30 minutes. The gel was dried onto W hatmann 
3 M M  paper and laminated.
7.13 Sequencing of tumours with abnormal SSCP bands
Sequencing was performed by one o f  two methods using the PCR primers as 
sequencing primers:
1.) Subcloning o f  a PC R  product containing exons 7-9 o f  the p53 gene into 
pG E M 7Z f+
A  P C R  product containing exons 7-9 o f  the p53 gene was cloned into the pG EM - 
Zf7+ plasmid vector (Prom ega) after amplification using the above PCR conditions 
and the following primers
890- 5 'G A G A G A A G C T T G C C A C A G G T C T C C C C A A G G C G A A
891- 5 'A G A G A G G G A T C C A C T T T C C A C T T G A T A A G A G G T C C C A A G
The PC R  product was blunt ended using 0 .5m M  dN TP and 5U o f  Klenow fragment 
(Life Technologies) in the EcoRI restriction enzyme buffer (Boehringer M annheim) at 
30 °C  for 15 minutes. The reaction was stopped by heating at 75 °C  for 10 minutes. 
The resulting blunt ended PCR fragment was cloned into the Smal restriction enzyme 
site o f  the pG EM 7Zf+  vector by a blunt ended ligation using 5U o f  T4 D N A  ligase in 
the appropriate  buffer (Boehringer Mannheim). Ligations were diluted 1/5 and used to 
transform D H 5 a  competent cells as per the manufacturers protocol (Life 
Technologies). Briefly, l- lO ng o f  diluted ligated D N A  was added to 20 pi o f  D H 5 a  
cells in a chilled microfuge tube and left on ice for 30 minutes. Cells were heat 
shocked at 4 2 °C  for 40 seconds and returned to ice. 80pl o f  SOC medium 
(Appendix) was added and the tubes were placed in a 37°C  orbital shaker for 1 hour
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The cells were applied to L-Amp plates (Appendix) with dpi o f  200mg/ml IPTG 
(isopropylthio-|3-D-galactoside) and 40pl o f  20mg/ml X-Gal (5-B rom o-4-chloro-3- 
indolyl-P-D-galactoside) for blue white colony screening (Prom ega) and left at 37 °C  
overnight. Briefly, cloning into the polylinker o f  pG E M 7Z f+  disrupts the vector Jaca 
gene. This leads to a loss o f  functional a -p ep tid e  with no resulting complementation 
with the host cell lacZ gene product to produce functional p-galactosidase when 
plated with X-Gal and IPTG. Resulting colonies are therefore white not blue. Plates 
w ere  placed at 4 °C  for 8 hours and approximately 100 white colonies were pooled 
and used to seed 10ml L-broth (Appendix) with lOpg/ml ampicillin for selection o f  
plasmids which contains the bacterial ampicillin resistance gene.
Plasmid D N A  was prepared using the Wizard Mini-prep kit (Promega). Briefly, 1- 
3mls o f  cells were pelleted and resuspended in 200pl Cell Resuspension solution 
(Appendix). The cells were lysed by the addition o f  200j.il Cell Lysis buffer 
(Appendix) and mixed by inverting gently 4-5 times. The samples w ere neutralised by 
the addition o f  200j.il Neutralisation solution (Appendix). Precipitated proteins were 
pelleted by centrifugation and the supernatent added to 1ml o f  Wizard Mini-prep 
resin. The mix was then applied to the Mini-prep column and applied to the column 
using a 2ml luer syringe. 2 mis Column Wash solution (Appendix) was applied to the 
column. Residual Column Wash was removed from the resin by centrifugation. 
Plasmid D N A was eluted by the addition o f  TE buffer heated to 65^C, left for 1 
minute, centrifuged and collected.
D N A  was sequenced by the chain termination method using the PC R -SSC P primers 
as sequencing primers and (J 5S)dATP (Amersham) as per the manufacturers protocol 
for dsD N A  (United States Biochemicals, Sequenase Version 2.0). Briefly, 3-5|_ig 
D N A  w ere  added to IX  Reaction Buffer (Appendix), lpm ole  primer and deionised 
w ater  to  a volume o f  10j.il. Primer was annealed to the D N A  by heating to 6 0 °C  and 
cooled to  less than 35 °C  over 30 minutes. Samples w ere than placed on ice and 0 . 1M 
dithiothreitol, IX  Labelling Mix (Appendix), 5j.iCi ( ^ S ) d A T P  and Sequenase enzyme 
added and mixed gently. Samples were labelled at room  tem perature  for 2-5 minutes. 
R eactions w ere  terminated by the addition o f  3.5j.il labelled mix to 2.5j.il o f  each 
dideoxynucleotide at 37 °C  for 5 minutes. The termination reaction was stopped by 
the addition o f  4j.il o f  sequencing stop solution. Samples were maintained at -20°C  
until required. Samples were denatured at 95 °C  for 5 minutes, and separated by 
electrophoresis through a prewarmed 50°C  6% urea/acrylamide gel (Appendix).
After electrophoresis, the gel was fixed for 10 minutes in a 10% methanol/10% acetic 
acid solution, dried onto W hatmann 3M M  paper, and exposed to autoradiograph film 
overnight.
2.) P C R  amplif icat ion o f  exons 5-6 using a biotinylated upstream primer and 
separation o f  the DNA strands using Dynabeads.
E xons 5-6 o f  p53 w ere amplified using a biotinylated upstream primer as follows 
5 'A G G A G G T G C T T A C A C A T G T T
with the exon 6 reverse primer as above under the above PCR conditions. The D N A  
w as separated into single strands by the use o f  magnetic Dynabeads as per the 
manufacturers instructions (Dynal). Briefly, the biotinylated PCR products  were 
mixed with 25j.il o f  avidin coated magnetic beads previously washed in 100j.il TES 
(Appendix). The biotinylated D N A  was allowed to absorb onto the avidin coated 
beads for 5 minutes at room  temperature. The supernatent was removed using a 
magnet to  'fix' the D N A  attached beads to the side o f  the tube. The D N A strands were 
separated by the addition o f  freshly prepared 0 .15M NaOH at room tem perature for 5 
minutes. The supernatent containing the complementary single stranded D N A  was 
recovered using a magnet and ethanol precipitated with 200pil 100% ethanol at -2 0 °C  
for 2 hours. The complementary DNA was washed with 70%  ethanol and 
resuspended in 20j.il distilled water. The biotinylated D N A  strand remained bound to 
the avidin coated beads and was washed with 100j.il TES followed by 100j.il o f  
distilled w ater  and resuspended in 20j.il water. Sequencing was performed as above.
7.2 Is the A/CC gene involved in Colorectal Carcinogenesis?
7.21 Clinical material and DNA preparation
The xenografts w ere passaged in SCID mice by techniques previously described 
(M cQ ueen  et al., 1991). Patients were selected on the basis o f  their age at diagnosis. 
Family histories were established by interview o f  the patients and relatives and 
confirmed by reference to histopathology reports and death registers (Data collected 
by N orm a  Brown).
High molecular weight D N A  was prepared from xenograft tissue as previously 
described. D N A  was extracted from corresponding blood samples by the addition o f  
blood lysis buffer (Appendix) for 30 minutes. An equal volume o f  TE saturated 
phenol was added and mixed thoroughly then centrifuged at 3k rpm for 20 minutes. 
The upper layer w as removed and to it was added 0.5X 7.5M  ammonium acetate and 
3X cold isopropanol. This was mixed and left at -20°C  overnight. The D N A  pellet 
w as recovered by centrifugation as above, dried and resuspended in TE.
7.22 PCR-SSCP of exons 1-17
The polymerase chain reaction was performed on 0.1-1 gg paired blood and xenograft 
genom ic D N A  samples, in a 50j.il reaction containing 20nmoles o f  each 
deoxynucleotide, 50pmoles o f  each primer, and 2 units o f  a thermostable Taq 
polymerase in the relevant buffer. PCR was performed in a D N A  thermocycler with 
the following tem perature profile: 1 cycle o f  94 °C  for 5 minutes, 30 cycles o f  94°C
for 1 minute, an annealing temperature calculated by subtracting 2 °C  from the melting 
tem pera ture  (see below) o f  each primer for 1 minute, 72 °C  for 1 minute and 1 cycle 
o f  7 2 °C  for 10 minutes. The primers w ere as indicated (Table 5). The melting 
tem pera ture  for a given primer can be roughly estimated using the following formula: 
M elting tem perature  (Tm) in °C  = 4(total number o f  G and C residues) + 2(total 
num ber o f  A and T residues).
The samples w ere prepared for SSCP analysis as previously described. SSCP gels 
w ere  run in lx T B E  on the SE600 PAGE apparatus (Hoefer Scientific) at 25°C , 20W  
for 2-3 hours. Additionally alternative conditions o f  4 °C  in the absence o f  glycerol 
w ere  used in some cases. Bands were visualised by a silver stain as previously 
described. The gel was dried onto 3M M  paper and laminated.
7.23 Sequencing of polymorphic exons
Sequencing was performed as previously described either by Dynabead separation 
(Dynal) or by subcloning o f  the PC R  fragment in to a plasmid vector (pGEM -7Zf(+), 
Prom ega). Samples w ere then sequenced by the chain termination method using 
Sequenase Version 2.0 as above (United States Biochemicals).
Table 5. PCR PRIM ERS AND SIZE OF A M P L IF IC A T IO N
PRODUCT FOR M CC EXONS.
EXON SIZE IN BASE 
PAIRS






































































7.3 Targeting of the A PC  gene in a colon carcinoma cell line
7.31 Generation of a hit and run targeting vector pPNT.APC
The vecto r  pPN T .A PC  was generated by insertion into the plasmid pPN T o f  a 2.8kb 
P C R  product amplified from genomic D N A  from exon 15 o f  the APC gene 
nucleotides 3232-6017. This region spans the truncating mutation at codon 1338 o f  
APC  in SW 480 cell line. pPN T  is a pUC based vector containing the neomycin 
resistance gene m o  and the Herpes Simplex Virus thymidine kinase gene tk , both 
under a PG K  prom oter  (obtained from the Centre for G enom e Research Edinburgh,
S. Fiering).
P C R  amplification o f  the region o f  APC  exon 15 (nucleotides 3232 to 6017) was 
performed using 1 pig o f 'norm al '  mucosal genomic DN A  prepared as above in a 50j.il 
reaction containing 200pM  o f  each deoxynucleotide, 50pmoles o f  each primer, and 2 
units o f  a thermostable Taq polymerase in the relevant buffer. PCR was performed in 
a D N A  thermocycler with the following tem perature profile: 1 cycle o f  9 4 °C  for 5 
minutes, 4 cycles o f  94 °C  for 1 minute, 56°C  for 1 minute, 72°C  for 1 minute, 26 
cycles o f  9 4 °C  for 1 minute, 48°C  for 1 minute, 72°C  for 1 minute, and 1 cycle o f  
72 °C  for 10 minutes.
The primers w ere as follows (5' to 3'):
S W 480A P C up .5 T A T G A A T T C T A T A C T G A G A G C A C T G A T G  
SW 480A PC rev.2  A T A T G G A T C C T G A T G C T T G A G G T T T
The primers w ere designed to include restriction enzyme sites (bold type) at either end 
to  allow directional cloning o f  the fragment into the plasmid vector (SW 480A PC up.5  
contains a Bam H I site whilst SW 480APCrev.2 contains an EcoRI site). The 2.8kb 
P C R  fragment was extracted once with 24:1 chloroform:isoamyl alcohol to remove 
any mineral oil from the PC R  reaction. The fragment was then separated from other 
P C R  reaction constituents by cleaning with a Wizard Clean-Up column as per the 
manufacturers protocol (Promega). Briefly the sample is mixed with the Wizard 
Clean-up resin and applied to the column as described above for the Wizard Mini-prep 
procedure. The column is washed with 2ml 80% isopropanol and the sample collected 
as described. Both the eluted PCR fragment and 5pg  o f  pPN T  were digested with the 
appropriate  amount o f  the restriction enzymes BamHI and EcoRI in BamHI buffer 
(Boeringer Mannheim) at 37 °C  for four hours.
The digestion reaction com ponents were separated from the PCR fragment and the 
vecto r  using the Wizard Clean-up columns as described above and quantified against 
know n D N A  standards. Samples containing 1:1, 3:1 and 10:1 molar ratios o f  PC R  
fragment to vector and 5-10U T4 D N A  ligase in an appropriate buffer were placed at 
16°C  overnight. 1/5 dilutions o f  the ligation mixes were used to transform D H 5 a  
com petent cells as previously described. Plasmid DN A  was extracted using the 
W izard Miniprep Kit. Eluted plasmid DNA was digested with both BamHI or EcoRI 
or  both  as described above, mixed with 2 pi loading buffer (Appendix) and separated 
by electrophoresis through a 0.8% agarose gel (Flowgen) to identify plasmids
containing the 2.8kb APC fragment. Plasmids containing the fragment w ere replated 
and regrown.
M axipreps o f  pPN T .A PC  were prepared according to the m anufacturers protocol 
(Qiagen Tip 500). Briefly, 500ml o f  cells were pelleted by centrifugation at 4 °C  for 
15 minutes at 6000xg. The supernatent was removed and the cells resuspended in 
50ml buffer P I  (Appendix). The cells were lysed by the addition o f  50ml o f  buffer P2 
(Appendix), mixed gently and left at room  tem perature for 5 minutes. The sample was 
neutralised by the addition o f  50ml o f  chilled buffer P3 (Appendix), mixed and left on 
ice for 30 minutes. The precipitated proteins were pelleted by centrifugation at 4 °C  
for 2X  15 minutes at 20,000xg. A Q IAGEN-tip  2500 was equilibrated by the addition 
o f  35ml o f  buffer QB T (Appendix) and the column allowed to empty by gravity flow. 
The clear supernatent was applied to the column and again allowed to empty by 
gravity flow. The sample was washed by 4X 50ml buffer QC (Appendix) and the 
sample finally eluted with 35ml buffer QF (Appendix). The DNA was precipitated 
with 0.7 volumes o f  isopropanol centrifuged at greater than 20,000xg at 4 °C  for 30 
minutes. The D N A  pellet was washed with 5ml cold 70%  ethanol and air dried before 
resuspension in TE buffer.
The 2.8kb APC fragment in pPN T.A PC  was sequenced using the Erase-a-Base 
system (Promega). This involves the generation o f  plasmids containing unidirectional 
nested deletions o f  the insert DN A  using exonuclease III (Exo III). ExoIII digestion 
proceeds at a uniform rate at a given temperature and removal o f  timed aliquots 
allows deletions o f  a predetermined length to be created. An adjacent sequencing
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primer site is protected from digestion by creating a 4-base 3' overhang by restriction 
digestion. The ends o f  the deleted sequences are repaired and the plasmid used to 
transform com petent cells as above. The 2.8kb APC fragment was excised from 
pP N T .A PC  by a Bam H I/EcoR I double digest as previously described and cloned into 
the vecto r  pGEM -Zf7+. The pG EM 7Zf+  vecto r  contains a number o f  unique 





















A m p ic i l l in  res is tance  gene
Figure 25. A map of  the vector pGEM 7Zf(+)  as shown in Erase-a-Base technical  
manual .
Nicked and linear D N A was removed from the supercoiled plasmid D N A  by the 
following protocol; 0.1 volumes o f  3M sodium acetate pH 5.2 w ere added to the 
plasmid D N A  sample and precipitated with ethanol as described. The D N A  pellet was
resuspended in deionised w ater and 2M sodium acetate pH 4.0 was added to a final 
concentration o f  50m M  and 2M NaCl to a final concentration o f  75mM. At 4 °C , an 
equal volum e o f  acid-phenol (Appendix) was added and mixed. After centrifugation 
at 10,000xg for 5 minutes the aqueous phase was recovered and the acid-phenol step 
repeated  2-3 times. After extraction, 0.05 volumes o f  1M Tris.HCl pH 8.6 was added 
and the sample extracted with 1 volume o f  chloroforrmisoamylalcohol (24:1). To the 
aqueous phase, 0.1 volumes 2M  NaCl was added and the D N A  precipitated with 
ethanol. The pellet was rinsed with 70% ethanol, dried and resuspended at 0.5-1 pg/pl 
in TE buffer.
In order to  generate an exonuclease 111 sensitive 5' overhang, 5pg  o f  the recovered 
D N A  w ere digested with BamHI as described, overnight at 37°C. The digested D N A  
w as extracted with phenohchlorofonn (1:1) and chloroforrmisoamylalcohol (24:1) 
and precipitated with 3M sodium acetate and ethanol. The pellet was resuspended and 
digested overnight with SacI to generate an exonuclease III resistant 3' overhang (see 
Figure 25). The digest was extracted as above and the dried pellet resuspended in 60p  
1 exonuclease III (ExoIII) buffer (Appendix). The D N A was warmed to 37 °C  in a 
w ater  bath and 300U ExoIII were added. At 37°C  digestion proceeds at 
approximately 450 bases/minute with a 20-30 second lag before digestion begins. 2.5 
pi samples w ere  removed at 30 second intervals and mixed with 7.5pl SI nuclease 
mix (Appendix) on ice. The samples were placed at room tem perature for 30 minutes 
before the addition o f  1 pi o f  SI stop buffer (Appendix) and heat inactivation at 70°C  
for 10 minutes. The samples were transferred to 37 °C  and lp l  Klenow mix added
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(Appendix). After incubation for 3 minutes, lp l  dN TP mix (Appendix) was added and 
the samples incubated for a further 5 minutes. At room  temperature, 40pl ligation mix 
(Appendix) was added, mixed and incubated for 1 hour. 10pl o f  each ligation reaction 
w as added to  20p.l D H 5 a  competent cells and transformation proceeded as previously 
described. 6 transformants per time point were selected and individual colonies were 
picked and smeared near the bottom  o f  a sterile microfuge tube, the remaining cells 
w ere streaked onto a fresh L-Amp plate and incubated at 37°C . 50pl lOmM ED T A  
pH  8.0 was added to the cells in the microfuge tube and the cells resuspended. 50j.il 
cracking buffer (Appendix) was added and the cells vortexed. To this was added 1.5j.il 
4M  KC1 and 0.5j.il o f  0 .4%  bromophenol blue and the samples placed on ice for 5 
minutes. The samples were centrifuged and 25pl o f  the supernatent were separated by 
electrophoresis on a 0,7% agarose gel. The plasmid sizes were estimated by running 
against know n supercoiled plasmid markers (Life Technologies). Correctly sized 
plasmids w ere  grow n as overnight cultures and plasmid DNA was extracted as above. 
Sequencing was performed using 1 pinole o f  a commercial sequencing primer (SP6, 
P rom ega) as previously described.
7.32 Generation of the targeting vector pPNT.APCwt
p P N T .A P C w t was generated as described for pPN T .A PC  above, except that the 
template D N A  used to amplify the 2.8kb APC fragment w as mucosal D N A  from non­
colon cancer bearing individuals (provided by M. Dunlop). pPN T .A P C w t remains to 
be sequenced to  confirm the absence o f  mutations.
7.33 Culture and analysis of SW480 cells
SW 480 cells w ere obtained from the Laboratories o f  the ICRF (C Marshall) and 
g row n in L-15 medium supplemented with heat inactivated 10% new-born calf serum 
(Sigma and Life Technologies). Cultures were maintained in a humidified incubator at 
3 7 °C  with 5% C 0 2 .
Cells g rew  as a monolayer in isolated clumps o f  epithelial like cells. Tumorigenicity 
w as assessed by the subcutaneous injection o f  107 SW 480 cells in 0.2ml phosphate 
buffered saline (PBS) into SCID mice maintained in isolators. Tum ours w ere detected 
in all animals by three weeks after injection. The tum ours were removed, fixed and 
examined histologically by A.H.Wyllie. The histological characteristics o f  the original 
parental tum our i.e. adenocarcinoma were retained (Figure 23).
7.331 A P C  analysis of SW480
A  2Kb APC probe was generated by PCR amplification o f  normal genomic D N A  
under the following conditions. In a 50pl reaction, 15nmoles deoxynucleotides, 
50pmoles primer, and 2 units o f  a thermostable Taq polymerase in the relevant buffer
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w ere  amplified in a DN A  thermocycler with the following tem perature  profile: 1 cycle 
o f  9 4 °C  for 5 minutes, 4 cycles o f  94 °C  for 1 minute, 56°C  for 1 minute, 72 °C  for 1 
minute, 26 cycles o f  94 °C  for 1 minute, 4 8 °C  for 1 minute, 72 °C  for 1 minute, and 1 
cycle o f  72°C  for 10 minutes. Primer sequences were as follows (5 '-3 ').
63ON C A C C G A A T T C G A A T A C T A C A G T G T T A C C  
63 IN  A A G A G G A T C C A T C T G G A G T A C T T T C
Amplified product was cloned into pG EM 7Zf+  as previously described to generate a 
vecto r  pAPC.KC. Plasmid DNA was extracted as described and labelled with 22P by 
nick translation using the Megaprime kit as per m anufacturers instruction 
(Amersham). Briefly, 25ng o f  plasmid DNA were denatured at 100°C for 5 minutes in 
the presence o f  random nonamer primers in a 50pil reaction volume. The D N A  and 
primers w ere  allowed to anneal at room tem perature and 10j.il M egaprime reaction 
buffer (Appendix) added. 50uCi (22P) dCTP and 2U Klenow fragment were added, 
mixed and placed at 37 °C  for 30 minutes.
SW 480 D N A  was prepared by the proteinase K method previously described. D N A  
w as digested with PstI in an appropriate buffer (Boehringer Mannheim) and the 
digests electrophoresed with 1/5 volume loading buffer on a 0 .8%  agarose gel. The 
gel was depurinated in 0.25M HC1 for 10 minutes and rinsed in distilled water. A 
capillary blot was set up for an alkali transfer using 0.4M  N aO H  and the D N A  
transferred to a Hybond N +  (Hybond) membrane by capillary action overnight. The 
m em brane was briefly rinsed in 2XSSC (Appendix) and dried between sheets o f  3M M  
paper. Radiolabelled probe was denatured at 100°C for 5 minutes prior to addition to
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the filter after prehybridisation o f  the filter in hybridisation solution (Appendix) at 
6 5 °C  in hybridisation bottles (Hybaid). The probe was hybridised to the D NA  on the 
filters at 6 5 °C  overnight. The next day, the probe was removed and the filter washed 
in 2xSSC  at 6 5 °C  for 30 minutes and then 2xSSC, 0 .5%  SDS at 6 5 °C  for 2 hours 
(constituting a medium stringency wash). Filters w ere wrapped in Saran wrap and 
placed in a light p ro o f  cassette with X -O M A T  film (Kodak). X-ray film was 
developed after 24 hours.
7.332 Fluorescence in-situ Hybridisation (FISH) analysis of APC in 
SW 480
M etaphase  spreads o f  SW 480 were prepared by the addition o f  1 pig/ml colchicine to 
the culture medium. Cells were left at 37 °C  for 2 hours, rinsed in PBS and harvested 
using 0 .2%  trypsin. Cells were centrifuged at 2.5K for 5 minutes and swollen by the 
addition o f  10ml fresh hypertonic 0.075M  KC1 for 10 minutes. Cells were centrifuged 
at 2 .5K for 5 minutes and the KC1 removed. The cell pellet was disrupted by gentle 
tapping o f  the tube and 3; 1 methanol to glacial acetic acid fix was added drop by 
drop. Centrifugation and addition o f  fix was repeated 3X. Spreads were obtained by 
dropping the cell/fix solution from approximately 2 metres onto ice-cold, clean 
m icroscope slides and allowed to dry (Figure 26).
Y A C  and cosmid APC clones were used as probes for FISH analysis.
The Y A C  clone w as obtained from K.Kinzler and isolated from yeast chrom osom es 
by S.Farrington. Briefly this involved the growth and lysis o f  yeast cultures and
Figure 26. M etaphase spread of SW 480 chromosomes
A metaphase spread o f  SW 480 cell with 55 chromosomes.

separation under pulsed field gel electrophoresis against yeast markers. The gel was 
fixed and the D N A  transferred to a nylon membrane. Southern analysis was 
perform ed with the 2kb APC probe to locate the APC YAC D N A  (data not shown). 
The gel was rerun and a gel slice containing the YAC D N A  (calculated from the 
previous gel) was extracted. Preparation o f  YAC D N A  involved the digestion o f  the 
agarose, and subsequent addition o f  linker sequences to the D N A  to provide PC R  
primer sites. A PC R  reaction was then performed and the amount o f  D N A  generated 
w as estimated.
The APC cosmid was prepared as described in Hampton et al., 1992 and W ard et ah, 
1993 and w as performed by J. Fantes.
The Y A C  and cosmid D N A  were labelled with biotin and used as probes for FISH 
analysis on the SW 480 chrom osom e spreads. Briefly probes were biotinylated by nick 
translation, applied to the chrom osom e spreads, the signal amplified by avidin and 
biotin linked antibodies and visualised by avidin/FITC conjugated secondary 
antibodies. Cells were counter-stained using propidium iodide or 4', 6'-diamidino-2- 
phenylindole (DAPI) and observed under a Zeiss Axioplan fluorescent microscope 
linked to an Apple Macintosh com puter with a photometric  camera and Digital 
Scientific software or by a confocal scanning microscope (BioRad) linked to a similar 
com puter  package.
Additionally, FITC or Texas Red labelled chrom osom e paints were used either 
independently or in conjunction with the YAC or cosmid probes to identify 
chrom osom es 5 and 20. (Cambio, as per instruction).
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7.34 Transfection of targeting vector pPNT.APC
Electroporation conditions were established as follows. A range o f  conditions 
(voltages from 0.2-1KV  and resistance from 3-500piF) were applied to the 
e lectroporation o f  30pig pPN T.A PC  into aliquots o f  106 SW 480 cells. Cells were 
plated at densities o f  5x105, 10 5, 104, and 103 in L-15 medium supplemented with 
10% H IN C S. After 24 hours, 600pg/ml G418 was added to the plates containing 
5 x l 0 5 and 105 cells, and at all subsequent media feeds (every tw o days). After one 
w eek, the number o f  viable cells was calculated at all initial plating densities by 
washing in PBS, fixing with 70% ethanol and staining with 5% Giemsa. The number 
o f  colonies grow n on the plates originally containing 103 and 104 cells w ere counted 
and the number o f  viable cells remaining for each electroporation condition calculated.
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Figure 27: Viability o f  cells at different e lectroporation conditions.
Legend.
A l: 0.4KV, 3uF - 104cells E l: 25uF, 0.2KV - 104cells
A2: 0.4KV. 3uF - l()3ce"s E2: 25uF. 0.2KV - IQ3 cells
B i: 0.4KV. 125uF - IO4 ce,,s FI: 25uF. 0.4KV - 104cells
B2: 0.4KV, 125uF- 103cells F2: 25uF. 0.4KV - 103cells
C l: 0.4KV. 250uF - 104cclls G l: 25uF. 0.6KV - 104cells
C2: 0.4KV. 250uF - 103celis G2: 25uF. 0.6KV - I03cel‘
DI: 0.4KV, 50 Ou F - I04cells HI: 25uF. 1.0KV - I04cells
D2: 0.4KV. 500uF - IQ3 cells H2: 25uF. l.OKV - I03eells
The plates containing cells originally plated at densities o f  5xlCP and 105 and
subsequently placed in G418 selection were stained as above and the number o f  
colonies counted to obtain a rough estimate o f  the number o f  cells to be 
e lectroporated in order to obtain sufficient G418 resistant clones for analysis. Cells 
plated at a density o f  5x106 generated approximately 20 G418 resistant clones (data 
not shown).
pP N T .A PC  D N A  was linearised with Nsil in an appropriate buffer for 4 hours at 
3 7 °C  (Boeringer Mannheim). IO8 SW 480 cells were transfected with 800pg  
linearised pPN T .A PC  by electroporation at 25uF and O.ókV in a BioRad 
e lectroporation cuvette in the Gene Pulser (BioRad). Transfected cells were plated at
cell densities o f  either 107 or 5 x l0 6 cells per plate with culture medium. After 24 
hours the medium was supplemented with 600j.ig/ml G418 sulphate (Life 
Technologies BRL). Medium with G418 was replaced every two days.
After three w eeks colonies o f  G418 resistant cells w ere  readily visible by eye and 
colonies w ere  picked using a finely drawn Pasteur pipette in a still air hood and placed 
in 24 well plates with G418 supplemented media. Individual colonies that grew  to 
confluence w ere  removed by trypsinisation and half o f  each colony was placed in 
freezing media (Appendix) and frozen at -70°C  overnight and transferred to liquid 
nitrogen. D N A  was extracted from the remaining cells using the proteinase K m ethod 
previously described. Approximately 5 pg  o f  D N A  was digested with StuI (Boeringer 
M annheim ) and electrophoresed on a 0.8% gel. Alkali blotting was performed as 
previously described.
A PPEN D IX
C I T R A T E  BUFFER:
7m M  Citric acid pH6
L Y S IS  B U F F E R :
50mM  Tris pH 8.0 




0.5 m M  spermidine
TE:
lOmM  Tris.HCl pH 7.4 
Im M  E D T A  pH 8.0
S E Q U E N C I N G  ST O P SOLUTIO N:
98%  deionised formamide 
lOmM E D T A  pH 8.0 
0 .025%  xylene cyanol FF 
0 .025%  bromophenol blue
S O C  M E D IU M :
Prepared  as described in transformation protocol (Life Technologies).
2%  bactotryptone 
0 .5%  yeast extract 
1 OmM NaCl 
2 .5m M  KC1 
1 OmM M gC l2 
lOmM M gSO q 
20m M  glucose
L - A M P  PLATES:
1% bacto-tryptone 
0 .5%  Bacto  yeast extract 
1% sodium chloride 
1.2% bacto agarose
10j.ig/ml ampicillin (added when agarose has cooled to less than 60°C).
L -B R O T H :
1% bacto-tryptone 
0 .5%  Bacto yeast extract 
1% sodium chloride
W I Z A R D  M IN I-PREP SO L U T IO N S
C E L L  R E S U S P E N S IO N  BUFFER:
50mM Tris.Hcl pH 7.5 
lOmM E D T A  
100ug/ml RNase A
C E L L  LYSIS BUFFER:
0.2M  NaO H  
1% SDS
N E U T R A L I S A T I O N  BUFFER:
1.32M KAc pH 4.8
C O L U M N  W ASH :
200 mM  NaCl 
20m M  Tris.HCl pH 7.5 
5mM  E D T A
Dilute with 95%  ethanol to a total ethanol concentration o f  55%.
S E Q U E N C I N G  S O L U T IO N S
5X R E A C T IO N  BUFFER:
200m M  Tris.HCl pH7.5 
lOOmM M gC l2 
250m M  NaCl
5X L A B E L I N G  MIX:
7.5uM  dGTP 
7.5uM  dCTP 
7 .5uM  dTTP
6% S E Q U E N C I N G  GEL:
6%  acrylamide:bisacrylamide (40:1)
8M  urea 
lx T B E
lp l  25%  ammonium persulphate per ml o f  gel 
l p l  T E M E D  per ml o f  gel
lOmM Tris-HCl pH 8.0 
Im M  E D TA  
lOOmM NaCl
B L O O D  LYSIS  BUFFER:
O .lM T r is  pH 8.0 
20m M  NaCl 
Im M  E D T A  
4%  SDS
G E L  L O A D I N G  BUFFER:
30%  w /v glycerol 
0.25 %  xylene cyanol FF 
0.25 %  bromophenol blue
TES:
OTAGEN M A X I-P R E P  S O L U T IO N S  
PI:
50m M  Tris.HCl 
lOmM  E D T A  pH 8.0 
1 OOpig/ml R N ase A
P2:
200m M  N aO H  
1% SDS
P3:
3M  K A c pH 5.5
B U F F E R  OBT:
750m M  NaCl 
50mM M O PS 
15% ethanol pH 7.0 
0 .15%  Triton X-100
B U F F E R  P C :
1M NaCl 
50mM M O PS 
15% ethanol pH 7.0
B U F F E R  OF:
1.25M NaCl 
50m M  Tris.HCl 
15% ethanol pH 8.5
E R A S E - A - B A S E  S O L U T IO N S
A C ID  PHENOL:
500ml 50mM  N aA c pH 4.0 added to 500g phenol. Dissolve 3-4 hours 
R em ove upper aqueous phase, add 500ml 50mM  NaAc. Repeat until pH o f  
aqueous layer is less than 4.1
IPX EXOIIT BUFFER:
660m M  Tris.HCl pH 8.0 
6 .6m M  M g C ^
SI N U C L E A S E  MIX:
IX  SI buffer 
2-3 U S I nuclease 
deionised w ater to Sul
7.4X SI BUFFER:
0.3M  K A c pH 4.6 
2 .5m M  NaCl 
lOmM Z n S 0 4 
50%  glycerol
SI S T O P  BUFFER:
0.3M  Tris base 
0 .05M  ED T A
K L E N O W  MIX:
IX  Klenow buffer 
3U Klenow
K L E N O W  BUFFER:
20m M  Tris.HCl pH 8.0 
lOOmM M gC l2 
d N T P  MIX:
0 . 125mM each dATP, dCTP, dGTP, dTTP
L I G A T I O N  M IX :
IX  ligase buffer 
5% PE G  
' Im M  D T T  
1 U T 4  D N A ligase 
deionised w ater to 40j.il
IPX L IG A T IO N  BUFFER:
500m M  Tris.HCl pH 7.6 
lOOmM M gC l2 
lO m M A T P
2X C R A C K I N G  BUFFER:
2 ml 5M N aO H  
2.5ml 10% SDS 
lOg sucrose
deionised w ater to 50ml
S O U T H E R N  H Y B R ID IS A T IO N  S O L U T IO N S  
M E G A P R I M E  R E A C T IO N  BUFFER:
dATP, dGTP, dTTP in concentrated reaction buffer containing Tris.HCl pH 
7.5, M gC l2 and 2-mercaptoethanol (as described in m anufacturers protocol).
2PX SSC:
3M NaCl
0.3M  trisodium citrate pH 7.0
H Y B R I D I S A T I O N  BUFFER:
10% dextran sulphate 
6X SSC 
1% SDS
1 OOpig/ml denatured salmon sperm DNA
F R EEZIN G  MEDIA:
10% DM SO
50%  Heat Inactivated Newborn Calf Serum
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M A N U F A C T U R E R S  A N D  SUPPLIE RS
A M E R S H A M  IN T E R N A T IO N A L :
Amersham Place, Little Chalfort, Buckinghamshire,
H P 7 9NA.
Tel: 0800 616928
B IO -R A D  LABS LTD.
Bio-rad House, Maylands Ave., Hemel Hempstead, Herts., HP2 7TD 
Tel: 0800 181134
B O E H R I N G E R  M A N N H E I M  (UK) LTD.
Bell Lane, Lewes, East Sussex, BN7 1LG 
Tel: 0800 521578
C A M B I O  LTD.
34 Millington Rd., Cambridge, CB3 9HP 
Tel: 0223 66500
C A M B R I D G E  BIO SC IEN C E.
25 Signet Court, N ew m arket Road, Cambridge, CB5 SLA 
Tel: 0223 316855
D A K O  LTD.
22 The Arcade, The Octagon, High Wycombe, Bucks, H P 1 1 2H T 
Tel: 0494 452016
D Y N A L  UK LTD.
Station House, 26, Grove St., New Ferry, Wirral, Merseyside 
Tel: 051 644 6555
FLOYVGEN IN S T R U M E N T S  LTD.
B road  Oak Enterprise Village, Broad Oak Road,
Sittingbourne, Kent, M E9 8AQ 
Tel: 0795 429737
H O E F E R  LTD.
Unit 12, Croft Road W orkshops, Croft Road, Newcastle-Under-Lyme, 
Staffordshire, ST5 0TW.
Tel: 0782 617317
H Y B A I D  LTD.
111-113 W aldegrave Road, Teddington, Middlessex, TW1 1 8LL 
Tel: 081 977 3266
IBI LTD.
36 Clifton Road, Cambridge, C B 1 4ZR
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Tel: 0800 581700 
K O D A K  LTD.,  See IBI 
LIF E T E C H N O L O G I E S  LTD.
3 Fountain  Drive, Inchinnan Business Park, Inchinnan PA4 9RF 
Tel: 0800 838380
O N C O G E N E  SCIENCE, see Cambridge Bioscience  
O S W E L  D N A  SERVIC E.
Dept, o f  Chemistry, University o f  Edinburgh, Kings Buildings, West 
M ains Rd., Edinburgh EH 9 3JJ 
Tel: 031 650 4792 "
P H A R M A C I A  B IO T E C H .
23, G rosvenor Rd., St. Albans, Herts, ALI 3AW.
Tel: 0727 814000
P R O M E G A  B IO TEC H .
Delta  House, Chilworth Res. Centre, Southampton SOI 7NS 
Tel: 0800 378994
Q U I A G E N  Ltd.
Unit 1, Tillingbourne Court, Station Rd., Dorking, Surrey RH4 1HJ 
Tel: 0306 740444
S I G M A  LTD.
Fancy Road, Poole, Dorset, BH17 7Nh 
Tel: 0800 373731
S T R A T A G E N E .
140 Cambridge Innovation Centre, Science Park, Milton Rd., Cambridge 
CB4 4GF.
Tel: 0800 585370
U N IT E D  ST A T E S  B I O C H E M I C A L S  (USB),  see Amersh am
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SH O R T  R EPO R T
A study of stabilisation of p53 protein versus point mutation in colorectal 
carcinoma
K .J . C rip p s ,  C .A . P u r d ie 1, P.J. C a rd e r2, S. W hite ,  K. K o m in e ,  C .C . Bird &  A .H . W yllie
C R C  Laboratories, Department o f  Pathology, University M edical School, Edinburgh, E H 8 9AG, UK
Abnormalities o f the p53 tumour suppressor gene occur 
in many types o f cancer including approximately 60% of 
colorectal carcinomas. This study investigates in 47 
colorectal carcinomas the relationship between stabilised 
p53 protein detected by immunocytochemistry (ICC), 
and p53 mutation. 27 cases stained positively with the 
antibody P A bl801. Sequencing o f exons 5 - 8  revealed 
19 mutations in 18 of these cases (one tumour contained 
two different mutations). A rapid, non-radioactive 
method was developed to screen for mutations in this 
region of the gene involving Single Strand Conforma­
tional Polymorphism analysis (SSC P) and a MspI 
restriction digestion. This screen detected 17/19 (89% ) 
of the sequenced mutations, and a further four mutations 
in 20 PAM 801 negative cases that were confirmed by 
sequencing. Reproducibility o f ICC in detecting stabi­
lised protein was assessed by restaining the 47 cases with 
the antibody D 0 7  after pre-treatment to optimise 
detection. Fewer cases were negative with D 0 7  although 
overall concordance with PA bl801 was good. A 
substantial proportion of carcinomas with stabilised p53 
as detected by ICC do not contain mutations in exons 
5 - 8 ,  whilst some mutations (the majority in exon 6) are 
not associated with stabilisation.
Abnormalities of the p53 tum our suppressor gene are 
amongst the commonest genetic alterations recorded in 
human neoplasia. M utations in p53 occur in primary 
cancers in many sites including lung, breast, brain and 
colorectum (Nigro et al., 1989). G reater than 60% of 
colorectal carcinomas show allelic deletion of the 
region 17p 13 containing the p53 gene and the 
remaining allele often contains a point m utation, 
usually arising at about the time of adenom a to 
carcinoma conversion (Vogelstein et al., 1988; Baker 
et al., 1989). 90% of point m utations tend to cluster in 
one of five evolutionary conserved regions and are 
commonly missense m utations resulting in a protein 
with an altered conform ation (Nigro et al., 1989; 
G annon et al., 1990; Soussi et al., 1990; Hollstein et al.,
1991). M any m utations alter the biochemical properties 
of p53, including its ability to bind DNA, and act as a 
transcriptional transactivator (Raycroft et al., 1990; 
Kern et al., 1991).
In norm al cells, p53 is expressed at a low level and
Correspondence: K.J. Cripps
Current addresses: 'D epartm ent o f Pathology, Royal Infirmary. 
Glasgow G40SF: "D epartm ent o f H istopathology. St James Hospital. 
Leeds, UK
Received 1 February 1994: accepted in revised form 18 M ay 1994
has a short half-life (6 min in the spleen; Rogel et al., 
1985). A change in molecular configuration leads to 
stabilisation of the protein product so that its half life 
is greatly extended, thereby allowing detection by 
immunocytochemistry (ICC) (Jenkins et al., 1985). 
Many of the tum our-associated missense m utations in 
p53 cause protein stabilisation and it has often been 
assumed that stabilised p53 visualised by ICC is 
equivalent to m utated p53. Recently however, it has 
become clear that the association between stabilisation 
and m utation is far from absolute (W ynford-Thomas,
1992). This may reflect both the type of m utation and 
the nature of the celi in which it occurred. A study of 
p53 in 33 lung cancer cell lines revealed a correlation 
between missense m utations of the gene and strong 
overexpression of the protein (Bodner et al., 1992), but, 
not all p53 m utations result in a stabilised protein 
product. For example, L i-F rau m en i patients carry 
germline p53 m utations yet m utant protein is 
detectable in only a proportion of cases (Frebourg et 
al., 1992). Conversely not all stabilised protein is 
m utated. Wild type p53 protein levels rise after DNA 
damage as the natural response to agents such as UV 
irradiation and the protein assumes a stable config­
uration detectable by ICC (Hall el al., 1993), whilst 
some cancer family patients express stabilised unm u­
tated p53 protein in a substantial proportion of their 
cells (Barnes et al., 1992). An enzyme-linked im m u­
noassay has recently shown that p53 stabilisation 
occurs in some colorectal adenomas in the absence of 
m utation (Tominga et al., 1993). A study o f p53 
staining in breast cancers revealed cytoplasmic staining 
of wild-type p53 protein in 37% of cases, suggesting 
that nuclear exclusion may be a further mechanism in 
the inactivation of p53 tum our suppressor activity in 
some tum ours (Moll et al., 1992). Finally there is 
evidence to suggest that stabilised wild type p53 protein 
can arise due to the activation of other genes already 
implicated in cancer, such as c-myc and ras (Lu et al., 
1992; W ynford-Thomas, 1992). Recently it has been 
suggested that the tum our cell environment may 
impose a stable configuration on wild type protein, 
perhaps causing the loss of its normal growth 
regulatory responses (Vojtesek & Lane, 1993).
In this paper we have attem pted to determine the 
frequency with which m utation and stabilisation occur 
in colorectal tum ours. There are particular reasons for 
studying p53 in colorectal cancer in this way. Firstly it 
has been shown that the presence of stabilised p53 
correlates with a particular class of cancers in which 
there are multiple divergent, near-tetraploid tum our 
cell clones and the suggestion has been made that such 
abnorm al p53 may facilitate endoreduplicative events 
leading to aneuploidy (Carder et al., 1993). Secondly,
2740 K.J .  C R I P P S  et al.
there are interesting com parisons to be made between 
prim ary cancers of the colorectum and at other sites. 
Existing evidence suggests that p53 can be involved in 
carcinogenesis in different ways. Thus, both colorectal 
and breast cancer show frequent stabilisation, but 
point m utation frequency in breast cancer is relatively 
low, commonly 2 0 -3 0 %  (Bartek et al., 1991; Dunn et 
al., 1993) (although a recent paper by Jacquem ier et al.
(1994) indicates that the correlation between stabilisa­
tion and m utation of p53 in breast cancers may be 
higher than the previous studies suggest) whilst in 
existing series of colorectal cases, the incidence of p53 
point m utations is greater than 50% (Nigro et al., 
1989; Rodrigues et al., 1990). Overexpression of p53 
protein w ithout m utation in non-H odgkin’s lym pho­
mas has also been dem onstrated (Villuendas et al., 
1993). Thirdly, p53 ICC on colorectal tum ours as in 
other cancers shows a variety of staining patterns. In 
some, staining is intense and affects the majority of 
nuclei within the section, in others it is widespread but 
involves fewer nuclei, and in some there is only focal 
staining that may affect a very low proportion o f nuclei 
(Vojtesek et al., 1993). R ather little is known o f the 
biological meaning o f these different patterns.
Accordingly we studied 47 colorectal carcinomas 
originally classified as positive or negative dependent 
on staining with the m onoclonal antibody PAbl801 
(Purdie et al., 1991; Carder et al., 1993). M utations 
were defined in ICC positive cases by sequencing 
through exons 5 - 8 ,  the region in which over 90% of 
all p53 m utations have been shown to occur in 
previous studies (Levine et al., 1991). We then 
validated a m ethod for screening for m utations using 
PCR-SSCP and an MspI restriction enzyme digest in 
ICC positive cases and applied it to ICC negative 
cases. Finally, the 47 cases were re-examined with a 
second antibody, D 0 7 , under conditions which were 
more sensitive in detecting stabilised p53. M utations 
outside exons 5 - 8  were searched for in the few cases in
which strongly positive staining was not associated 
with m utations within this region. The combined data 
support a strong relationship between stability and 
m utation, but highlight specific situations where 
stability and m utation are not concordant.
M utation analysis of PA bl801 positive tumours
Paraffin sections o f 47 colorectal carcinomas fixed in 
PLPD , were stained with the antibody PAbl801 as 
previously described (Purdie et al., 1991). In this 
analysis any nuclear reaction product in a section 
was deemed sufficient to classify the tum our as ICC 
positive and so included all three staining patterns 
described above. Positive staining was observed in 27 
of the tum ours. A total of 19 m utations in 18 (67%) of 
these cases were found by sequencing exons 5 -8  
(Table 1). (One case T4, contained two different 
m utations, CG C->CA C in codon 175 and 
C G G ->C A G  in codon 248.) The majority of muta­
tions (12/19) clustered within two recognised hotspots 
at codons 175 and 248 (Hollstein et al., 1991). One case 
(T8) was found at an exon/intron boundary (G->A of 
the first base of intron 5), and another (T12) was a 
conservative base change at codon 227. This last 
m utation is unlikely to be responsible for the 
stabilisation of the protein, which must therefore be 
attributable either to a second m utational event outside 
the region studied or to a non-m utational mechanism. 
O f 19 m utations 17 were either C->T or G->A 
transitions, 13 occurring at CpG  dinucleotides. The 
remaining two cases were a G ->T and a T->G 
transversion. The nature of these m utations thus 
concords with the published literature in which the 
majority of p53 m utations in colorectal cancer are 
transitions at CpG dinucleotides within recognised 
hotspots (Hollstein et al., 1991). O f the 27 tumours 
with stabilised p53, nine (33%) did not contain a
T a b l e  1 A com parison between location o f m utation in 23 tum ours and im m unocytochem istry with PAbl801
Immunocytochemistry positive Immunocytochemistry negative Amino
Case SSCP positive SSCP negative SSCP positive SSCP negative acid change
T1 Exon 5 codon 152 C CG -C TG Pro-Leu
T2 codon 175 CG C-CA C Arg-His
T3 codon 175 CGC-CAC Arg-His
*T4 codon 175 CGC-CAC Arg-His
T5 codon 175 CG C -C TC Arg-Leu
T6 codon 179 CAT-TAT His-Tyr
T7 codon 180 G A G -T A G Glu-stop
T8 exon/intron 5 G gt-G at
T9 Exon 6 codon 202 C G T-C A T Arg-His
T10 codon 203 G T G -A TG Val-Met
T 1 1 codon 213 C G A -TG A Arg-stop
T12 Exon 7 codon 227 TG CT-TC G Ser-Ser
T13 codon 245 G G C -A G C Gly-Ser
T14 codon 248 C G G -T G G Arg-Trp
T15 codon 248 C G G -T G G Arg-Trp
T16 codon 248 C G G -T G G Arg-Trp
T17 codon 248 C G G -T G G Arg-Trp
T18 codon 248 C G G -T G G Arg-Trp
*T4 codon 248 C G G -C A G Arg-Gin
T19 codon 248 C G G -CA G Arg-Gin
T20 codon 248 C G G -CA G Arg-Gin
T21 codon 248 C G G -CA G Arg-Gin
T22 Exon 8 codon 281 GAC-AAC Arg-Asn
All individual tum ours in which a m utation was detected by sequencing except * in which the two m utations were detected in the same tumour. 
In addition T23. a tum our negative for immunocytochemical staining and for SSCP in exons 5-8 contained a T TC -TCC  (Phe-Ser) mutation at 
codon 113 o f exon 4
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m utation within exons 5 - 8 .  In order to determine 
whether this was due to m utations outwith exons 5 - 8 ,  
the entire coding region was sequenced in three of these 
cases showing strong staining of the majority of nuclei 
with both antibodies (data not shown). A m utation in 
exon 4 was detected in one of the tum ours resulting in 
a phenylalanine to serine amino acid change at codon 
113. Exons 4 and 9 were then sequenced in the 
remaining six cases but no further m utations were 
found. Therefore 8/27 (30%) cases with positive 
immunocytochemistry appear to have no m utation 
suggesting stabilisation of p53 by other means.
P C R -SS C P /M spI screening for mutations in PA bl801  
positive tumours
Rather than search for m utations in all the PAbl801 
negative cases by sequencing, we sought to develop a 
more rapid but accurate screening m ethod based upon 
SSCP of exons 5 - 8 .  This method derived from that of 
Orita et al. (1989) but did not use radioactive isotope. 
To validate the m ethod we first applied it to the 
PAbl801 positive tum ours where the sequence within 
these exons was known. 13/19 (68%) of the sequence- 
detected m utations revealed an abnorm al band 
m igration pattern under standard SSCP conditions 
(room tem perature and 5% glycerol; Figure 1). Six 
m utations were not detectable as an SSCP. One of 
these was the exon/intron boundary m utation which 
would have been masked by the PCR primers used in 
the SSCP m ethod. The conservative base change at 
codon 227 was also undetectable as an SSCP. The 
remaining four cases were all codon 248 C G G -»C A G  
m utations. These cases presumably represent nucleo­
tide changes insufficient to alter the secondary 
conform ation to a level detectable by SSCP. SSCP 
was repeated under different conditions (4°C with a 
glycerol free gel), but no further m utations were 
detected. In order to extend this screening m ethod to 
include reliable detection of the common codon 248 
m utations, a PCR fragment containing exons 7 - 9  
(primers 890 and 891; Figure 2) was digested with the 
restriction enzyme M spl. Disruption of the CCGG 
MspI recognition site at codon 248 by m utation 
resulted in the loss of 135 bp and 168 bp bands and 
addition of a 303 bp band (Figure 2). The combination 
of SSCP and M spl digestion detected 89% of 
m utations known to exist in exons 5 - 8  on the basis 
of sequencing. M oreover, all SSCP abnormalities were 
confirmed as m utations (no false positives). This 
method of screening for p53 m utations has the further 
advantage of being non-isotopic and substantially 
faster than sequencing.
Screening for mutations in PAM 801 negative tumours
O f the 47 tum ours studied, 20 were classified as ICC 
negative. In these, no PAbl801 staining was seen 
within the section. Nonetheless four (20%) of these 
ICC negative tum ours had m utations detected by the 
screening m ethod (all showed SSCP abnormalities) and 
confirmed by sequencing (see Table 1). One of the 
m utations was at codon 175 within exon 5, whilst the 
remaining three were all in exon 6. In contrast, no exon
N T N T
Figure I Single Strand Conform ational Polymorphism gel o f 
exon 6 from two cases (T10 and T i l )  showing extra bands in the 
tum our samples as com pared to the corresponding normals. (N- 
normal, T-tum our.) The polymerase chain reaction was 
performed on a 0 .1 -1 /ig  paired norm al and tum our genomic 
D N A  samples, in a 100/¡I reaction containing 200pM o f each 
dioxynucleotide, 50pm oles o f each prim er, and 2 units o f a 
therm ostable Taq polymerase in the relevant buffer. PC R  was 
perform ed in a D N A  thermocycler (Hybaid) with the following 
tem perature profile: 1 cycle o f 94°C for 5 min, 30 cycles o f 94°C 
for 1 min, 5B°C for 1 min, 72°C for 1 min and 1 cycle o f 72°C for 
10 min. The primers were as follows (5' to 3'): exon 5 up- 
T TC C TC TTC C TA C A G TA G TC  and 5 reverse-CGAT G G T  - 
G A G C A G C T G G G . exon 6 up-CCTC A CTG A TTG CTCTTA - 
G G  and 6 reverse-CTG A G G TC TG G TTTG CA A C T. exon 7 up- 
T G TG T TA T C TC C T A G G T T G G  and 7 reverse-GTCA G GA G C- 
C A CTTG CCA . exon 8 up-TC C T A T C C TG A G T A G T G G T  and 8 
reverse-CG A G G TA A G CA AG C A G G A . The samples were ex­
tracted once with 24:1 chloroform /isom ylalcohol to  remove any 
mineral oil. 5 -1 0 p l  were then denatured in 8 0 pM N aO H , 10/rM 
ED TA  at 48°C for 5 min, 2 pi sequencing stop solution was 
added, and the whole sample loaded onto a 5% glycerol, 0.5 x 
M D E Hydronlink gel (Hoefer Scientific). The gel was run in 
lx T B E  on the SE600 PA GE apparatus (Hoefer Scientific) at 
25°C, 20W for 2 - 3 h (additionally alternative conditions o f 4°C 
in the absence o f glycerol were used in some cases). Bands were 
visualised by a silver stain (BioRad) as per m anufacturers 
instructions. The gel was dried onto 3M M  paper and laminated
6 m utations were found amongst the PAM801 positive 
cases.
D O -7 Immunocytochemistry
It is possible that failure to identify stabilised product 
in the presence of m utated p53 merely reflected the 
sensitivity of the method of staining. To address this, 
we restained the sections under optimised conditions of 
microwave pre-treatm ent with the human p53 specific 
murine monoclonal antibody DO-7 (Cattoretti et al.,
1993). The two antibodies showed similar patterns of 
staining with the three classes of staining pattern 
discussed above readily discernible. Although micro­
wave pre-treatm ent and DO-7 staining produced fewer 
negative cases than PAbl801 (nine vs 20), the four 
PAbl801 negative cases with m utation were also all 
clearly negative with DO-7. The epitopes recognised by 
PAbl801 and DO-7 are both within the N-terminal 
domain of p53 (Banks et al., 1986; Vojtesek et al.,
1992) and it was therefore possible that both antibodies 
might fail to detect a genuinely stabilised protein 
through some epitope masking phenomenon. To 
exclude this, the three cases with exon 6 m utations 
that were negative with both antibodies were stained
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Figure 2 (A) Sequencing gel o f exon 7 from two cases showing
the two different codon 248 m utations (a) (T19) C G G -C A G  and 
(b) (T14) C G G -T G G . (B) Single Strand C onform ational 
Polymorphism gel o f the two cases above showing an 
abnorm ality (indicated by arrow ) in (b) but not (a). (C) 3% 
agarose gel o f an M spl restriction digest o f exons 7 - 9  in both 
norm al and tum our samples from cases (a), (b) and a non­
m utated control case (c). The m utations a t codon 248 are seen as 
a loss o f the 135 and 168 base pair bands due to m utation o f a 
M spl site resulting in a 303 base pair band, in addition to the 
constant 276 and 290 base pair bands. (The presence o f the 135 bp 
and 168 bp bands in tum our sample a.) is due to contam inating 
norm al tissue). (N -norm al, T -tum our, M -D N A  m olecular weight 
m arker.) Sequencing was perform ed by one o f three m ethods 
using the PCR primers as sequencing primers: (1) Cycle 
sequencing o f PC R amplified exons 5 - 8 .  Briefly, the com ponents 
o f a chain term ination reaction were cycled through a 
tem perature profile o f heat denaturation  at 95°C for 1 min, 
annealing a t 58”C for 1 min and extention a t 72°C for 1 min in the 
presence o f y-3 'P-labelled prim er and 50 fmoles o f PC R product 
(after purification with Promega Magic C lean-up Columns). 
(2) Subcloning of a PCR product containing exons 7 - 9  using 
prim ers 890 and 891 into pUC18, pooling o f approx. 100 
transform ed colonies, and m iniprep DNA preparation  using 
Magic M ini-prep kit (Prom ega) followed by the chain term ina­
tion m ethod with [a35S] as per the m anufacturers protocol for 
dsD N A  (United States Biochemicals, Sequenase Version 2.0) 
890-5 - G A G A G A A G C TT G C C A C A G G TC T C C C C A A G G C G A - 
A: 891-5 '-A G A G A G G G A TC C A C TTTC C A C TTG A TA A G A G -
G TCCC A A G . (3) Separation o f the two strands by Dynabeads 
(Dynal) after PCR am plification of exons 5 - 6  using a 
biotinylated upstream  prim er and the exon 6 reverse prim er (see 
PCR-SSCP), followed by the chain term ination m ethod as above. 
Biotinylated prim er as follows (5'-3') A G G A G G T G C T T A C A - 
C A TG TT. Samples were then denatured at 95°C for 5 min, 
electrophorised through a 6% urea/acrylam ide gel, fixed for 
lOmin in a 10% m ethanol/10%  acetic acid solution, dried on 
3MM paper, and exposed to autoradiographic film overnight
with the polyclonal antibody CM-1 and no positive 
staining was seen although CM-1 convincingly detected 
stabilised protein in three further known DO-7 positive 
cases included in the same run (data not shown). 
Finally, no cases with single scattered positively 
staining nuclei with either PAbl801 or DO-7 con­
tained m utations, but m utations were found in two 
cases with only 3 0 -5 0 %  moderately strongly positive 
nuclei on staining with DO-7. As mentioned earlier, 
two tum ours in which the majority of nuclei stained 
strongly with both antibodies failed to reveal m utations 
in the entire coding region of the gene.
Discussion
The data clearly show that positive ICC staining with 
either of the antibodies studied does not correlate 
exactly with p53 m utation. It is difficult to give 
absolute figures for this disparity as the proportion of 
cells staining differs with the m ethod used and the 
percentage of positive cases is also dependent upon the 
extent to which tum ours with sparsely or focally 
distributed positive nuclei are included. This study 
shows however that m utations can be found in 
approximately 20% of colorectal carcinom as that are 
ICC negative, and that m utation in exons 5 - 8  cannot 
be found in as many as 33% o f ICC positive colorectal 
cancers. The group o f ICC positive cancers without 
apparent p53 m utation in exons 5 - 8  contains all the 
cases in which stabilised p53 protein was evident only 
in rare widely-dispersed nuclei. However there were 
also three cases that showed the more familiar staining 
pattern, with the majority o f nuclei strongly positive. 
One o f these was shown to contain an exon 4 mutation 
at codon 113. Occasional m utations in both exons 4 
and 9 have been reported in the literature and although 
this was the only m utation recorded outwith exons 5 -  
8 in this study, these observations suggest that previous 
studies restricted to exons 5 - 8  may have slightly 
underrepresented the true incidence of p53 mutations 
in colorectal tum ours. Amongst the m utated cases that 
were ICC negative we noted a predominance of 
m utations in exon 6. It is probable that these tumours 
contained only m utant protein as two o f the three cases 
showed loss of alleles within p53 in the tum our whilst 
the remaining case was non-inform ative with a variety 
of polymorphic probes (data not shown). Previous 
studies of ICC and m utation in colorectal and ovarian 
cancers also show that exon 6 m utations often fail to 
result in a stabilised protein (Cunningham  et al., 1992; 
K ikuchi-Yanoshita et al., 1992; Teneriello et al., 1993). 
Taken together these results suggest that exon 6 
includes a region of the gene in which mutations 
frequently fail stabilise p53, whilst still conferring a 
selective growth advantage. The presence of mutations 
in occasional ICC negative tum ours and the absence of 
m utations in some strongly ICC positive tumours 
suggests that alternative mechanisms of p53 abnor­
mality (stabilisation, m utation or both) occur relatively 
frequently in colorectal cancers, a tum our type in 
which identity between stabilisation and m utation has 
often been assumed. An absence of direct correlation 
between stabilisation and m utation has been reported 
in other tum our types including breast carcinoma and 
non-H odgkin’s lymphoma (Dunn et al., 1993; Villuen- 
das et al., 1993). As larger case numbers accrue in 
which the distinction is made between m utational and 
non-m utational mechanisms of stabilisation, it will be 
possible to determine whether this distinction is 
accompanied by differences in tum our behaviour. This 
paper provides details of a non-radioactive method by 
which almost all p53 m utations can be rapidly and 
accurately identified, so facilitating such studies.
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M utational Analysis o f the MCC  Gene 
by Single-strand Conformational 
Polymorphism Analysis
K.J. Cripps, L.J. Curtis and A.H. Wyllie
A r e g io n  on chrom osom e 5 q 2 1 is com m only deleted in sporadic 
colorectal carcinomas, and has been shown to contain the gene 
responsible for familial polyposis coli (FPC), an inherited form 
of colorectal cancer [1, 2]. Several genes have been m apped  to 
this region including both  A P C  and A iC C  [3-6]. A P C  has since 
been shown to be the gene responsible for FP C , and is also 
m uta ted  somatically in the majority o f  sporadic colon cancers. 
T h e  role of  A iC C  is, however, still uncertain. N o  mutations of  
AiCC have been found in F P C  patients ,  and only six somatic 
muta tions in sporadic tum ours  have been reported [6, 7].
This  s tudy screened the 17 exons o f  the coding region o f  the 
Ai C C  gene for muta tions in a small subset o f  clinically im portan t  
colorectal tum ours  from five non-poiyposis patients  who p re ­
sented with the disease at a relatively young age (Table 1). We 
considered it possible tha t  defects in AiCC might be im portan t  
in colorectal tumorigenesis in this subset of  younger non- 
polyposis patients whilst having little inpu t  on the development 
of  sporadic tum ours  in older patients. Mutational analysis was 
performed by the technique of  single-strand conformational 
polym orphism  analysis after amplification by the polymerase 
chain reaction (PCR-SSCP) on normal and tum our  tissue as 
described previously [6] using PCR primers previously p u b ­
lished [8]. W e used D N A  from these tum ours previously grown 
as xenografts in SCID mice to eliminate the presence o f  any 
normal stromal e lements which may have rendered mutational 
analysis difficult.
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T h e  m ethod detected abnormalities in all 5 previously 
reported cases with the AiCC mutation. N o  mutations, however, 
were found in the coding region of  M C C  in any of  the 5 
young patients,  although several polymorphisms were noted. A 
deletion polymorphism in exon 10 and a C -T  conservative base 
change at codon 708 of  exon 15 have been reported previously 
[9]. A novel polymorphism was observed in two of  the 5 patients. 
Sequencing of  these samples revealed a two base pair change 
(GC-TG) with in intron 13 immediately prior  to exon 14. This 
polym orphism  appeared to be linked to the polymorphism in 
exon 15 and this was confirmed by extending the study o f  these 
two exons to an additional 19 constitutional D N A  samples from 
young non-polyposis colorectal cancer patients and 18 normal 
control patients. T h e  allele frequency o f  the novel polym orphism  
(B1 in T able  1) was 83% compared to the published sequence of 
the gene. N o  difference in frequency was observed between the 
normal and  young colon cancer populations.
A recent study from this laboratory showed that whilst allele 
loss on 5q21 invariably involved b o th 0 M C C  and A P C , no 
mutations of  AiCC could be detected by PCR-SSCP in the 
remaining copy o f  the gene [10]. These com bined studies suggest 
tha t M C C  does not have a role as an independent  tum our 
suppressor gene in colorectal cancer, at least at the level studied.
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Mutation of the p53 gene precedes aneuploid clonal divergence in 
colorectal carcinoma
PJ C a r d e r 1, K J  C r ip p s 2, R  M o r r i s 2, S C ollins2, S W h ite 2, C C  B ird2 a n d  A H  W yllie2
'Academ ic Unit o f  Pathology, Algernon Firth Building, University o f  Leeds, Leeds L S 2  9JT, UK; 2C R C  Laboratories, Department 
o f  Pathology, University o f  Edinburgh, Teviot Place, Edinburgh EH 8 9AG, UK.
Summary To establish whether p53 m utation precedes or follows clonal divergence in hum an colorectal 
carcinom as, 17 tum ours were analysed at multiple sites (2 -5  each) for single-strand conform ation polym or­
phisms (SSCP) within exons 5 -8  o f the p53 gene. A previous study had dem onstrated subclones o f differing 
DNA ploidy in these tum ours, but all showed immunocytochemical evidence for p53 stabilisation, using the 
m onoclonal antibody PAb 1801. M utations within exons 5 -8  o f p53 were identified by the presence o f an 
abnorm ally migrating band in 10 o f the 17 carcinomas: five in exon 5, four in exon 7 and one in exon 8. In 
each o f these positive cases, samples from different parts o f the carcinom a showed identical gel migration 
patterns in SSCP analysis. Similarly, the remaining seven tum ours were concordant for absence of band shift 
across all samples o f each tum our. Six SSCP-positive cases contained multiple populations differing in DNA 
ploidy, while four were homogeneously diploid o r aneuploid throughout. Very sim ilar proportions were 
observed in the SSCP-negative cases. In four positive tum ours the m utation was confirmed by sequencing or 
through alteration o f nucleotide-specific restriction enzyme cleavage. Identical m utations appeared in every 
sample from the same tum our. The results provide unequivocal evidence that the same m utant allele o f p53 is 
present throughout each tum our bearing a m utation, regardless o f the clonal variation identified by analysis o f 
DNA ploidy. We conclude that in colorectal tumorigenesis m utation o f p53 occurs as a single event which 
precedes and may facilitate the aneuploid clonal divergence o f carcinomas.
Keywords: colorectal carcinoma; p53, SSCP; clonal evolution
Inactivation o f  the tum our-suppressor gene p53 is an  im por­
tant step in the development o f  the majority o f  hum an 
cancers (Hollstein et al., 1991). Functional inactivation 
occurs most commonly as a result o f  missense muta tion  
(Baker et ah, 1989) but can also result from interaction with 
oncogenic viral or  cellular proteins (Mietz et ah, 1992; 
M o m an d  el ah, 1992). The p53 protein is a sequence-specific 
DN A-bind ing  protein tha t is active as a transcription factor 
(Bargonetti et ah, 1991) and can interact directly with the 
replication appara tus  (D utta  et ah, 1993). There is good 
evidence that its norm al function is to establish G, check­
point control in response to D N A  damage, so allowing time 
for D N A  repair (Kastan  et ah, 1991) or  the initiation of  
apoptosis  (Clarke et al., 1993). Lack of  functional p53 p ro ­
motes genomic instability (Bischoff et ah, 1990: Harvey et ah,
1993), which is probably  a key factor in acquisition of  the 
multiple ‘hits ' required for carcinogenesis (Nowell, 1976).
We have recently shown that hum an colorectal carcinomas 
containing immunohistochemically detectable p53 are more 
likely to contain multiple aneuploid D N A  stem lines than 
those which are p53 negative (Carder et ah, 1993). This result 
is in keeping with a relationship between p53 and genomic 
instability. We also reported that in carcinomas containing 
stabilised p53 the abnorm ality  was almost always present 
th roughout the tum o ur  even though D N A  analysis revealed 
the presence o f  divergent stem lines. F rom  these findings we 
concluded that p53 stabilisation is a critical early event in 
cancer evolution favouring the development o f  tetraploid and 
other  aneuploid sublines. Since it is now clear tha t p53 
stabilisation can be the result o f  the tum our  cell environment, 
independent o f  m uta t ion  (Vojtsek and Lane, 1993), we felt it 
was im portan t  to re-examine these cases for more definitive 
evidence, firstly, tha t m uta t ion  o f  p53 had occurred and. 
secondly, tha t it preceded clonal divergence in tum our p ro­
gression. To this end we used the technique o f  single­
stranded conform ation polymorphism (SSCP) analysis (Orita 
et ah, 1989; Glavac and Dean, 1993) to identify m utant  
alleles o f  p53 and confirm that the same m utant  allele was 
present in all o f  the samples taken from any one carcinoma, 
despite independent evidence o f  clonal divergence between 
these samples.
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M a te r ia ls  and m ethods
Samples
Sixty-four samples from 17 colorectal carcinomas from our 
previously published series (Carder et ah, 1993) were studied. 
An average o f  four samples per tum our (range 2 - 5 )  were 
analysed and compared with normal colonic mucosa from 
the same individual. All samples o f  all tum ours contained 
stabilised p53 as determined by immunohistochemistry using 
PAb 1801 (Oncogene Science). Flow cytometry was per­
formed on frozen tissue and immunohistochemistry was per­
formed on tissue fixed in periodate lysine paraformaldehyde 
(PLPD), both  as described previously. To minimise possible 
confusion between tum our  and non-neoplastic stroma, 
samples were assessed as diploid only if tum o ur cells 
occupied in excess o f  50% of  tissue sections from which the 
corresponding flow cytometric analysis showed a diploid 
main peak. Samples were considered aneuploid if a separate 
peak, distinct from the diploid peak, was identified, and 
aneuploid populations from different samples o f  the same 
tum our  were considered identical unless they differed in 
D N A  index by more than 0.1. Samples were considered 
tetraploid if a separate peak with D N A  index between 1.9 
and 2.1 comprised more than 10% of  the nuclei.
Single-strand conformation polymorphism  ( P C R -SS C P )  
analysis
The polymerase chain reaction (PCR) was performed on 
0 .1 -1  pg o f  genomic D N A  samples, in an 100 pi reaction 
containing 200 pM o f  each deoxynucleotide, 50 pmol o f  each 
primer and 2 units o f  a thermostable Taq polymerase in the 
relevant buffer. PC R  was performed in a D N A  thermocycler 
(Hybaid) with the following tem perature profile: one cycle o f  
94°C for 5 min. 30 cycles o f  94°C for 1 min, 58°C for 1 min. 
72°C for 1 min, and one cycle o f  72°C for 10 min. The 
primers were as follows (5' to 3'): exon 5 up T T C C T C T T C - 
C T A C A G T A G T C  and 5 reverse C G A T G G T G A G C A G C -  
T G G G ; exon 6 up C C T C A C T G A T T G C T C T T A G G  and 6 
reverse C T G A G G T C T G G T T T G C A A C T ;  exon 7 up 
T G T G T T A T C T C C T A G G T T G G  and 7 reverse G T C A G - 
G A G C C A C T T G C C A ; exon 8 up T C C T A T C C T G A G T A G - 
T G G T  and 8 reverse C G A G G T A A G C A A G C A G G A . The
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samples were extracted once with 24:1 chloroform / 
isoamylalcohol to remove any mineral oil and 5 - lO f t l  was 
then denatured in 80 |um  sodium hydroxide, 10p,M  E D T A , at 
48°C for 5 min. Two microlitres sequencing stop solution was 
added, and the whole sample loaded onto  a 5%  glycerol, 
0.5 x  M D E  Hydrolink gel (Hoefer Scientific). The gel was 
run in 1 x  TBE on the SE400 P A G E  ap para tus  (Hoefer 
Scientific) at 25°C, 20 W, for 2 - 3  h.
Norm al and tum o ur  samples from the same individual 
were run together for comparison. T u m o u r  samples were 
classified as SSCP positive if a discrete additional band was 
observed. Bands were visualised by a silver stain (BioRad) as 
per the m anufactu rer’s instructions with additional washes. 
The gel was dried on to 3M M  paper and laminated.
Sequence analysis
A total o f  nine samples from two cases with band shift on 
SSCP throughout  were sequenced by the dideoxy chain- 
termination technique as described previously (Cripps et a!.,
1994) using a commercial kit (Sequenase, Amersham).
Restriction enzym e digestion using M sp /
A total o f  eight samples from two cases with band  shift on 
SSCP th roughout and known to contain a C G G -X C A G  
m uta t ion  in codon 248 were analysed by restriction enzyme 
digestion using M spl. As described previously (Cripps et al.,
1994), disruption o f  the C C G G  recognition site by m uta tion  
results in loss o f  the 135 bp and 168 bp bands and creates an 
additional 303 bp band.
216
elsewhere (Cripps et al., 1994), in a larger num ber o f  cases 
including the present 17.
T1 T2 T3 N
Figure 1 Identical band shifts are revealed by SSCP analysis in 
all divergent subpopulations o f a colorectal carcinom a. N, nor­
mal tissue; T 1 — 3, multiple samples from the same carcinoma 
(D N A  index: T l. 1.5/1.6; T2, 1.5; T3, 1.6).
R esu lts
Seventeen carcinomas which had been sampled at  multiple 
sites and dem onstrated  immunmohistochemical positivity for 
PA b 1801, and for which D N A  ploidy values were available, 
were studied. In 14 cases the majority o f  nuclei stained 
intensely. Three cases showed the ‘mosaic’ pattern,  in which 
positive nuclei were scattered sparsely th roug hou t the 
tumour. Twelve cases contained multiple clonally distinct 
subpopulations as determined by assessment o f  D N A  ploidy 
by flow cytometry, with eight containing two and  four con­
taining three variant subpopulations.
F rom  each tum o ur  sample exons 5 - 8  o f  the p53 gene were 
amplified individually an d  analysed by SSCP. Band shifts 
indicating the presence o f  a m utan t  p53 allele with altered 
conform ation were detected by SSCP in 10 o f  the 17 ca r­
cinomas (59%). An average o f  four samples per tu m o u r  were 
studied, and the same band shift was present in all samples 
o f  each SSCP-positive case, suggesting a single clonal m u ta ­
tion event (Figure 1). The presence o f  a m uta tion  in the 
amplified p53 fragment revealing the band shift was con­
firmed in nine samples o f  two cases by direct nucleotide 
sequence analysis. Six samples from one case contained a 
C G C -x C A C  m uta tion in codon 175 and three samples from 
the other  case contained a C AT-X TAT m uta tion  in codon 
179 (Figure 2). In two further cases a m uta tion  in codon 248 
was confirmed in a total o f  eight samples using the M spl 
restriction enzyme digestion technique (Figure 3). In all, five 
m uta tions occurred in exon 5, four in exon 7 and one in exon 
8. Six cases with SSCP-confirmed muta tions contained multi­
ple divergent populations as detected by assessment o f  D N A  
ploidy, indicating clonal evolution subsequent to m uta tion  
(Figure 4). All samples o f  the SSCP-negative cases were 
concordan t  for absence o f  band shift, confirming that m u ta ­
tion had not occurred (at any rate in this commonly affected 
part o f  the p53 gene) during carcinoma progression in these 
cases. All cases with m uta tion  dem onstrated  strong positive 
staining for PAb 1801 in a majority o f  tum our  cell nuclei, 
but four cases with similarly strong staining were SSCP 
negative in exons 5 - 8 .  The relationship between 
immunocytochemistry and m uta tion  is described more fully
G A T C G A T C G A T C
T1 | T2 | T3
Figure 2 Dideoxynucleotide sequencing conform s a C A T-xTA T 











Figure 3 Mspl restriction digestion o f exons 7 - 9  confirms a 
m utation  in codon 248 in all tum our samples. Loss o f the CCGG 
recognition site creates an additional 303 bp band and results in 
loss o f the smaller 135 bp and 168 bp bands. The smaller bands 
are due to contam inating norm al tissue.
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Figure 4 Relationship between p53 m utation  and clonal evolu­
tion. Over all sampled stem lines from any one tum our, band 
shifts on SSCP analysis o f exons 5 -8  were either uniformly 
present (closed symbols) or uniformly absent (open symbols), o, 
diploid; O, tetraploid; o ther symbols aneuploid with different 
aneuploid stem lines within the same tum our being designated by 
different stem lines. D, diploid; T, tetraploid; A, and A2, aneu­
ploid.
Discussion
We have used the technique o f  single-stranded conform ation 
polymorphism (SSCP) analysis to detect clonality o f  p53 
m uta t ion  in colorectal carcinomas. SSCP provided a sensitive 
m ethod o f  detecting mutations, as m utant  alleles generate 
characteristic band shifts on electrophoresis under non­
denaturing conditions (Orita el a/., 1989). The technique is 
sufficiently powerful to allow distinction between sequences 
differing in a single base pair (Cripps el al., 1994). While in 
theory one might expect a m utant  allele to create at least two 
additional conformers (one from each strand), often only one 
is observed, and it appears  tha t most new conformers derive
from the purine-rich strand (Glavac and Dean, 1993).
Using SSCP we have demonstrated identical band shifts in 
the same exon in subclones o f  carcinomas that diverge in 
D N A  ploidy, and also in carcinomas which are hom ogene­
ously diploid or  aneuploid. We interpret this to indicate that 
p53 mutation occurs prior to divergence o f  clones differing in 
D N A  ploidy, and hence any one tum o ur  possesses a single 
p53 m uta tion  throughout. In a large series o f  carcinomas 
reported separately (Cripps el aI., 1994) we have confirmed 
by sequencing that band shifts detected by SSCP invariably 
denote mutation, and that the technique used here identifies 
more than  70% of  all naturally occurring muta tions in the 
region o f  p53 studied (exons 5 -8 ) .  It may be argued that 
identical band  shifts might still represent different point 
muta tions within the same amplified fragment. We feel that 
this interpretation is unlikely for three reasons. Firstly, even 
minor differences in nucleotide substitution (e.g. in adjacent 
positions o f  the same codon) can lead to p rofound differences 
in band shift by SSCP analysis using the methods employed 
here (Cripps el al., 1994). Secondly, in the now considerable 
literature on p53 muta tions in cancer, the occurrence o f  two 
distinct mutations in the same exon in any one tum our is 
uncommon. Finally, we have used direct sequencing to 
confirm identity o f  muta tion  th roughout in two cases, and in 
a further two we have used a rapid restriction enzyme diges­
tion technique to confirm identity o f  muta tion  site.
The observation that an identical muta tion  in p53 occurs 
throughout affected carcinomas, including those with and 
without clonal divergence in D N A  ploidy, provides strong 
evidence for a single muta tional event early in the develop­
ment o f  these cancers. Around 2 0 - 3 0 %  of  all colorectal 
carcinomas containing immunohistochemically stable p53 
appear not to contain p53 mutations (Wynford-Thomas, 
1993; Baas et al., 1994; Cripps el al., 1994) but examples of  
these in this series also showed divergent subclones concor­
dant in p53 immunocytochemistry. Hence, even the non- 
mutational abnormalities that affect p53 stability may also be 
an early event. The da ta  presented here emphasise the central 
role o f  wild-type p53 in preventing one type o f  genomic 
instability. This instability appears to result from continued 
D N A  replication in the presence o f  D N A  damage (Lane, 
1992; Livingstone el al., 1992; Yin et al., 1993) and tends to 
produce near-tetraploid subclones (Carder et al., 1993). It is 
interesting tha t the selective growth advantage afforded by 
this instability appears to be a feature favouring carcinoma 
rather  than  adenom a growth, since p53 mutations are 
unusual in adenomas. Other lesions involved in colorectal 
tumorigenesis but unrelated to p53, such as m uta tion  in the 
D N A  repair genes implicated in hereditary non-polyposis 
colon cancer (Peltomaki et al., 1993), also initiate genomic 
instability, albeit o f  a different type, and associate preferen­
tially with carcinoma rather than adenoma.
In conclusion we establish here by D N A  analysis the im­
pression gained from our previous immunohistochemical 
study: in colorectal tumorigenesis p53 mutation  is a critical 
early lesion occurring as a single clonal mutational event 
which precedes and probably facilitates the emergence of  
divergent aneuploid tum o ur  subpopulations.
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